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1 General introduction and objectives of the thesis  
  Overview  
The aim of the thesis is to develop a tool that harnesses the great potential of 
wastewater analysis to enable real time estimation of public exposure to well-known 
and newly identified chemicals. A real time profiling of community health and 
lifestyle has been highlighted as an emergent necessity to establishing public health 
decision making strategies. For many years population health status and habits have 
been investigated through methodologies such as general population surveys, 
questionnaires and surveillance studies that provided a comprehensive picture of the 
community only after years making it difficult to employ effective and successful 
policies. To overcome the above limitations a new monitoring programme needed to 
be undertaken. A real-time measurement of human health indicators can be achieved 
through analysing wastewater. Wastewater fingerprinting for obtaining information at 
community level population is a pioneering approach which, although still in infancy, 
is currently used as complementary tool in the assessment of populations health and 
lifestyle. This approach assumes that after internal exposure to chemicals (e.g. EDCs), 
human metabolic products (urinary biomarkers) are collected and pooled by the 
wastewater systems and are transported to wastewater treatment plants (WWTPs), 
providing evidence of the population exposure. Considering that WWTPs serve well-
defined populations (in terms of numbers), estimation of both internal and external 
exposure to chemicals (e.g. pharmaceuticals usage, drugs consumption, EDCs 
exposure) in a given period (e.g. day, week) can be made based on analysis of 
wastewater (usually with sensitive and selective mass spectrometry techniques) after 
considering human metabolism patterns (and possible transformation in WWTPs) of 
target analytes. In the longer term the tool will allow for an evaluation of the relevance 
between exposure and effects permitting prompter and more efficient strategies to 
lower the general risk associated to the exposure to selected chemicals. In order to 
achieve that four objectives were identified. 
 Aim of the research programme 
The aim for the research programme is to better understand exposure to endocrine 





To achieve that a list of compounds of interest consisting in poorly investigated 
chemicals not intended for human consumption will be identified (objective 1). Since 
the metabolism of the selected compounds has been scarcely investigated a new tool 
to identify metabolites suitable as biomarkers of exposure combining WBE and in 
vitro techniques will be developed (objective 2). Once new metabolites suitable as 
biomarkers of exposure will be identified applying the newly developed tool 
(objective 3) a new analytical method will be developed and validated to investigate 
the presence of the selected compounds, biomarkers and newly discovered potentially 
toxic chemicals (along with their metabolites) in different environmental matrices to 
understand internal and external exposure (objective 4). 
 Objective 1 
Objective one is to identify a list of EDCs (or suspected to be) used in personal care 
and consumer products not intended for consumption whose exposure patterns and 
long-term effect are mostly unknown. The exposure to the commonly used plasticizer 
bisphenol A via analysis of its metabolite bisphenol A sulphate will be proposed as 
case study to highlight the great potential of wastewater based epidemiology (WBE) 
approach.   
 Objective 2 
The first objective of the thesis is to develop methodology enabling identification of 
biomarkers of exposure via wastewater fingerprinting. The analysis of metabolic 
biomarkers of target chemicals is crucial to distinguish between internal exposure and 
direct disposal, since many sources contribute to chemicals being discharged into 
wastewater. As there were many gaps in literature with regards to the metabolism of 
many of the selected compounds denoting many difficulties in selecting biomarkers 
of exposure to undertake population studies, a key aspect of the project will be the 
development of a new tool for identifying new metabolites suitable as biomarkers of 
exposure for wastewater analysis. In order to identify human specific metabolites 
excreted with urine and consequently present in wastewater, and to assess exposure to 
a wide range of chemicals, a new systematic workflow involving the employment of 





 Objective 3 
The third objective of the thesis is to identify biomarkers of exposure to EDCs in 
personal care products. The developed method which combines in vitro incubation 
techniques with urine and wastewater analysis will be applied to commonly used 
compounds for which there is scarce knowledge about their metabolism. The results 
will permit the selection of suitable candidate biomarkers of human exposure for 
possible application in wastewater-based epidemiology. 
 Objective 4 
The fourth objective is to develop a comprehensive framework for quantitative 
analysis of EDCs and retrospective identification of metabolites. A multi-residue and 
sensitive methodology for the targeted analysis of chemically diverse suspected and 
proven EDCs in sewage and environmental matrices will be developed and validated. 
Liquid chromatography coupled to high resolution mass spectrometry will be used to 
permit the identification of metabolites and biodegradation products and eventually 
retrospective analysis. The developed and validated method will be applied to pooled 
environmental samples to assess the presence of the potentially toxic and persistent 
chemicals. Finally, once EDCs will have been detected and quantified in all 
investigated environmental matrices the study will focus on the identification of new 
and known biomarkers of exposure for specific EDCs in influent wastewater in order 
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Background Molecular epidemiology in human biomonitoring allows for verification 
of public exposure to chemical substances. Unfortunately, due to logistical difficulties 
and high cost, it evaluates only small study groups and as a result does not provide 
comprehensive large-scale community-wide exposure data. Wastewater fingerprinting 
utilising metabolic biomarkers of exposure that are excreted collectively by studied 
population into urine and ultimately into community’s wastewater, provides a timely 
alternative to traditional approaches.  
Objectives This study aimed to provide comprehensive spatiotemporal community-
wide exposure to bisphenol A (BPA, including BPA intake) using wastewater 
fingerprinting.  
Methods Wastewater fingerprinting was undertaken using high resolution mass 
spectrometry retrospective data mining of characteristic BPA human metabolism 
marker (Bisphenol A sulphate), applied to a large geographical area of 2,000 km2 and 
a population of ~1.5 million accounting for >75% of the overall population in the 
studied catchment.   
Conclusions Community-wide BPA intake was found to be consistently below the 
tolerable daily intake (TDI) level set by the European food safety agency (EFSA) 
suggesting overall low exposure, with an exception of two locations, where higher 
BPA sulphate loads corresponding to higher intakes (above the TDI threshold) were 
observed. Characteristic temporal variations of BPA intake were noted in most studied 
wastewater treatment plants (WWTPs) with the lowest intake occurring during 
weekends and the highest during weekdays. Further work needs to be undertaken to 
fully understand sources of BPA and BPA sulphate that might be contributing to the 











Real time assessment of communities’ health status is crucial for optimal decision-
making strategies and resources investment for the prevention, control and mitigation 
of exposure risks aiming at improving populations health and well-being. The standard 
of living has improved but at the same time the incidence of illness such as cancer or 
obesity is increasing with very little understanding of their causes. One potential 
reason could be an augmented human exposure to a wide range of man-made 
environmental chemicals in e.g. household chemicals such as personal care products 
(PCPs). By comparing community levels of environmental stressors with observed 
health effects, conclusions could be drawn as to whether elevated levels of certain 
chemicals could be linked with particular diseases. For many years, epidemiological 
information about lifestyle habits, public health and wellbeing has been gathered via 
methodologies such as general population surveys and other surveillance tools that 
relied on patient's experience and sense of wellbeing (not necessarily objective). These 
approaches are prone to self-reporting bias and require long time for data collection 
and analysis, which makes active prevention of exposure risks by policy makers 
extremely difficult. Therefore it is crucial to undertake more timely and efficient 
approaches to identify cause-effect linkages between environmental stressors and 
communities health status (Daughton 2012b), with particular focus on the effects that 
complex mixtures might have on human population (particularly with regard to 
reproductive health)(Kortenkamp et al. 2011). These approaches monitor biological 
responses rather than diseases in human populations through the usage of biomarkers.  
Biomarkers (the biological endpoints) are quantifiable entities defining physiological 
or pathological biochemical processes occurring in the body e.g. unusual chemical 
metabolites, in vivo genetic changes, and alterations in gene expression, proteins and 
cell-based markers. The use of biomarkers in epidemiological research provides 
invaluable and objective information about patient’s health and disease status, even if 
not detected via classical endpoints when variations are undetectable and/or without 
immediate effect on health, and therefore do not necessarily correlate with a patient's 
experience and do not correspond to patients' clinical state. Hence the measurement of 
biomarkers allows a snap-shot of health and disease of a given individual or 
population, its state or increased risk for disease, which are vital to the field of 





endpoints such as disease incidence or mortality and have positive impact on public 
health (Bonassi and Au 2002). However, a limitation of molecular epidemiology, due 
to logistical difficulties and high cost, is the restricted size of study groups and inability 
to gather comprehensive information on the complexity of combined (and cumulative) 
spatial and temporal exposure to mixtures of endocrine disrupting chemicals (EDCs) 
and their effects (Bonassi and Au 2002). Therefore the community lacks robust 
measures that can be used to gather real-time information on community-wide health.  
 
2.3.1 Wastewater-based epidemiology for public health assessment 
The advancement of the new field of wastewater-based epidemiology (WBE) and its 
unique approach towards retrieving epidemiological information from wastewater via 
the analysis of human biomarkers might overcome the above limitations and could 
provide for the first time real-time measurements of community-wide exposure to 
household EDCs. This highly innovative approach has been pioneered by the SCORE 
(www.score-cost.eu) and Sewprof groups (www.sewprof-itn.eu), and, although still in 
its infancy, is currently used to determine community-wide illicit drug use (Ort et al. 
2014; Thomas et al. 2012). A significant study carried out in 2013 outlines the great 
potential of this approach. In this work involving 23 cities in 11 different European 
countries, samples of wastewater from wastewater treatment plants (WWTPs) serving 
a total of over 24 million people were analysed permitting the monitoring of 
consumption patterns of cocaine, amphetamine, methamphetamine, cannabis and 
MDMA with cocaine found in almost every city investigated while the consumption 
of other drugs of abuse varied in different European regions (Ort et al. 2014). Another 
example is represented by the study carried out by Castrignanò et al. in 2018 in which 
enantiomeric profiling of chiral illicit drugs in wastewater serving 4.9 million people 
in eight European cities was undertaken to verify potency of drugs use and to estimate 
the extent of consumption vs direct disposal of unused drugs to the sewerage system 
(Castrignanò et al. 2018).  
The key concept of this approach is that human biotransformation products of both 
endogenous or exogenous compounds resulting from exposure to xenobiotic agents 
such as drugs, food toxicants and pollutants are collected and pooled by the wastewater 





exposure for the population (Fig. 1). As WWTPs serve well-defined populations (in 
terms of numbers), estimation of exposure to chemicals (e.g. drug consumption) in a 
given period can be made based on analysis of wastewater (usually with sensitive and 
selective mass spectrometry techniques) after taking into account human metabolism 
patterns (and possible transformation in WWTPs) of target analytes. Earlier work with 
therapeutic drugs has demonstrated the close correspondence between the known 
amounts consumed by the population and the amounts estimated from concentrations 
of metabolic drug residues in wastewater (Heberer and Feldmann 2005; Kasprzyk-
Hordern et al. 2009) or in surface waters (ter Laak et al. 2010).  
Table 2.1 gathers examples of WBE application in public health and lifestyle 
assessment. For example, Ryu et al. (Ryu et al. 2016b)  reported a Europe-wide 
monitoring of an oxidative stress biomarker, 8-iso-PGF2α and found that increased 
levels of 8-iso-PGF2α were observed at the inner-city level correlating with the degree 
of urbanization and levels of nicotine use. Rousis et al. (Rousis et al. 2017b) studied 
community-wide exposure to pyrethroid pesticides in Italian cities. Gracia Lor et al. 
(Gracia-Lor et al. 2017) undertook Europe-wide profiling of caffeine use. Lopardo et 
al. (Lopardo et al. 2017) identified new biomarkers of internal exposure to endocrine 
disruptors. González-Mariño et al. (González-Mariño et al. 2017) investigated 
community-wide exposure to phthalate plasticizers in Spain.  
Table 2.1 WBE for public health and lifestyle assessment 
Compounds Biomarker 
Health status - 
comments 
References 
Illicit and abused drugs 
 




(Andrés-Costa et al. 
2017; Castrignanò et 
al. 2017, 2018; Jones 
et al. 2014; Kasprzyk-
Hordern et al. 2008; 






(Reid et al. 2011; Ryu 






(Gracia-Lor et al. 











(Lai et al. 2017; Ryu 
et al. 2016b) 
Pharmaceuticals 
Specific pharmaceuticals 




al. 2016; Jones et al. 
2014; Kasprzyk-
Hordern et al. 2008; 
Petrie et al. 2015) 
Endocrine disruptors Urinary metabolites Health  
(Lopardo et al. 2017, 
2018) 
Pesticides 




(Rousis et al. 2016, 
2017a, 2017b) 
Phthalates Urinary metabolites Health 
(González-Mariño et 
al. 2017) 
Oxidative stress 8-iso-prostaglandin F2alpha Health (Ryu et al. 2015) 
Cancer mtDNA Health (Yang et al. 2017) 
 
 
2.3.2 WBE as epidemiology tool for human exposure assessment from EDCs in 
household products 
EDCs are exogenous chemicals with the potential to interfere with the hormonal 
regulation, hence with the endocrine system, consequently affecting health and 
reproduction in animals and humans. In addition to developmental and reproductive 
effects, their potential for contributing to metabolic disorders such as obesity is 
drawing more and more attention (Casals-Casas and Desvergne 2011). In the recent 
EU document ‘State of the art assessment of endocrine disrupters’ (Kortenkamp et al. 
2011) there is an urgent call for new approaches to establish further evidence for 
humans’ exposure to EDCs, especially those chemicals which are still not regulated 
(such as many suspected EDCs in personal care and consumer products). Regulatory 
decisions about endocrine disruptors will have to rely on weight-of-evidence 
procedures which are yet to be established (Kortenkamp et al. 2011). It is therefore 
important to develop new tools which will allow for long term real-time monitoring 
of collective community-wide exposure to and effects from EDCs.  
WBE has a potential to overcome some of the above difficulties and is able to assess 





allow for an evaluation of the relevance between exposure and effects due to the 
utilisation of both biomarkers of exposure (EDCs and their characteristic metabolites) 
and biomarkers of effects (e.g. DNA or protein adducts, gene mutations).  
Exposure assessment can be undertaken through the analysis of both parent EDCs and 
their metabolites in wastewater and in the environment. There are several points of 
verification. For example, the presence of characteristic metabolites in wastewater is 
an indication that EDCs have found their way into the body (internal exposure 
resulting from e.g. consumption of EDCs with food, accidental ingestion due to EDCs 
absorbed onto indoor dust, or absorption through skin of EDCs used in PCPs) (Fig 1).  
The EDCs to which we are exposed to in our households are chemicals in personal 
care and consumer products, high volume environmental stressors with suspected or 
proven endocrine disruption actions (and with environmental fate and toxicological 
effects requiring additional study and evaluation). The list includes (but is not limited 
to) several man-made chemicals: plasticizers (e.g. phthalates, bisphenol A), UV filters 
(e.g. 4-methyl benzylidene camphor, octocrylene), surfactants (e.g. alkyphenols), 
preservatives (e.g. parabens), pesticides (e.g. vinclozolin); fragrances (e.g. musks), 
flame retardants (e.g. tetrabromobisphenol A), antimicrobials (e.g. triclosan and 
trichlorocarban). For most of these compounds, mainly non-regulated pollutants, there 
is no epidemiological exposure data (e.g. parabens (Kortenkamp et al. 2011)). 
2.3.3 Metabolic biomarker section critical to public exposure estimation via 
water fingerprinting 
The crucial step in the evaluation of public exposure to chemicals via WBE is the 
selection of suitable biomarkers of exposure, which must meet several sets of criteria. 
Gracia-Lor et al. highlighted the main requirements of a biomarker of exposure (i.e. 
high excretion rate in urine, detectability and stability in wastewater (Gracia-Lor et al. 
2016)), which allow the distinction between internal exposure and direct disposal since 
many sources contribute to chemicals discharged into wastewater (Figure 2.1). As 
opposed to many compounds listed in Table 2.1, the EDCs investigated in this study 
are not meant for human consumption, hence, over the past years there has been little 
interest in their human metabolism patterns. Lack of characteristic metabolic 
biomarkers of EDCs evidencing internal exposure translates to major difficulties when 





presented in Table S 2.1. However, given their extensive use in personal care and 
consumer products direct dermal exposure (amongst others) cannot be neglected and 
a deeper understanding of toxicokinetic processes (i.e. metabolism) is critical. An 
example of a work aiming to aid the identification of metabolic biomarkers of 
exposure to EDCs is the study carried out by Lopardo et al. (Lopardo et al. 2017). In 
this study a new analytical framework based on combining in vitro techniques with 
urine and wastewater analysis was developed (Figure 2.1). The observation of specific 
human metabolites (identified after in vitro experiments) of the antimicrobial 4-
chloro-3-methylphenol in urine and wastewater proved that there is a critical need for 
expanding the list of biomarkers of exposure as the exposure to chemicals not intended 
for human consumption needs to be re-evaluated.  In another study by Lopardo et al. 
(Lopardo et al. 2018) eight additional EDCs with unknown metabolic pathways 
(benzophenone-1 (BP-1); benzophenone-2 (BP-2); 4,4’-dihydroxybenzophenone 
(4,4’-DHBP); 4-benzylphenol (4-BenzPh); homosalate (HO); octocrylene (OC); 3-
benzylidene camphor (3-BC); ethylhexylmethoxycinnamate (EHMC)) and two EDCs 
with known metabolism (bisphenol A (BPA) and benzophenone-3 (BP-3)) were 
tested.  As a result of this study five metabolic biomarkers were identified (2-hydroxy-
benzoic acid, 2-cyano-3,3-diphenyl-2-propenoic acid, 4-benzyl phenol sulphate, 4-
benzyl phenol hydroxylated and sulphated and 4-benzylphenol-bi-hydroxylated and 
sulphated). The presence of metabolic biotransformation products of studied UV 
filters was confirmed in wastewater and this provides evidence for internal exposure 
of studied populations to these chemicals and needs to be investigated further. 
This is the first study aimed to estimate community-wide exposure to BPA (including 
BPA intake) using wastewater fingerprinting. This study covers a large geographical 
area of 2,000 km2 (including several rural and urban settlement) and a population of 















































 Experimental section 
2.4.1 Materials and chemicals 
Bisphenol A sulphate (BPA sulphate, CAS 847696-37-1) was purchased from Toronto 
Research chemicals (TRC, Canada) (Table S 2.2). The internal standard used was: 4-
chloro-3-methylphenol-d2 (QMX (UK)). Water was purified using a Milli-Q 
purification system from Millipore (Nottingham, UK). Methanol, formic acid (>95 
%), HCl (concentrated), 1M NaOH, 1M NH4OH, NH4F, 2-propanol and bisphenol A 
(BPA) were purchased from Sigma (UK) and Fisher (UK). All solvents used were of 
LC grade or higher. All the glassware was deactivated using 5 % DMDCS (Sigma, 
UK) to prevent losses from analyte adsorption. The deactivation procedure consisted 
of washing the glassware once with 5 % DMDCS followed by two washes with 
toluene and lastly three washes with methanol. 
2.4.2 Sampling and sample collection 
Wastewater (untreated, after physical screening) was collected between June and 
October 2015 from 5 major WWTPs contributing to one river catchment in the South-
West UK and covering an area of approximately 2,000 km2 and the population of ~1.5 
million (this constitutes >75% of the overall population in the catchment).  
Wastewater was collected on 7 consecutive at each WWTPs as volume proportional 
24 h composites with sample collection frequencies of 10 min using ISCO 3700 
portable samplers packed with ice (RS Hydro, Worcestershire, UK) (Petrie et al. 
2015). All samples were transported to the laboratory on ice for further processing.  
Grab samples of digested sludge were also collected at one of the sites (Site E) which 
had anaerobic digestion facilities.   
2.4.3 Biomarker stability in wastewater 
Biomarker stability in wastewater was performed in PVC bottles in aerobic conditions. 
Two wastewater aliquots were investigated in duplicate (4° and 17°) to simulate 
respectively sampler and room temperature. Change in concentration was monitored 
over 24 h which is the maximum period of time a sample can remain in the sampler 
awaiting for collection. Samples (100 mL each) were taken at the following interval 





2.4.4 Sample preparation and analysis 
Liquid samples were filtered using GF/F glass microfibre filter 0.75 µm (Fisher 
Scientific, UK) and solid phase extraction (SPE) was performed using Oasis HLB 
(Waters, UK) according to the procedure described elsewhere (Lopardo et al.(Lopardo 
et al.)). Briefly 100 mL of filtered wastewater were loaded onto HLB cartridges which 
were preconditioned with 2 mL of MeOH followed by 2 mL of H2O. After loading the 
cartridges were dried for 30 minutes and analytes were eluted with 4 mL of MeOH. 
Extracts were dried using a TurboVap evaporator (Caliper, UK) under a gentle 
nitrogen stream in a water bath at 40°C then reconstituted in 250 µL 80:20 
H2O:MeOH. The SPE extraction recovery was evaluated at two different 
concentrations in duplicate using the following equation: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑖𝑒𝑠 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =
(𝐴𝑠𝑝𝑖𝑘𝑒𝑑 𝑏𝑒𝑓𝑜𝑟𝑒 𝑆𝑃𝐸 − 𝐴𝑏𝑙𝑎𝑛𝑘)
(𝐴𝑚𝑜𝑏𝑖𝑙𝑒 𝑝ℎ𝑎𝑠𝑒)
∗ 100 
SPE recoveries were calculated as corrected recoveries (i.e. taking the internal 
standard concentration into consideration) by the ratio of the concentration of target 
analytes in wastewater solutions when spiked before SPE (minus the concentration of 
analyte in the blank wastewater sample), divided by the standard mobile phase 
concentration.  
Digested sludge samples were treated by using microwave assisted extraction (MAE) 
as described by Petrie et al (Petrie et al. 2015). Briefly samples were frozen, freeze-
dried and 0.5 g samples were spiked with 50 ng of 4-chloro-3-methylphenol-D2.  
Extraction was achieved by heating the samples at 110 ºC using a 800 W MARS 6 
microwave (CEM, UK) and 25 mL of 50:50 MeOH:H2O (pH 2).  MAE methanolic 
extracts were adjusted to <5 % of MeOH using H2O (pH 2).  SPE was performed using 
Oasis MCX cartridges (Waters, UK) conditioned with 2 mL MeOH followed by 2 mL 
H2O (pH 2).  Samples were loaded and dried as described previously.  Elution was 
performed using 2 mL 0.6 % HCOOH in MeOH.  Once dried extracts were 
reconstituted in 500 µL 80:20 H2O:MeOH and filtered using pre-LCMS 0.2 μm PTFE 
filters (Whatman, Puradisc).  Finally samples were analysed using Dionex Ultimate 
3000 HPLC coupled with a Bruker Maxis HD Q-TOF according to (Lopardo et al. 
(Lopardo et al.)).  Briefly, a multi-step gradient was used to separate the analytes at a 





using mobile phase A (1 mM ammonium fluoride in water) and mobile phase B 
(methanol). The mass spectrometer was equipped with an ESI source and was operated 
in both positive and negative ionisation mode. The source settings were as follows: 
capillary voltage was set at 4.5 kV, the end plate offset was set to 500 V, a pressure of 
3 Bar was used for the nebulizer gas, the drying gas (nitrogen) flow was 11 L min-1 
and the drying temperature was set at 220°C. Analysis was run in both full scan mode 
(MS) and broadband collision induced dissociation (bbCID) mode. Calibrant solution 
was injected before each run. Quality control samples were run every 10 samples and 
blanks were run every 3 injections. For details see Lopardo et al. (Lopardo et al.) and 
Table S 2.3. 
2.4.5 Method performance 
Linearity was established by triplicate injection of a 13-point calibration curve ranging 
in concentration from 0.01 to 100 ng mL-1. Instrumental detection limits (IDLs) and 
instrument quantitation limits (IQLs) were calculated according to the lowest 
concentration which gave a signal to noise ratio of ≥ 3 and ≥ 10 respectively. Recovery 
of target chemicals was determined by spiking crude wastewater at a concentration of 
4 and 50 ng L-1. BPA and BPA sulphate validation parameters are listed in Table S 2.4 
and S 2.5. 
2.4.6 Daily mass loads and BPA intake 
Daily mass loads of BPA were calculated by multiplying the concentrations (ng L-1) 
found in a 24 h pooled raw wastewater sample by the daily wastewater flow rate (m3 
day-1). Total BPA concentrations in raw wastewater were calculated taking into 
account both the amount of BPA absorbed onto solid particulate matter (SPM) and the 
amount dissolved into liquid fraction. Mass loads (mg day-1) were then normalized to 
the number of people served by each WWTP (mg/ day/1000 inhabitants), in order to 
compare results between different WWTPs. Population-wide BPA intakes were 
calculated using the following equation: 
𝐵𝑃𝐴𝑖𝑛𝑡𝑎𝑘𝑒 =
(𝑐𝑜𝑛𝑐. 𝑥 𝑉)𝑥 𝐶𝐹
𝑃
 
where: conc. is the concentration of BPA sulphate (ng/mL) in influent wastewater, V 
is the volume of wastewater received by the WWTP per day (m3/day), P stands for the 





et al. (Zuccato et al. 2008a) to estimate populations drug abuse and later by Rousis et 
al. (Rousis et al. 2017a) to evaluate population intake of pesticides.  CF was calculated 
taking into account the molecular mass ratio between BPA and BPA sulphate and BPA 
sulphate excretion ratio. There are published studies that investigated the presence of 
BPA sulphate in urine. Ye et al. (Ye et al. 2005) found that BPA sulphate represented 
21% of BPA metabolites in urine (n=30). Ho et al. (Ho et al. 2017) analysed  140 urine 
samples finding that BPA sulphate represented 6.25 % of BPA metabolites. Thayer et 
al. (Thayer et al. 2015) instead observed that only 3% of the total BPA-d6 ingested by 
14 volunteers was excreted in urine as BPA sulphate and that the totality of BPA-d6 
was excreted within 24h from consumption. CF for BPA sulphate was therefore 
calculated as 0.161, using 8.41% as BPA sulphate excretion factor (weighed mean of 
the percentage of BPA sulphated excreted against the number of urine samples in the 



















 Results and discussion 
2.5.1 BPA sulphate as a biomarker of BPA intake 
Bisphenol A is one of the most extensively studied contaminants  because of its 
ubiquity and its suspected endocrine disrupting activity (Joint Fao Oms Expert 
Committee On Food Additives 2010; Rochester 2013). Because of its toxicity the 
EFSA (European Food Safety Agency) has temporary lowered the tolerable daily 
intake (TDI) from 50 g kg-1 day-1 to 4g kg-1 day-1 until the outcome of a long-term 
study will help reducing uncertainties about potential health effects (European Food 
Safety Authority (EFSA) 2015a). Even though BPA is not intentionally added as 
ingredient to personal care products or in the food production process, its presence 
might be due to migration from polycarbonate containers, epoxy resins coating or to 
the degradation of the BPA-containing material (Hartle et al. 2016; Poustka et al. 
2007). Geens et al. (Geens et al. 2012) summarised all the dietary (generally 
considered to be the main source of BPA) and non-dietary exposure (e.g. dust, thermal 
paper, dental materials, etc.) (Vandenberg et al. 2007). Christensen et al. (Christensen 
et al. 2012) concluded that the non-dietary exposure to be one-third of the cohort 
median exposure. Up to date the extent of the exposure to BPA is generally assessed 
using two approaches. The first one entails the monitoring of concentrations of 
contaminants in exposure media with exposure media contact rates (Lu et al. 2018). 
Interestingly the European Union (Aschberger et al. 2010) and EFSA (European Food 
Safety Authority (EFSA) 2015b) found the dietary intake to vary significantly with 
age, indicating major exposure risk for infants (up to 13 g kg-1 day-1) and 1.5 g kg-
1 day-1 for adults. The second approach relies on human biomonitoring. This approach 
measures the concentration of BPA and metabolites in biological fluids to back-
calculate the overall exposure including both known and unknown sources (Dekant 
and Völkel 2008).  
In this study BPA sulphate was selected as a biomarker of exposure to BPA and BPA 
loads were monitored alongside. In our previous work (Lopardo et al. (Lopardo et al. 
2018)), BPA sulphate was selected as a characteristic metabolic biomarker of human 
internal exposure to BPA. Research undertaken in this paper confirmed its high 





2.5.2 Estimation of public BPA intake via wastewater fingerprinting 
BPA and BPA sulphate were identified and quantified (Table S 2.6) in all samples 
collected from 5 major wastewater treatment plants contributing to a large river 
catchment in the South-West UK and covering an area of approximately 2,000 km2 
and the population of ~1.5 million (this constitutes >75% of the overall population in 
the catchment). BPA sulphate was found at higher concentrations than parent BPA, 
possibly due to higher hydrophobicity and sorption potential to SPM in the case of 
BPA(Petrie et al. 2019). Its concentrations ranged from 0.7 to 6 µg L-1 for WWTPs A, 
C and D and from 3 to 120 µg L-1 for WWTPs B and E. BPA was found at much lower 
concentrations than its metabolite with an exception of WWTP E. Concentrations of 
BPA ranged from 0.5 to 0.9 µg L-1 in WWTPs A and C, while in WWTPs B, D and E 
they ranged from 1.3 to 51 µg L-1 with the highest concentrations recorded in WWTP 
E being circa 100 µg L-1. Recorded SPM concentrations ranged from 0.03 to 0.27 µg 
L-1 in WWTPs A, C and D while in WWTPs B, and E they ranged from 0.1 to 7.7 µg 
L-1 with the highest concentrations recorded in WWTP E being circa 15 µg L-1.  
Analysis of the liquid fraction of activated sludge and digested sludge revealed that 
only a minor fraction of BPA sulphate adsorbs onto solid matter (< 7%). That was 
expected given the greater hydrophilicity of BPA sulphate compared to BPA.   
Due to sampling being conducted in WWTPs located in 5 different geographical 
locations within the same river catchment, considerable spatial variability in daily 
BPA and BPA sulphate loads could be observed and because sampling at each WWTP 
was operated over 7 consecutive days (Wednesday to Tuesday) it was possible to 
gather information about both spatial and temporal variability for a full week. BPA 
loads ranged from 180 to 600 mg day-1 per 1000 inhabitants at WWTPs A, C and D. 
At WWTP E, BPA loads were on average two orders of magnitude greater but on 
weekends lower loads were registered. WWTP B showed the greatest variability with 
BPA loads ranging from 500 to 7000 mg day-1 per 1000 inhabitants (Figure 3). These 
loads correspond to concentrations of BPA in wastewater up to 100 g L-1 which is 
considerably more than what is generally observed since BPA can be usually found in 
urban wastewater at concentrations around 1 g L-1 (Gatidou et al. 2007; Lopardo et 
al.; Petrie et al. 2015). The reason why such high concentrations of BPA were observed 





et al. (Petrie et al. 2018). Higher BPA loads were in fact observed downstream from a 
paper producing plant from Fuerhacker in 2003 (Fuerhacker 2003). Interestingly, the 
high load of BPA at WWTP E did not correspond with high loads of BPA sulphate 
(Figure 2.2). These loads correspond to concentrations of BPA in wastewater up to 
120 g L-1 which is considerably more than what is generally observed since BPA can 
be usually found in urban wastewater at concentrations around 1000 ng L-1 (Gatidou 
et al. 2007; Lopardo et al.; Petrie et al. 2015). The reason why such high concentrations 
were observed at WWTPs B and D might be industrial wastewater contribution. 
Higher BPA loads were in fact observed downstream a paper producing plant from 
Fuerhacker in 2003 (Fuerhacker 2003). In fact, two high loads of BPA did not 
correspond high loads of BPA sulphate (see WWTP D, Figure 2.4). Average BPA 
sulphate loads ranged instead at WWTPs A, C and E from 469 to 682 mg day-1 per 
1000 inhabitants (Figure 2.2) whereas average loads at WWTPs B and D were an order 
of magnitude greater (from 4633 to 5347 mg/day per 1000 inhabitants, Figure 2.2). 
Temporal variability (calculated as RSD %) below 40 % was observed at WWTPs A 
and D (Figure 2.2). This showed BPA sulphate loads here were relatively consistent 
supporting the hypothesis that population exposure pattern is also relatively consistent 
throughout the week. On the other hand, BPA sulphate loads variability was higher at 
other WWTPs (ranging from 50 to 131 %), indicating generally lower exposure during 
weekends compared to weekdays (Figure 2.2). In particular at WWTPs D and E loads 
were registered to be 6 to 7 times lower on Saturdays and Sundays compared to 
Mondays to Thursdays. WWTP B showed the greatest variability due to loads being 






Figure 2.2 Temporal variability of BPA and BPA sulphate influent wastewater loads 
(left) and estimated BPA daily intake (right) during 7 consecutive days in the 5 
WWTPs investigated namely A, B, C, D and E serving a population of respectively 

















2.5.3 Estimation of public BPA intake via wastewater fingerprinting  
Community-wide BPA intake (internal exposure) was estimated using the WBE 
(wastewater-based epidemiology) approach as described in section 2.5. Calculated 
loads of BPA sulphate at WWTPs A, C and E corresponded to an estimated BPA 
intake (Figure 2.2) which was consistently below TDI level set by EFSA (at 4g kg-
1 day-1) suggesting overall low exposure. On the other hand, WWTPs B and D were 
characterised by higher loads corresponding to higher intakes that were above the TDI 
threshold for several days during the sampling period. WWTP B results indicate that 
accidental release of BPA linked with elevated exposure occurred on or just before 
Wednesday. On the other hand, WWTP D shows overall high exposure. Further work 
will need to be undertaken in this particular location to verify possible BPA exposure 
patterns, as well as to fully understand sources of BPA sulphate that might be 
contributing to the biomarker concentration levels in the studied catchment. 
It is also interesting to note that characteristic temporal variations of BPA intake are 
observed in all studied WWTPs with the lowest intake occurring during weekends and 
the highest during weekdays. This is an important observation indicating that public 
exposure to BPA is much higher during working days. There are several possible 
reasons for this including healthier diet during weekends vs higher exposure of 
workers in industrial settings during weekdays. 
 
Figure 2.3 Comparison between weekly average BPA and BPA sulphate loads in the 








































2.5.4 Cumulative BPA loads versus daily BPA intake 
Comparison of population normalised daily BPA and BPA sulphate loads revealed 
that the presence of BPA in wastewater allowing for estimation of community wide 
external BPA exposure is not indicative of its actual intake. As can be seen in Figure 
2.3, BPA loads in WWTP B and E are higher due to possible industrial contribution.  
On the other hand, WWTPs B and D have the highest loads of BPA sulphate 
























This study provided comprehensive spatiotemporal community-wide exposure to 
BPA (including BPA intake) using wastewater fingerprinting applied to a large 
geographical area of 2,000 km2 and a population of ~1.5 million accounting for >75% 
of the overall population in the studied catchment.  Community-wide BPA intake was 
found to be consistently below TDI level set by EFSA (at 4g kg-1 day-1) suggesting 
overall low exposure in most locations. However, at two WWTPs, higher BPA 
sulphate loads corresponding to higher intakes that were above the TDI threshold were 
observed. Characteristic temporal variations of BPA intake were observed in most 
studied WWTPs with the lowest intake occurring during weekends and the highest 
during weekdays. This is an important observation indicating that public exposure to 
BPA is much higher during working days. There are several possible reasons for this 
including healthier diet during weekends vs higher exposure of workers in industrial 
settings during weekdays. Further work will need to be undertaken to fully understand 
sources of BPA and BPA sulphate that might be contributing to the biomarker 
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Classification: Hazard 
Class and Category 
Code(s): Aquatic 
Acute 1, Aquatic 
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and food dyes  
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#51:15 (31 Jul 2008). 
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Release and Transfer 
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Category Code(s): 
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PFOA-related 
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(EC) No 1907/2006 is 
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accordance with the 
Annex to this 
Regulation. The 
measures provided for 
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Table S 2.2 General information about BPA sulphate 
 
Table S 2.3 UHPLC-QTOF parameters used in the determination of BPA and BPA 
sulphate 
 
Table S 2.4 UHPLC-QTOF instrument performance parameters 





















1.39 - 103.4 0.9972 98.3 2.1 0.41 1.39 
*concentration levels: 0.1, 5 and 100 ng/mL used for precision and accuracy 
 
Table S 2.5 SPE-UHPLC-QTOF method performance parameters 
Analyte Wastewater  






BPA 100.4±2.6 0.003 0.007 
BPA sulphate 63.7±6.3 0.016 0.055 
* based on duplicate extractions at two concentration levels 
 
Chemical CAS number Molecular 
Weight 
Formula Structure 
Bisphenol A 80-05-7 228.3 C15H16O2 
 
Bisphenol A sulphate 
 
847696-37-1 308.1 C15H16O5S 
 







SRM transition Fragment Structure 
Bisphenol A 










Table S 2.6 BPA and BPA sulphate concentrations in wastewater 
Analyte Concentration [ng L-1] 















Figure S 2.1 Main requirements of biomarkers modified from [31] 
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Molecular epidemiology approaches in human biomonitoring are powerful tools that 
allow for verification of public exposure to chemical substances. Unfortunately, due 
to logistical difficulties and high cost, they tend to evaluate small study groups and as 
a result might not provide comprehensive large-scale community-wide exposure data. 
Urban water fingerprinting provides a timely alternative to traditional approaches. It 
can revolutionise the human exposure studies as urban water represents collective 
community-wide exposure. Knowledge of characteristic biomarkers of exposure to 
specific chemicals is key to the successful application of water fingerprinting. This 
study aims to introduce a novel conceptual analytical framework for identification of 
biomarkers of public exposure to chemicals via combined human metabolism and 
urban water fingerprinting assay. This framework consists of: Step 1 - In vitro 
HLM/S9 assay; Step 2 – In vivo pooled urine assay; Step 3 - In vivo wastewater 
fingerprinting assay; Step 4 - Analysis with HR-MSMS; Step 5 - Data processing and 
Step 6 - Selection of biomarkers. The framework was applied and validated for PCMC 
(4-chloro-m-cresol), household derived antimicrobial agent with no known exposure 
and human metabolism data. Four new metabolites of PCMC (hydroxylated, 
sulphated/hydroxylated, sulphated PCMC and PCMC glucuronide) were identified 
using the in vitro HLM/S9 assay. But only one metabolite, sulphated PCMC, was 
confirmed in wastewater and in urine. Therefore, our study confirms that water 
fingerprinting is a promising tool for biomarker selection and that in vitro HLM/S9 
studies alone, although informative, do not provide high accuracy results. Our work 












3.3.1 Antimicrobials in personal care products and public exposure  
Antimicrobials are extensively used as additives in a broad range of personal care and 
consumer products to preserve the integrity of the products against biological agents, 
although their effectiveness against the potential hazard has been questioned(Aiello et 
al. 2007). In particular, antimicrobials are added to soaps, cosmetics and disinfectants 
to protect against the growth of microorganisms, including bacteria, viruses and fungi. 
Some of these chemicals, their metabolites and/or their degradation products have 
been reported to be potentially bioaccumulative(Dhillon et al. 2015), endocrine 
disrupting(Ahn et al. 2008), ecotoxic in aquatic ecosystems(Rostkowski et al. 2011) 
and leading to microbial resistance(Aiello et al. 2005; Gautam et al. 2014). However 
very little is known about actual human exposure to antimicrobials in personal care 
products and therefore about the possibility to cause long term health effects. Even 
though available information concerning the percutaneous absorption of 
antimicrobials in humans is still scarce, it is known that some of them can be absorbed 
through the skin(Moss et al. 2000), suggesting that exposure results mostly from 
topical application of personal care products. However, ingestion of contaminated 
food and water (Loraine and Pettigrove 2006; Wu et al. 2013) and inhalation of indoor 
dust(Geens et al. 2009) represent other important indirect/environmental sources of 
exposure. Antimicrobials can be metabolised in humans followed by excretion of 
parent compound and their metabolites primarily with urine. Because the presence of 
those compounds in blood, serum and urine has been demonstrated(Allmyr et al. 2008; 
Asimakopoulos et al. 2014; Heffernan et al. 2015; Wu et al. 2010; Ye et al. 2011) and 
their environmental persistence and widespread use documented, it is unsurprising that 
they can be found in wastewater and in the receiving environment(Coogan and La 
Point 2008; Kumar et al. 2014). Their omnipresence, potential for bioaccumulation 
and possible synergistic effects of mixtures  have raised public concern regarding their 
possible effects on human health as well as their role in the development of 
antimicrobial resistance(Yazdankhah et al. 2006). There is therefore the need to 
consider a greater range of factors contributing to potential health effects of combined 
exposures within the risk assessment process. Risk assessment of mixtures is known 
to be difficult due to complexity of contributing factors when compared to the 





risk assessment and evaluation of public exposure to antimicrobial agents in personal 
care products are therefore critically needed. 
By comparing community levels of environmental stressors (both external and 
internal) with observed health effects, conclusions could be drawn as to whether 
elevated levels of certain chemicals could be linked with particular diseases. Such 
epidemiological studies are currently being undertaken via traditional approaches 
which use simple tools including case histories, questionnaires, or molecular 
epidemiology, which combines the above with sensitive laboratory techniques. These 
approaches monitor biological responses, rather than diseases in human populations 
through the usage of biomarkers(Chen et al. 2014). However, a limitation of molecular 
epidemiology, due to logistical difficulties and high cost, is the restricted size of study 
groups and inability to gather comprehensive information on the complexity of 
combined (and cumulative) exposure to mixtures of chemicals and their effects. 
Therefore the community lacks robust measures that can be used to gather real-time 
information on community-wide health.  
3.3.2 Urban water fingerprinting for human metabolic biomarkers - a new 
approach in epidemiological human exposure studies 
Urban water fingerprinting for human metabolic biomarkers is a new approach in 
epidemiological exposure studies that can revolutionise the way we estimate public 
exposure to chemicals. This approach is also known wastewater-based epidemiology 
(WBE). WBE is a new concept that aims to overcome the above limitations and to 
provide spatial and temporal near-real time estimation of community-wide exposure 
to wide range of chemicals. This unique approach assumes that epidemiological 
information can be retrieved from wastewater via the analysis of human metabolic 
biomarkers. Although still in its infancy, it is currently used to determine illicit drug 
use trends at the community level through the analysis of urinary biomarkers in 
wastewater(Baker et al. 2014; Daughton 2012a; Yang et al. 2016). This approach can 
be also extended to make a real time assessment of population health status(Reid and 
Thomas 2011). WBE postulates that specific human metabolic biomarkers (e.g. 
characteristic metabolites of toxicants or pollutants) excreted with urine and faeces, 
and resulting from exposure to certain chemicals, are pooled by the urban wastewater 





a population contributing to the analysed water, has been exposed. Urban water 
fingerprinting can therefore provide anonymous and comprehensive estimation of the 
community-wide health status in near-real time. 
 
3.3.3 Difficulties with identification of biomarkers of exposure in WBE 
The selection of unique metabolic biomarkers that are characteristic for each 
individual chemical and route of exposure is a critical step in order to verify public 
exposure to these chemicals via WBE, e.g. in order to distinguish between internal and 
external exposure, and to account for direct disposal, since many sources contribute to 
chemicals being discharged into wastewater. Unfortunately, in the case of many 
chemicals, especially those that are not intended for human consumption (e.g. 
antimicrobials), there is no public knowledge of characteristic metabolic biomarkers 
that could be utilised in WBE. Nevertheless, due to their extensive use in personal care 
and consumer products(Schebb et al. 2011) dermal absorption is considered to be one 
of the main routes of human exposure. Understanding toxicokinetic process, including 
metabolism, is therefore crucial in the determination of toxicological effects and 
potential for bioaccumulation of these chemicals, as well as in the identification of 
biomarkers of exposure. Still, there are only a few studies which reported their in vivo 
or in vitro biotransformation. Wu, Liu and Cai (2010)(Wu et al. 2010) investigated the 
metabolism of triclosan in vivo and in vitro. They observed both oxidative and phase 
II metabolites and identified glucuronidated triclosan as the major metabolite. Schebb 
et al. (2011)(Schebb et al. 2011) reported that the 0.6% circa of the amount of 
triclocarban present in bar soaps (70 ± 15 mg) was absorbed through the skin and that 
the 25% of total amount was excreted in urine almost exclusively as N-glucuronides. 
Unfortunately, most antimicrobials still remain hardly investigated.  
3.3.4 Objectives 
We are proposing a novel conceptual framework for identification of metabolic 
biomarkers via combined human metabolism and urban water fingerprinting assays. 
In this study, we identified, for the first time, human specific metabolites of the 
antimicrobial agent, 4-chloro-3-methylphenol (PCMC), as potential biomarkers of 
community-wide exposure to PCMC via WBE. This antimicrobial agent, also known 





estrogenic activity determined by an in vitro yeast bioassay(Miller et al. 2001). PCMC 
is also known to have an effect on Ca2+ homeostasis being a strong activator of the 
ryanodine receptors in the endoplasmic reticulum(Ortopedico et al.) and to interfere 
with the thyroid hormone functions(Ghisari and Bonefeld-Jorgensen 2009). To the 
authors’ knowledge, there is no published data on metabolic pathways of PCMC in 
humans.  
 Experimental section 
3.4.1 Reagents and analytical standards 
Pooled human liver microsomes (HLM), S9 fraction pooled from human liver, β-
nicotinamide adenine dinucleotide 2′-phosphate reduced (-NADPH ≥ 95%), Uridine 
5′-diphosphoglucuronic acid trisodium salt (UDPGA 98-100%), alamethicin from 
Trichoderma viride (≥ 98%), 3′-phosphoadenosine 5′-phosphosulphate lithium salt 
(PAPS ≥ 60%), 4-chloro-3-methylphenol (p-chlorocresol), potassium phosphate 
monobasic tetrasodium salt hydrate (KH2PO4), magnesium chloride hexahydrate 
(MgCl2), were purchased from Sigma-Aldrich (Gilligam,UK). The internal standard: 
4-chloro-3-methylphenol-2,6-d2, was purchased from QMX Laboratories Ltd.  
Solvents were of HPLC purity and were purchased from Sigma-Aldrich (Gilligam, 
UK). Stock standard solutions were prepared in methanol and stored in the dark at -
20°C. 24h volume-proportional (100 mL every 15 minutes) composite wastewater 
influent samples were collected in PTFE bottles from a local wastewater treatment 
plant (WWTP) serving 70000 inhabitants on the 8th of June 2015. They were then 
transported to the laboratory in cool boxes packed with ice blocks and filtered through 
GF/F 0.7 µm glass fibre filter (Whatman, UK).  
3.4.2 In vitro assays for verification of metabolic profile of PCMC in humans 
Two in vitro assays were selected in this study: HLM and combined HLM and S9 
fraction. Currently HLM represents the most commonly used in vitro model, providing 
an affordable way to give a good indication of the cytochrome P450 (CYP) and uridine 
5'-diphospho-glucuronosyltransferase (UGT) metabolic profile (Ballesteros-Gómez et 
al. 2014). Unfortunately, the absence of other enzymes such as N-acetyltransferase 
(NAT), glutathione S-transferase (GST) and sulphotransferase (ST) implies, as a 
result, an incomplete range of metabolites being formed. A valid alternative to the use 





fractions (phase I and phase II metabolic enzymes) that lead to the formation of a range 
of metabolites giving, as a result, more representative metabolic profile when 
compared to HLM only. However, the overall amount of metabolites formed is lower 
due to lower enzyme activity in the S9 fraction when compared to microsomes. This 
might result in minor metabolites to remain unnoticed(Brandon et al. 2003). Therefore, 
in this paper, method development included different subcellular fractions (HLM and 
a combination of HLM and S9 fraction). 
3.4.3 In vitro HLM assay for verification of metabolic profile of PCMC  
10 µL of a phosphate buffer (50mM KH2PO4, pH 7.4, 5mM MgCl2), 10 µL of analyte 
solution (50 µM) were mixed with 10 µL human liver microsomes spiked with 1 µL 
of an alamethicin solution 12.5 mg/mL and 10 µL of a 100µM UDPGA solution. The 
reaction was initiated by addition of 10 µL of a 10 mM NADPH solution followed by 
incubation at 37°C for 1.5 h. After 1.5 h of incubation 10 µL of a 100µM PAPS 
solution were added and the incubation continued under the same conditions for 1.5 
h. The negative controls with either no analyte or no HLM were incubated as described 
above to exclude all the non-enzymatic reactions. Each specific incubation was 
performed in duplicate. The reaction was quenched with 100 µL of acetonitrile ice 
cold, followed by centrifugation at 10000 rpm for 10 min (Centrifuge 5418, 
Eppendorf). The supernatant was removed and transferred to a new eppendorf tube 
and gently dried down by a stream of nitrogen at 40°C using TurboVap evaporator 
(Caliper, UK). The resulting residue was reconstituted with 50 µL of a 80:20 
H2O:MeOH solution containing the internal standard (100 ng/mLM) and transferred 
into a polypropylene vial for analysis.   
All analyses were undertaken using a Dionex Ultimate 3000 HPLC (Thermo Fisher 
UK Ltd.) coupled with a Bruker Maxis HD Q-TOF (Bruker) equipped with an 
electrospray ionization source. Nitrogen was used as nebulising gas at a flow rate of 
11 L/min at a temperature of 220°C and at a pressure of 3 Bar. Capillary voltage was 
set at 4500 V and End Plate offset was set at 500 V. The analyses were performed in 
both positive and negative modes and acquisition was performed in both full scan 
mode (MS) and broadband CID acquisition mode (MS/MS). HyStar™ Bruker was 
used to coordinate the LC-MS system. Chromatographic separation of the metabolites 





mm x 2.1 mm, 1.7 µm) and the following mobile phase composition: 1 mM 
ammonium fluoride in water (A) and methanol (B). The gradient elution both in ESI 
positive and negative mode was as follows: 5% B (0 -3 min) - 60% B (3 - 4 min) - 
60% B (4 -14 min), - 98% B (14 - 17 min) - 5% (17.1 - 20 min). The flow rate was 
kept constant at 0.4 ml/min and the column temperature was set at 40 °C. The source 
and operating parameters were optimized as follows: capillary voltage, 4500 V; dry 
gas temperature, 220 oC (N2); dry gas flow 12 L h
−1 (N2); quadrupole collision energy, 
4 eV; collision energy, 7 eV MS (full-scan analysis) and 20 eV MS/MS (bbCID mode).  
Nitrogen was used as the nebulising, desolvation and collision gas.  The method was 
fully quantitatively validated for PCMC (intra-day, accuracy 120.2%, precision 2.4%; 
inter-day, accuracy 120.2%, precision 3.5%; IQL, 22 ng/L; IDL, 6.6 ng/L; linearity 
range, 0.07-27.5 mg/mL; R2 0.9987; MDL, 0.013 ng/L; MQL, 0.045 ng/L).  
3.4.4 In vitro combined HLM/S9 fraction assay for verification of metabolic 
profile of PCMC  
Two incubation mixtures were prepared in duplicate by mixing 10 µL of phosphate 
buffer (50mM KH2PO4, pH 7.4, 5mM MgCl2), 10 µL of analyte solution (50µM), 10 
µL of the100µM UDPGA solution and 10 µL of HLM spiked with 1 µL of an 
alamethicin solution 12.5 mg/mL. The reaction was initiated by addition of 10 µL of 
a 10 mM NADPH solution followed by incubation at 37°C. The incubation was carried 
out for 3 h under the same conditions for three of the four samples. At 3 h 10 µL of S9 
fraction and 10 µL the 100µM PAPS solution were added to the samples to be 
incubated for six h and incubation was continued. The negative controls with either 
no analyte or no enzymes were prepared as well for each time point. After quenching 
the reaction with 100 µL of acetonitrile ice cold, samples were prepared for analysis 
as described above.  
3.4.5 In vivo pooled urine assay 
Seven pooled urine samples were collected from a UK festival event. They came from 
five different urinals sampled on three different days. Solid phase extraction (SPE) 
was performed on pooled urine samples using HLB Oasis® cartridges Water, UK) to 
reduce the matrix effect and to concentrate each sample by 4-fold. SPE procedure was 
as follows: 2 mL of pooled urine were loaded onto Oasis HLB cartridges, which were 





were dried for 30 min and analytes were eluted with 4 mL MeOH. Extracts were then 
dried under a gentle nitrogen stream using a TurboVap evaporator (Caliper, UK, 
40◦C). Dry extract was then reconstituted in 500 µL 80:20 H2O:MeOH, transferred to 
polypropylene vials and analysed using Dionex Ultimate 3000 HPLC coupled with a 
Bruker Maxis HD Q-TOF according to the procedure described above. 
3.4.6 Wastewater fingerprinting assay  
Raw wastewater samples collected from local wastewater treatment works, were 
filtered using GF/F glass microfibre filter 0.75 µm (Fisher Scientific, UK) followed 
by a solid phase extraction (SPE) using HLB Oasis® cartridges Water, UK) to reduce 
the matrix effect and to concentrate each sample by 400-fold. SPE procedure was as 
follows: 100 mL of filtered wastewater were loaded onto Oasis HLB cartridges, which 
were preconditioned with 2 mL MeOH followed by 2 mL H2O. After loading, the 
cartridges were dried for 30 min and analytes were eluted with 4 mL MeOH. Extracts 
were then dried under a gentle nitrogen stream using a TurboVap evaporator (Caliper, 
UK, 40◦C). Dry extract was then reconstituted in 250 µL 80:20 H2O:MeOH, 
transferred to polypropylene vials and analysed using Dionex Ultimate 3000 HPLC 
coupled with a Bruker Maxis HD Q-TOF according to the procedure described above. 
After analysis, data extracted from the Bruker system were processed with MetID 
software (Advanced Chemistry Development, Inc., ACD/Labs, UK) in order to predict 
metabolite structures. However, the software predicts a large number of possible 
metabolites, of which a rather small number is actually observed in in vitro 
experiments. We therefore developed a systematic workflow as presented in Figure 






Figure 3.1 A systematic workflow for verifying human exposure to chemicals via 
combined in-vitro HLM/S9 and in-vivo pooled urine and wastewater profiling assay 
 
 Results and discussion 
3.5.1 In vitro assays 
The in vitro metabolism of PCMC catalysed by CYP and SULT enzymes has been 
investigated using a combination of pooled HLM an S9 fraction tests. Hydroxylation 
of un-substituted carbon atoms was expected to be the major biotrasformation reaction 
catalysed by CYPs whilst conjugations with phase II cofactors were expected to be 
the major reactions catalysed by UGT and ST. Phase II conjugations were expected to 
occur directly or following mono- and/or di-hydroxylation phase-I biotransformations.   
3.5.2 In vitro HLM assay 
 After incubating PCMC with HLM a number of peaks were detected using LCMS. 
Initial analysis of samples, performed using ACDLabs software, identified two 
potential metabolites. A representative extracted ion chromatogram (XIC) of PCMC 
metabolites detected are reported in Figs. S3.1 and S3.2. All samples were analysed in 
negative and in positive ionisation modes. However, all the potential metabolites had 





Incubation of PCMC produced a metabolite (m/z 157.0057) with elemental 
composition of the deprotonated molecule denoting C7H6ClO- (-3.6 ppm mass error) 
and a second one (m/z 317.0422) with elemental composition of the deprotonated 
molecule denoting C13H14ClO7- (-3.8 ppm mass error). ACDLabs analysis led to 
their identification as mono-hydroxylated metabolite (Fig S3.1b) and glucuronide 
conjugated (Fig. S3.2b). PCMC hydroxylate did not provide a distinctive 
fragmentation pattern in bbCID mode which necessitated MS/MS analysis. 
Fragmentation of ions with m/z 157.0062 +/- 0.005 at 31 eV led to the formation of a 
fragment 121.0284 which corresponded with the loss of a chlorine moiety from the 
precursor ion (Fig. S3.1c). PCMC glucoronate instead produced in bbCID mode a 
fragment ion at m/z 141.0108 (C7H6ClO-, + 3.5 ppm mass error) that was assigned to 
[C6H8O6] loss, and was related to the presence of a glucuronate group (Fig. S3.2c, 
bottom). The fragments obtained confirmed the chemical structure of the metabolites. 
Additionally, two chlorine isotope peaks at m/z 158.0086 and m/z 159.0024 (Fig. 
S3.1d) and at m/z 318.0452 and m/z 319.0390 (Fig. S3.2d) were observed. The peaks 
had small mass errors (<5 ppm) and their relative heights match those expected from 
a compound with one chlorine within 5% of the predicted abundance.  
PCMC metabolites have not been previously documented in literature, therefore the 
results of this study are of considerate importance. However, sulphate metabolites that 
were initially thought to be suitable as a biomarker were not detected in the in-vitro 
HLM assay. This could be due to two main factors. Firstly, the incubation time may 
not have been sufficiently long to allow detectable amounts of metabolites to be 
formed, as well as also not allowing the higher number of metabolites to be produced. 
Secondly this could be due to the lack of phase II enzymes being used such as 
sulphotransferases, of which HLM are deficient. To account for this, HLM/S9 fraction 
assay was undertaken (see below). 
3.5.3 In vitro combined HLM/S9 fraction assay 
 The in vitro combined HLM/S9 fraction assay included verification of quantitative 
and qualitative changes of metabolic profile in two time intervals (3 and 6 h). 
Moreover, due to the addition of the S9 fraction to the incubation mixture, further 





incubation of PCMC with pooled HLM/S9 fraction produced two further metabolites: 
sulphated PCMC and mono-hydroxylated sulphated PCMC (Fig. 3.2 and S3.3).   
 
Figure 3.2 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS 
following in-vitro HLM/S9 assay. XICs at m/z 220.9681 and 141.0113 (0.005-Da 
mass-window width) for analyte-sample (b) and control-sample (a). (c) (top) Low-
energy (full-scan analysis) and (bottom) high-energy (bbCID mode) spectra and 
structures of the metabolite and fragment ion observed. (d) XIC at m/z 220.9684, 
221.9713 and 222.9653 for PCMC sulphate and the two chlorine isotope peaks (top) 
and mass spectra (bottom). 
 
It can be seen in Fig. 3.2 that the in vitro test leads to the formation of a metabolite 
with retention time denoting 6.4 min (Fig. 3.2b, dark peak). This chromatographic 
peak was absent in the blank control (Fig. 3.2a). Spectral analysis performed using 
ACDLabs software identified the compound to be a sulphated metabolite (m/z 
220.9684). Elemental composition of the deprotonated molecule of the sulphated 
metabolite was assigned as C7H6ClO4S- (+ 1.3 ppm mass error). The fragment ion at 
















related to the presence of a sulphate group (Fig. 3.2c, bottom). To further confirm that 
the fragment ion originates from the suspected metabolite its chromatogram was 
extracted. The resulting XIC produced a peak whose elution time matched perfectly 
with that of the suspected metabolite (Fig. 3.2b, light peak).  Additionally, the presence 
of two chlorine isotope peaks at m/z 221.9713 and m/z 222.9653 (Fig. 3.2d) was 
observed. The peaks had small mass errors <5 ppm and their relative heights match 
those expected from a compound with one chlorine within 5% of the predicted 
abundance.  
The in vitro HLM/S9 fraction assay led to the formation of another PCMC metabolite 
with retention time of 6.3 min (Fig S3.3b, dark peak). This is the same 
chromatographic peak that was absent in the blank control (Fig. S3.3a). Spectral 
analysis performed using ACDLabs software identified the compound to be the 
sulphated and hydroxylated metabolite (m/z 236.9632). Elemental composition of the 
deprotonated molecule of the metabolite was assigned as C7H6ClO5S- (+ 1.3 ppm 
mass error). The fragment ion at m/z 157.0065 (C7H6ClO2-, + 1.9 ppm mass error) 
was assigned to [O3S] loss, and was related, as previously, to the presence of a sulphate 
group (Fig. S3.3c, bottom). To further confirm that the fragment ion originates from 
the suspected metabolite its chromatogram was extracted. The resulting XIC produced 
a peak whose elution time matched perfectly with that of the suspected metabolite 
(Fig. S3.3b, light peak). Also, as above, two chlorine isotope peaks at m/z 237.9664 
and m/z 238.9601 (Fig. S3.3d) were observed. The peaks had small mass errors <5 
ppm and their relative heights matched those expected from a compound with one 
chlorine within 5% of the predicted abundance.  
Phase II cofactor (PAPS) was added after 3 h to the incubation mixture to permit all 
the possible phase I metabolites to form before conjugation with sulphate took place. 
This approach attempts to replicate what happens in a living cell, where generally (but 
not necessarily) phase I minor biotransformations occur in preparation for successive 
phase II conjugation. Results are summarised in Fig. S3.4. It can be seen from Fig. 
S3.4 that hydroxylated metabolites are preferentially formed after 3 h of incubation 
time (88.7% against 11.3% conjugation with glucuronic acid). The hydroxylated 
PCMC was still the most abundant biotransformation product (40% of the total 





point phase II metabolites accounted for 59.8% of all the metabolites produced. In 
particular amongst the three phase II biotransformation observed after 6 h direct 
sulphation seemed to be the preferential conjugation route accounting for more than 
25% of total biotransformation.  
In summary, both HLM and HLM-S9 fraction assays allowed for the identification of 
metabolites that have not been previously documented in literature, although the latter 
assay allowed the identification of a higher number of metabolites due to the addition 
of the S9 fraction resulting in a more efficient sulphation. Moreover a two-step 
approach, which entails the addition of phase II enzymes and sulphation cofactor after 
3 h permits the identification of all the phase I and II metabolites and conjugated 
metabolites, providing a wider range of biotransformation products. The formation of 
PCMC sulphate conjugates means also that a more efficient sulphate conjugation takes 
place in the HLM-S9 fraction assay, when compared to the HLM assay. All the 
identified metabolites are presented in Tab. 3.1. The table reports also elemental 
composition and the mass accuracy measured in the two in vitro assays and in a 








Figure 3.3 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS 
following in-vivo poled urine assay.  (a) XICs at m/z 220.9681 and 141.0113 (0.005-
Da mass-window width). (b) (top) Low-energy (full-scan analysis) and (bottom) high-
energy (bbCID mode) spectra and structures of the metabolite and fragment ion 
observed. (c) XIC at m/z 220.9670, 221.9698 and 222.9640 (0.005-Da mass-window 
width) for PCMC and the two chlorine isotope peaks (top) and mass spectra (bottom). 
 
3.5.4 In vivo pooled urine assay  
The in vivo pooled urine assay led to identification of only one metabolite of PCMC, 
sulphated PCMC (Tab. 3.1 and Fig. 3.3).  Interestingly, hydroxylated and 
glucuronidated metabolites were not observed in analysed pooled urine samples. This 
is in contrast with in vitro assays where glucuronidated, sulphated and hydroxylated 
metabolites were identified. 
3.5.5 In vivo wastewater fingerprinting assay  
The aim of the two in vitro assays was to select potential biomarkers of exposure to 
PCMC. However, as the ultimate goal of this study was to verify community-wide 
exposure to these chemicals, analysis of untreated wastewater samples serving large 
community of 70 thousand people was undertaken. The identification of 
biomarkers was based on the systematic workflow presented in Fig. 3.1. The 
compounds detected in wastewater are summarised in Tab. 3.1.  As expected, given 

















in in vitro studies but still within set limits, with mass error values between 5 and 10 
ppm (Tab. 3.1).  
Table 3.3.1 PCMC and their metabolic biomarkers. 
 
In vivo wastewater fingerprinting assay resulted in the detection and identification of 
only one metabolite of PCMC, sulphated PCMC, in wastewater (Fig. 3.4). The loss of 
[O3S] deduced by TOF MS spectra has been crucial for justifying and suggesting 
possible chemical structures. Interestingly, hydroxylated and glucuronidated PCMC 
were not observed in analysed wastewater samples. This is in line with results obtained 
for in vivo pooled urine assay and it confirms that in vitro studies, although 



























































































































































Figure 3.4 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS 
following in-vivo wastewater profiling assay.  (a) XICs at m/z 220.9681 and 141.0113 
(0.005-Da mass-window width). (b) (top) Low-energy (full-scan analysis) and 
(bottom) high-energy (bbCID mode) spectra and structures of the metabolite and 
fragment ion observed. (c) XIC at m/z 220.9695, 221.9724 and 222.9664 (0.005-Da 




























This study proved that combined human metabolism and wastewater fingerprinting 
assay is a powerful tool to investigate human exposure to chemicals present in personal 
care products and a wider-group of chemicals that are not intended for human 
consumption and therefore lack comprehensive risk assessment data. We have 
proposed a systematic workflow that enables fast and comprehensive selection of 
characteristic biomarkers of public exposure to chemical substances (Fig. 3.1). The 
workflow consists of several steps: Step 1: In vitro HLM/S9 assay; Step 2: In vivo 
pooled urine assay; Step 3: In vivo wastewater fingerprinting assay; Step 4: Analysis 
with HR-MSMS; Step 5: Data processing and Step 6: Selection of biomarkers. In Step 
4, after the establishment of a list of suspected metabolites using ACDLab software 
(Step 4a), in order to avoid false positives, their accurate mass, retention time and 
fragmentation pattern are examined (Step 4b,c,d). Finally the structure of the suspects 
is confirmed by investigating the MS/MS fragmentation pattern in bbCID mode (Step 
4e). For those metabolites that do not provide an optimal MS/MS fragmentation 
pattern in bbCID mode, a further confirmation step performing a data-dependent 
MS/MS acquisition is required (Step 4f), i.e. an MS/MS analysis is triggered if a 
compound from a target ion list is detected. In contrast to targeted screening, non-
target screening starts without any a priori information on the compounds to be 
detected. However, this study falls in between these two categories, since the 
chemically meaningful structures which can be assigned to an unknown peak are 
limited to structures showing a close relationship with the parent compound. 
Four new possible metabolites of PCMC (hydroxylated, glucuronidated, sulphated and 
hydroxylated & sulphated PCMC) were identified after in vitro HLM/S9 studies and 
were proposed as biomarkers of exposure. The absence of phase I metabolites in the 
presence of phase II cofactor PAPS suggested that sulphation was the preferential 
metabolic pathway for this compound. Only one of these metabolites (PCMC 
sulphated) was confirmed in wastewater and in urine suggesting human internal 
exposure to PCMC despite the fact that this compound is utilised in products meant 
for external use. Consequently to the results obtained in this present work it seems 
evident that the impact of the exposure to PCMC and other chemicals not intended for 





impact on the aquatic ecosystem its identified metabolite should be also investigated 
to verify their potential environmental impact. 
The aim of this paper was to introduce a new assay for identification of new metabolic 
biomarkers in WBE. Further work will be undertaken to verify utility of selected 
























The support of the Leverhulme Trust (Project No RPG-2013-297) is greatly 
appreciated. We would also like to acknowledge TICTAC Communications (St 
George’s University of London, United Kingdom) for provision of pooled urine 
samples. All data supporting this study are provided as supporting information 























 Supplementary material 
3.8.1 List of figures 
Figure S3.1 XIC of hydroxylated PCMC metabolite produced with HLM. XICs at m/z 
157.0062 (0.005-Da mass-window width) for analyte-sample (b), blank control (a), 
fragmentation pattern of the metabolite obtained in MRM mode (c) and XIC at m/z 
157.0049, 158.0079 and 159.0017 for PCMC and the two chlorine isotope peaks (top), 
and mass spectra (bottom). 
Figure S3.2 Detection and identification of PCMC glucuronate metabolite by 
UHPLC-QTOF-MS following in-vitro HLM assay (3 hour time point). XICs at m/z 
317.0422 and 141.0110 (0.005-Da mass-window width) for analyte-sample (b) and 
control-sample (a). (c) (top) Low-energy (full-scan analysis) and (bottom) high-energy 
(bbCID mode) spectra of the metabolite and fragment ion observed. (d) XIC at m/z 
317.0422, 318.0452 and 319.0390 for PCMC glucoronate and the two chlorine isotope 
peaks (top), and mass spectra (bottom). 
Figure S3.3 Detection and identification of sulphated and hydroxylated PCMC by 
UHPLC-QTOF-MS following in-vitro HLM/S9 assay. XICs at m/z 236.9630 and 
157.0062 (0.005-Da mass-window width) for analyte-sample (b) and control-sample 
(a). (c) (top) Low-energy (full-scan analysis) and (bottom) high-energy (bbCID mode) 
spectra and structures of the metabolite and fragment ion observed. (d) XIC at m/z 
236.9632, 237.9660 and 238.9601 for PCMC hydroxylate & sulphate and the two 
chlorine isotope peaks (top) and mass spectra (bottom). 
Figure S3.4 Distribution of PCMC metabolites obtained with in-vitro HLM and 
HLM/S9 fraction assay over a 3 and 6 h incubation time. 












Figure S3.1 XIC of hydroxylated PCMC metabolite produced with HLM. XICs at m/z 
157.0062 (0.005-Da mass-window width) for analyte-sample (b), blank control (a), 
fragmentation pattern of the metabolite obtained in MRM mode (c) and XIC at m/z 
157.0049, 158.0079 and 159.0017 for PCMC and the two chlorine isotope peaks (top), 









Figure S3.2 Detection and identification of PCMC glucuronate metabolite by 
UHPLC-QTOF- MS following in-vitro HLM assay (3 hour time point). XICs at m/z 
317.0422 and 141.0110 (0.005-Da mass-window width) for analyte-sample (b) and 
control-sample (a). (c) (top) Low- energy (full-scan analysis) and (bottom) high-
energy (bbCID mode) spectra of the metabolite and fragment ion observed. (d) XIC at 
m/z 317.0422, 318.0452 and 319.0390 for PCMC glucoronate and the two chlorine 







Figure S3.3 Detection and identification of sulphated and hydroxylated PCMC by 
UHPLC- QTOF-MS following in-vitro HLM/S9 assay. XICs at m/z 236.9630 and 
157.0062 (0.005-Da mass-window width) for analyte-sample (b) and control-sample 
(a). (c) (top) Low-energy (full- scan analysis) and (bottom) high-energy (bbCID mode) 
spectra and structures of the metabolite and fragment ion observed. (d) XIC at m/z 
236.9632, 237.9660 and 238.9601 for PCMC hydroxylate & sulphate and the two 







Figure S3.4 Distribution of PCMC metabolites obtained with in-vitro HLM and 
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This study aimed to identify human specific metabolites of selected known or 
suspected endocrine disruptors (EDCs), mainly UV filters, used in personal care and 
consumer products whose metabolism has hardly been explored and to select suitable 
candidate biomarkers for human exposure studies using wastewater-based 
epidemiology (WBE). The analysis of metabolic biomarkers of target chemicals is 
crucial in order to distinguish between internal and external exposure, since many 
sources contribute to chemicals being discharged into wastewater. This was achieved 
through the employment of a new analytical framework for verification of biomarkers 
of exposure to chemicals combining human biomonitoring and water fingerprinting. 
Eight EDCs with unknown metabolic pathways (benzophenone-1 (BP-1); 
benzophenone-2 (BP-2); 4,4’-dihydroxybenzophenone (4,4’-DHBP); 4-benzylphenol 
(4-BenzPh); homosalate (HO); octocrylene (OC); 3-benzylidene camphor (3-BC), and 
two EDCs with known metabolism (bisphenol A (BPA) and benzophenone-3 (BP-3)) 
were tested. The biotrasformation observed consisted mainly in phase I processes such 
as hydrolysis and hydroxylation together with phase II conjugation reactions such as 
sulphation and glucuronidation. Only two chemicals (BP-1, BP-3) were identified in 
urine and three chemicals (BPA, BP-1, BP-3) in wastewater. Five newly discovered 
metabolites (HO-Met1, OC-Met1, 4-BenzPh-Met4, 4-BenzPh-Met5 and 4-BenzPh-
Met6) and one previously known metabolite (BPA-Met3) were detected in tested 
urine/wastewater samples from five WWTPs serving large communities ranging 
between 17 and 100 thousand inhabitants. The presence of metabolic 
biotransformation products of OC, 4-BenzPh, BPA and HO in wastewater provides 












The last decades have seen a rapid increase in usage of personal care products and 
resultant public exposure to chemicals contained in those products (Calafat et al. 
2015). Although the level of exposure to many of these chemicals might be low, the 
risk associated with it cannot be underestimated since simultaneous exposure to 
undefined mixtures might result in a synergistic effect making a comprehensive risk 
assessment process more complex compared to the assessment of a single chemical 
(Silins and Högberg 2011). Long-term exposure leading to chronic effects should also 
not be underestimated. However very little is known about actual human exposure and 
therefore about the possibility to cause long term effects. UV filters are extensively 
used in a wide range of products including plastics, adhesives, rubber and personal 
care and consumer products including cosmetics, body lotions, hair sprays, skin 
creams, hair dyes or shampoos to preserve the integrity of the products (or skin, in the 
case of cosmetic sunscreens) from damage caused by the ultra-violet (UV) component 
of sunlight (particularly UVB, 290–320 nm).  Some of these chemicals, their 
metabolites and/or their degradation products have been reported to be potentially 
bioaccumulative (Environment Agency 2008), leading to endocrine disrupting 
effects(Krause et al. 2012; Zhao et al. 2013) and ecotoxicity in aquatic ecosystems 
(Díaz-Cruz and Barceló 2009; Fent et al. 2008; Kaiser et al. 2012). In particular 
homosalate (HO), ethylhexylmethoxycinnamate (EHMC), octocrylene (OC) and 
benzophenone-3 (BP-3, regulated in the EU and commonly used in personal care 
products in the UK (Kerr 2011)), have been demonstrated to exert endocrine disrupting 
effects in vitro and/or in vivo. According to Schlumpf et al. (Schlumpf et al. 2001) HO 
showed estrogenic effects in vitro (median effective concentration (EC50) at 1.56 µM)  
and but not in vivo at similar concentrations, whereas EHMC has been proven to 
interfere with multiple endocrine pathways in rats (EC50 934 mg/kg/day). Seidlová–
Wuttke et al. (Seidlová-Wuttke et al. 2006) observed a weak estrogenic effect of 
EHMC at high concentrations (275 mg/day for 6 weeks) while Klammer et al. 
(Klammer et al. 2007) observed an alteration of the hypothalamo-pituitary-thyroid 
function in the animals after 5 days of treatment. OC instead has been proven to exert 
antiestrogenic activity in vitro and in vivo in fish by Kunz et al., 2006 (Kunz and Fent 
2006b). Additionally some of these compounds are capable of damaging DNA via 





Even though available information concerning the percutaneous absorption of UV 
filters in humans is still scarce, it is known that some of them can be absorbed through 
the skin (León-González et al. 2013), suggesting that exposure results mostly from 
topical application of personal care products (Ko et al. 2016). Moreover, Schlumpf et 
al. (Schlumpf et al. 2010) found a correlation between the presence of UV filters in 
human milk and the use of cosmetics, indicating that internal exposure resulted 
consistently from the usage of cosmetics. Ingestion of contaminated food and water 
(Loraine and Pettigrove 2006; Wu et al. 2013) and inhalation of indoor dust represent 
other important indirect/environmental sources of exposure (Geens et al. 2009; Wang 
et al. 2013). The presence of those compounds has been also demonstrated in urine 
(Asimakopoulos et al. 2014; Schauer et al. 2006b), wastewater and ultimately in the 
receiving environment as a consequence of their environmental persistence and 
widespread use (Gago-Ferrero et al. 2015; Gautam et al. 2014; Li et al. 2007; Poiger 
et al. 2004). Furthermore, given their physico-chemical properties, many of the 
compounds under investigation show great potential for bioaccumulation contributing 
to the formation of complex environmental mixtures raising public concern regarding 
their possible effects on human health and ecosystems (Balmer et al. 2005; Meyer et 
al. 2009). Dermal absorption of UV filters is considered to be one of the main routes 
of human exposure due to their extensive use in personal care and consumer products 
(León-González et al. 2013; Schauer et al. 2006b; Schebb et al. 2011). Understanding 
toxicokinetic process, including metabolism, is therefore crucial in the determination 
of toxicological effects and bioaccumulation of these chemicals, as well as in the 
identification of biomarkers of exposure. Still there are only a few studies which 
reported the in vivo or in vitro biotransformation of UV filters. The metabolism of 
benzophenone-type UV filters has been investigated by Jeon et al. (Jeon et al. 2008) 
in rats observing mainly oxidative metabolites. These results were in accord with 
Watanabe et al. (Watanabe et al. 2015) who observed oxidative metabolites of BP-3 
in vitro. Phase I and phase II metabolites of 3-(4′-methylbenzylidene)camphor (4-
MBC) were found in urine, after oral administration in rats, as well as after dermal 
administration in both humans and rats (León-González et al. 2013; Schauer et al. 






This study aims to identify human specific metabolites of selected endocrine 
disruptors (EDCs), mainly UV filters, used in personal care and consumer products 
whose metabolism has hardly been explored and to select suitable candidate 
biomarkers of human exposure studies to these chemicals and for possible application 
in wastewater based epidemiology (WBE). The analysis of metabolic biomarkers of 
target chemicals is crucial in order to distinguish between internal and external 
exposure (e.g. direct disposal), since many sources contribute to chemicals being 
discharged into wastewater. This could be achieved through the employment of a new 
analytical framework for verification of biomarkers of exposure to chemicals 
combining human biomonitoring and water fingerprinting that was proposed by 
Lopardo et al. (Lopardo et al. 2017). Table S 4.1 shows a list of eleven compounds 
that were prioritised in this study. The list includes nine chemicals (UV filters) used 
in personal care and consumer products, which are established or suspected EDCs and 
whose metabolism is yet unknown, and two compounds with known metabolism 


















 Experimental section 
 Reagents and analytical standards. 
Water and methanol were of HPLC purity level and were purchased from Sigma-
Aldrich. Pooled human liver microsomes (HLM), S9 fraction pooled from human 
liver, β-nicotinamide adenine dinucleotide 2′-phosphate reduced (-NADPH ≥95%), 
alamethicin from Trichoderma viride (≥98%), 3′-phosphoadenosine 5′-
phosphosulphate lithium salt (PAPS, ≥60%), uridine 5′-diphosphoglucuronic acid 
trisodium salt (UDPGA, 98-100%), were purchased from Sigma-Aldrich (Gilligam, 
UK). The reference standards: 4-chloro-3-methylphenol (PCMC), 4-benzylphenol (4-
BenzPh), bisphenol A (BPA), bisphenol A-D16, homosalate (HO), 3-benzylidene 
camphor (3BC), benzophenone-1 (BP-1), benzophenone-2 (BP-2), benzophenone-3 
(BP-3), 4,4’-dihydroxybenzophenone (4,4’-DHBP), , octocrylene (OC), potassium 
phosphate monobasic tetrasodium salt hydrate (KH2PO4), magnesium chloride 
hexahydrate (MgCl2), were purchased from Sigma-Aldrich (Gilligam,UK). The 
following internal standards: 4-chloro-3-methylphenol-2,6-d2, triclosan-d3, 
benzophenone 3-d5 and bezafibrate-d6 were purchased from QMX Laboratories Ltd. 
 In vitro assays 
Two step in vitro assay developed by Lopardo et al.(Lopardo et al. 2017), was 
undertaken in this study employing HLM and S9 fraction. 4-Cl-3-methylphenol was 
selected as a positive control to evaluate the performance of the assay. Two incubation 
mixtures were prepared in duplicate by mixing 10 μL of phosphate buffer (50 mM 
KH2PO4, pH 7.4, 5 mM MgCl2), 10 μL of analyte solution (50 μM), 10 μL of 100 μM 
UDPGA solution, and 10 μL of HLM spiked with 1 μL of an alamethicin solution 
(12.5 mg/mL). The reaction was initiated by the addition of 10 μL of a 10 mM NADPH 
solution followed by an incubation at 37 °C. The incubation was carried out for 3 hours 
under the same conditions for two of the four samples. At 3 hours, 10 μL of S9 fraction 
and 10 μL the 100 μM PAPS solution were added to the samples to be incubated for 
six hours and incubation was continued. The negative controls with either no analyte 
or no enzymes were prepared as well for each time point. The reaction was quenched 
with 100 μL of acetonitrile ice cold, followed by centrifugation at 10 000 rpm for 10 
min (Centrifuge 5418, Eppendorf). The supernatant was removed and transferred to a 





TurboVap evaporator (Caliper, UK). The resulting residue was reconstituted with 50 
μL of a solution 80:20 H2O/MeOH containing the internal standard (100 ng/mL), 
transferred into a polypropylene vial and analysed using Dionex Ultimate 3000 HPLC 
coupled with a Bruker Maxis HD Q-TOF according to the procedure described below. 
The range of metabolites produced and their relative ratios were investigated and 
compared (Table S 4.22).  
 In vivo pooled urine essay 
In vivo pooled urine essays were performed on seven pooled urine samples collected 
from a UK festival event. The samples were collected on three different days from 
five different urinals. Solid phase extraction (SPE) was performed using HLB Oasis® 
cartridges (Water, UK). For further details see Lopardo et al. (Lopardo et al. 2017). In 
addition HLB Oasis® cartridges, MCX and MAX Oasis® cartridges (Water, UK) 
were also used in this study. SPE extraction on the MCX and MAX cartridges was 
performed by loading 2 mL of pooled urine onto the cartridges, which were 
preconditioned with 2 mL MeOH (both cartridges) followed by 2 mL of H2O with 2% 
formic acid on MCX and 2 mL of H2O with 5% ammonium hydroxide on MAX. After 
loading, cartridges were dried for 30 min and elution was undertaken using 2 mL of 
MeOH (both cartridges), followed by 2 mL of MeOH with 7% ammonium hydroxide 
on MAX and 2mL of MeOH with 2% formic acid on MCX. Extracts were dried using 
a TurboVap evaporator (Caliper, UK,) under a gentle nitrogen stream in a water bath 
at 40°C then reconstituted in 500 µL 80:20 H2O:MeOH and analysed using Dionex 
Ultimate 3000 HPLC coupled with a Bruker Maxis HD Q-TOF according to the 
procedure described below. 
 Wastewater fingerprinting assay 
24h composite (flow proportional) samples of raw wastewater (after physical 
screening) were collected from 5 different wastewater treatment plants and filtered 
using GF/F glass microfibre filter 0.75 µm (Fisher Scientific, UK). Solid phase 
extraction (SPE) was performed using HLB (Lopardo et al., 2017), MCX and MAX 
Oasis® cartridges (Waters, UK). Extraction procedure included loading 100 mL of 
filtered wastewater onto Oasis cartridges which were preconditioned with 2 mL of 
MeOH for all cartridges followed by 2 mL of H2O for HLB, 2 mL of H2O with 2% 





After loading the cartridges were dried for 30 minutes and analytes were eluted with 
2 mL of MeOH for all cartridges followed by 2 more mL of MeOH for HLB cartridges, 
2 mL of MeOH with 7% ammonium hydroxide for MCX and 2 mL of MeOH with 
2% formic acid for MAX. Extracts were dried using a TurboVap evaporator (Caliper, 
UK,) under a gentle nitrogen stream in a water bath at 40°C then reconstituted in 250 
µL 80:20 H2O:MeOH and analysed using Dionex Ultimate 3000 HPLC coupled with 
a Bruker Maxis HD Q-TOF according to the procedure described below. 
 Liquid –chromatography coupled with tandem mass spectrometry 
All samples were analysed with a Dionex Ultimate 3000 HPLC (Thermo Fisher UK 
Ltd.) coupled with a Bruker Maxis HD Q-TOF (Bruker) equipped with an electrospray 
ionization source. Nitrogen was used as nebulising gas at a flow rate of 11 L/min at a 
temperature of 220°C end at a pressure of 3 Bar. Capillary voltage was set at 4500 V 
and End Plate offset was set at 500 V. The method was applied both in ESI positive 
and negative and acquisition was performed in data independent broadband collision-
induced dissociation acquisition mode (bbCID). In bbCID, precursor and product ion 
spectra were obtained by alternating low and high collision energy (respectively 7 and 
20 eV). HyStar™ Bruker was used to coordinate the LC-MS system. Chromatographic 
separation of the metabolites formed was achieved by using an ACQUITY UPLC 
BEH C18 column (50 mm x 2.1 mm, 1.7 µm) and the following mobile phase 
composition: 1 mM ammonium fluoride in water (A) and methanol (B). The gradient 
elution both in ESI positive and negative mode was 5% B from 0 to 3 min and then 
increased for B as follows: 5–60% B from 3 to 4 min, followed by isocratic conditions 
at 60% B until 14 min, and 60-98% B from 14.1 to 17 min. The last step was a decrease 
of B 98%-5% from 17.1 to 20 min to re-equilibrate with the initial mobile phase 
composition before the next injection. The flow rate was kept constant at 0.4 ml/min 
and the column temperature was set at 40°C (see Lopardo et al., 2017). Method 
validation data are shown in Tables S4.3 and S4.4. 
  Biomarkers identification 
Data extracted from the system after analysis of in vitro test samples were processed 
with MetID software from Advanced Chemistry Development, Inc. (ACD/Labs) for 
in silico prediction of suspected metabolite structures. The exact theoretical accurate 





leading in case of a positive match to the identification of a chromatographic peak. 
The criteria for the elimination of false positives and the identification of actual 
metabolites amongst the numerous structures suggested were: (i) high mass accuracy 
(mass error below 5ppm for metabolites produced by in vitro studies and below 10 
ppm for wastewater analysis) and (ii) lower Kow compared to the non-metabolised 
compound. The chemical structure was then confirmed through the analysis of the 
fragmentation pattern (identification of fragments predicted by ACD/Labs MS 
fragmenter) and isotope pattern (when distinctive). The same workflow was then 
applied to confirm the presence in urine and wastewater of positively identified 



















 Results and discussion 
 In vitro studies 
A comprehensive listing of all observed metabolites, their masses, retention times and 
metabolite’s respective identifying fragments generated at high energy (bbCID) mode 
is shown in Table S4.2. In most cases, at least one metabolite per UV filter was 
observed in in vitro studies (Table 4.1). Both negative and positive ionisation modes 
were tested for the analysis, however all the potential metabolites resulted in better ion 
intensity in the negative ionization mode. The most common enzymatic 
biotransformation reactions observed for the UV filters investigated were 
hydroxylation, sulphate conjugation, glucuronidate conjugation and combinations of 
hydroxylation and phase II biotransformation. The XIC of BP-1 Met2 (m/z 405.0827) 
produced two chromatographic peaks due to single hydroxylation occurring on two 
different positions, which lead to the identification of two different metabolites (Fig. 
S4.1, left). The XIC of 4-BenzPh Met5 (m/z 279.0333) also produced two 
chromatographic peaks due to single hydroxylation occurring on two different 
positions, which lead to the identification of two different metabolites (Fig. S4.1, 
right). Hydrolysis was observed only in the case of HO and OC that were broken down 
to smaller molecules. All the metabolites produced have not been previously 














Table 4.1 Presence of the metabolites identified via in vitro studies in the analysed 
matrices 
Compound 
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< LOD < LOD < LOD 









< LOD < LOD < LOD 
 








   
 
BP-3 
Parent(Ye et al. 2005)        
BP-1(Gonzalez et al. 2008; León 
et al. 2010) 
       
 
BP-1 
Parent *       









< LOD < LOD < LOD 
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< LOD < LOD < LOD 
 
HO 
Parent n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 





     
 
OC 
Parent n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 
Parent – C8H16 
(OC Met1) 
       
 
3-BC 
Parent n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 









< LOD < LOD < LOD 
*present as non-metabolized residue 
** n.d. (non detectable) 
*** WW (wastewater) 
****same accurate mass and retention time 
 
 In vivo pooled urine assay  
The in vivo pooled urine assay led to identification of two metabolites that were also 
identified via in vitro studies: 4-BenzPh Met6 and OC Met1 (Table 4.1).  The 
identification of the 4-BenzPh Met6 and OC Met1 in urine is reported in Figure 4.1. 
Figure 4.1a shows the XIC of 4-BenzPh twice hydroxylated and sulphated (m/z 
295.0279; Fig. 4.1b) with elemental composition of the deprotonated molecule 
denoting C13H12O6S- (1.0 ppm mass error). The analysis of the high-energy spectrum 
(bbCID mode; Fig. 4.1c) led to the identification of a fragment (m/z 215.0706) which 
corresponded with the loss of [SO3] from the precursor ion. Figure 4.1d shows the XIC 
of the hydrolytic metabolite of OC (m/z 248.0711; Fig. 4.1e) with elemental 
composition of the deprotonated molecule denoting C15H11NO2- (2.4 ppm mass error). 
The analysis of the high-energy spectrum (bbCID mode; Fig. 4.1f) led to the 
identification of a fragment (m/z 204.0815) which corresponded with the loss of 





analysed urine sample (Fig. S4.2). It is worth mentioning here that BP-1 can be also 
formed as a metabolite of BP-3. Interestingly, no BPA conjugated metabolites were 
observed in the analysed pooled urine samples.  
 
Figure 4.1 Detection and identification of 4-BenzPh Met6 (a;b;c) and OC Met1 (d;e;f) 
by UHPLC-QTOF-MS following in vivo pooled urine assay.  (a) XICs at m/z 295.0282 
(0.005-Da mass-window width) and 215.0706. Low-energy (full-scan analysis) (b) 
and High-energy (bbCID mode) (c) spectra and structures of 4-BenzPh Met6 and 
fragment ion observed. (d) XICs at m/z 248.0717 (0.005-Da mass-window width) and 
204.0815. Low-energy (full-scan analysis) (e) and High-energy (bbCID mode) (f) 
spectra and structures of OC Met1 and fragment ion observed.   
 
 Wastewater fingerprinting assay 
Finally, the presence of the discovered metabolites was investigated in wastewater to 
selected biomarkers of public exposure to these chemicals. Analysis of untreated 
wastewater samples serving five large communities ranging between 17 and 100 
thousand people was undertaken. The compounds detected in wastewater are 
summarised in Table 4.1.  Among them are: BPA and BPA-Met2, BP-3, BP-1, HO-
Met1, OC-Met1, 4-BenzPh-Met4 and 4-BenzPh-Met5.  
Initial analysis of samples, performed using ACDLabs software, identified four 
potential metabolites: (1) the hydrolytic product of octocrylene (OC Met1), (2) the 
hydrolytic product of homosalate (HO Met1), (3) 4-benzylphenol sulphated (4-
BenzPh-Met4) and (4) 4-benzylphenol sulphated and hydroxylated (4-BenzPh-Met5). 






Figure 4.2 Detection and identification of HO Met1 (a;b;c)  and OC Met1 (d;e;f) by 
UHPLC-QTOF-MS following  wastewater fingerprinting assay.  (a) XICs at m/z 
137.0244 (0.005-Da mass-window width) and 93.0350. Low-energy (full-scan 
analysis) (b) and High-energy (bbCID mode) (c) spectra and structures of HO Met1 
and fragment ion observed. (d) XICs at m/z 248.0717 (0.005-Da mass-window width) 
and 204.0834. Low-energy (full-scan analysis) (e) and High-energy (bbCID mode) (f) 
spectra and structures of OC Met1 and fragment ion observed. 
 
Figure 4.3 Detection and identification of 4-BenzPh Met4 (a;b;c)  and 4-BenzPh Met5 
(d;e;f) by UHPLC-QTOF-MS following  wastewater fingerprinting assay.  (a) XICs at 
m/z 263.0384 (0.005-Da mass-window width) and 183.0815. Low-energy (full-scan 
analysis) (b) and High-energy (bbCID mode) (c) spectra and structures of HO Met1 
and fragment ion observed. (d) XICs at m/z 279.0333 (0.005-Da mass-window width) 
and 199.0765. Low-energy (full-scan analysis) (e) and High-energy (bbCID mode) (f) 






Figure 4.2a shows the XIC of HO Met1 (m/z 137.0247; Fig. 4.2b) with elemental 
composition of the deprotonated molecule denoting C7H5O3- (2.2 ppm mass error). 
The analysis of the high energy spectrum (bbCID mode; Fig. 4.2c) led to the 
identification of a fragment (m/z 93.0350) which corresponded with the loss of [C9H18] 
from the precursor ion. It is worth mentioning here that HO Met1, salicylic acid, has 
different application, e.g. as a pharmaceutical. Further work is needed to verify 
contributions from HO in the overall salicylic acid load in wastewater. 
Figure 4.2d shows the XIC of OC Met1 (m/z 248.0735; Fig. 4.2e) with elemental 
composition of the deprotonated molecule denoting C15H11NO2- (7.2 ppm mass error). 
The analysis of the high-energy spectrum (bbCID mode, Fig. 4.2f) led to the 
identification of a fragment (m/z 204.0834) which corresponded with the loss of 
[COO] from the precursor ion.  
Figure 4.3a shows the XIC of 4-BenzPh-Met4 (m/z 263.0408; Fig. 4.3b) with 
elemental composition of the deprotonated molecule denoting C13H11O4S- (9.1 ppm 
mass error). The analysis of the high energy spectrum (bbCID mode; Fig. 4.3c) led to 
the identification of a fragment (m/z 183.0815) which corresponded with the loss of 
[SO3] from the precursor ion.  
Figure 4.3d shows the XIC of 4-BenzPh-Met5 (m/z 279.0350; Fig. 4.2e) with 
elemental composition of the deprotonated molecule denoting C13H11O5S - (6.1 ppm 
mass error). The analysis of the high-energy spectrum (bbCID mode, Fig. 4.3f) led to 
the identification of a fragment (m/z 199.0765) which corresponded with the loss of 
[COO] from the precursor ion.  
The relative intensities between the detected ions showed consistency compared to the 
in vitro experiments. BP-3, BP-1 (Fig. S4.3) and sulphated BPA (Fig. 4.4) were also 






Figure 4.4 Detection and identification of BPA Met3 by UHPLC-QTOF-MS following 
wastewater fingerprinting assay.  (a) XICs at m/z 307.0646 (0.005-Da mass-window 
width) and 227.1096. (b) Low-energy (full-scan analysis) and (c) High-energy (bbCID 
mode) spectra and structures of BPA Met 3 and fragment ion observed 
 
The presence of all the above metabolites detected in wastewater (including BPA 
sulphate) has not been previously documented in literature. As a result, there is no 
knowledge of the occurrence and effects of these chemicals in the context of 
environmental and public health. This study has proven that selected chemicals (4-
benzylphenol, homosalate, octocrylene) used in personal care and consumer products 
undergo metabolism in humans leading to the formation of new chemicals that are 
found in communal wastewater and can be discharged into the receiving environment. 
Further work is required (a) to verify public exposure to EDCs utilising WBE and (b) 
to understand fate and biological effects of EDCs and their metabolites in exposed 
ecosystems.  
To summarise, out of eleven chemicals were selected in this study, only two (BP-1, 
BP-3) were identified in urine and three (BPA, BP1, BP3) in wastewater. Five newly 





BenzPh-Met6) and one previously known metabolite (BPA-Met3) were detected in 
urine and/or wastewater. Such difference in detection patterns of selected EDCs and 
their metabolites was expected as: 
(1) They have different applications (Table S4.5), i.e. some (e.g. BP-3, HO, OC) 
are used mainly in personal care products and are applied directly to skin. 
Hence, due to direct exposure, they are more likely to be excreted with urine 
and discharged with wastewater as a result of e.g. showering. 
(2) They differ in frequency and volume of usage, i.e. only homosalate, 
octocrylene, and benzophenone-3 are in the top 10 of the most commonly used 
UV filters in the UK (Kerr 2011). Their usage is season dependent.  
(3) Some could not be detected due to analytical constraints, e.g. HO, OC and 3-
BC have higher hydrophobicity and could be more amenable to GC analysis. 
(4) Pooled urine and wastewater samples were collected at different time and 
location, therefore representing populations with different exposure signature.  
The presence of BPA, OC and HO and 4-benzylphenol metabolic residues as well as 
the confirmation of benzophenones in urine and wastewater is of significant 
importance. For example, BPA and 4-BenzPh are mostly employed in the production 
of epoxy-phenolic resins and polycarbonate plastics used as thin protecting coatings 
on the interior surface of metal cans but it can be also found in many products like 
dental sealants, food packaging, beverage cans, personal care products, baby bottles, 
building materials and flame-retardant materials. Consequently, there is a widespread 
potential for human exposure, which this study reports. Epidemiological studies along 
with animal and in vitro experiments reported BPA exposure as a potential cause of 
several adverse health effects, such as cancer, obesity and disorders in endocrine, renal 
and reproductive systems (Joint Fao Oms Expert Committee On Food Additives 
2010). Benzophenones, 4-BenzPh, OC and HO have been demonstrated in many 
studies to possess endocrine disrupting properties at rather high concentrations 
(Akahori et al. 2008; Fent et al. 2008; Kunz and Fent 2006b; Schlumpf et al. 2001), 
but as highlighted by Kunz and Fent (Kunz and Fent 2006a), for an adequate risk 
assessment when investigating endocrine disrupting properties, it becomes crucial to 
consider exposure to compound mixtures rather than single compounds given the 





compounds show great potential for bioaccumulation (Gago-Ferrero et al. 2015) and 
for ecotoxicological effects in aquatic ecosystems (Díaz-Cruz and Barceló 2009; Fent 
et al. 2008; Kaiser et al. 2012).  
 Conclusions 
This study presents a comprehensive examination of the in vitro metabolism of eleven 
EDCs used in personal care and consumer products (Table S4.5) in order to identify 
suitable biomarkers of exposure and their analysis in biological matrices such us urine 
and wastewater, and ultimately to verify the extent of public internal and external 
exposure to these chemicals. External exposure indicates the whole EDC dose to 
which an organism was exposed. Internal exposure indicates only the fraction of the 
initial chemical dose that was absorbed by and distributed throughout the body. The 
biotrasformations observed were mainly phase I processes such as hydrolysis and 
hydroxylation together with phase II conjugation reactions such as sulphation and 
glucuronidation. Eleven chemicals were selected in this study. Only two (BP-1, BP-
3) were identified in urine and three (BPA, BP1, BP3) in wastewater. Five newly 
discovered metabolites (HO-Met1, OC-Met1, 4-BenzPh-Met4, 4-BenzPh-Met5 and 4-
BenzPh-Met6) and one previously known metabolite (BPA-Met3) were detected in 
urine and/or wastewater.  
This new approach towards biomarkers selection shows a significant potential, 
especially in its future application in verification of public exposure to chemicals using 
WBE. Furthermore, an opportunity for further studies focussing on understanding of 
fate and effects of EDCs and their metabolites in the aquatic environment needs to be 
emphasised too. It is apparent that further work is needed to increase the pool of 
available biomarkers, increase selectivity and sensitivity of analytical methods, and 
analyse larger sets of samples allowing for the verification of spatial and temporal 
changes in exposure patterns to chemicals. When combined with further studies in this 
area, researchers will have a basis for fine tuning in vitro assays to better produce 
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Table S4.2 List of metabolites produced via in vitro studies, suggested structures and 
relative abundances. Accurate masses, retention times and confirmation fragmets 
structures produced in MS/MS mode are also provided. 















































































































































































































































































































































































































































































































































































































































































































Table S 4.3 UHPLC-QTOF instrument performance parameters 
Analyte IS Rt 
[min] 

































0.9975 110.4 8.3 110.4 15.0 1.5 5.0 
BP-2 Bezafibrate-d6 6.8 0.1-
88 










0.9995 138.8 9.8 136.6 26.5 5.7 19.0 
 
Table S4.4 SPE-UHPLC-QTOF method performance parameters 
Analyte Wastewater influent 




 [ng L-1] 
BPA 100.4 0.004 0.012 
BP-3 86.1 0.285 0.950 
BP-1 89.7 0.003 0.011 
BP-2 102.9 0.003 0.009 
4,4-DHBP 106.6 0.004 0.013 
4-BenzPh 105.2 0.015 0.050 
 
Table S4.5 Purpose, commercial use and potential exposure sources of the selected 
compounds 





Protective linings of canned 
food container, food packaging, 
dental sealants; thermal receipts 
and paper currencies 
European Food Safety Authority 
(EFSA); 





Personal care products 
including sunscreen, cosmetics, 
lotions, fragrances, shampoos, 
body washes, soap, and insect 
repellents 
US Dept of Health & Human 
Services. Household Products 
Database; 










ingredient, Pesticide ingredient, 
Plastic/Rubber 
US Dept of Health & Human 












Food additive, Household 
product ingredient, Personal 
care product/Cosmetic 
ingredient, Pesticide ingredient, 
Plastic/Rubber 
US Dept of Health & Human 


























Personal care product/Cosmetic 
ingredient/ Pesticide ingredient 
US Dept of Health & Human 















Household product ingredient, 
Medical/Veterinary/Research, 










Figure S4.1 XIC at m/z 405.0827 (0.005-Da mass-window width) (a) and mass spectra 
of the peak eluted at 6.4 minutes (b) and of the peak eluted at 6.6 minutes (c). XIC at 
m/z 279.0333 (0.005-Da mass-window width) (d) and mass spectra of the peak eluted 











Figure S4.2 Detection and identification of BP-1 (m/z 213.0557) and BP-3 (229.0859) 
by UHPLC-QTOF-MS following analysis of standard solutions and in vivo pooled 
urine assay.  (a) XIC at and m/z 213.0557 (0.005-Da mass-window width) of a BP-1 
standard solution; (b) XIC at and m/z 213.0557 (0.005-Da mass-window width) of a 
pooled urine sample and mass spectra (c). (d) XIC at m/z 229.0859 (0.005-Da mass-
window width) of a BP-3 standard solution; (e) XIC at and m/z 229.0859 (0.005-Da 





Figure S4.3 Detection and identification of BP-1 (m/z 213.0557) and BP-3 (229.0859) 





fingerprinting assay. (a) XIC at and m/z 213.0557 (0.005-Da mass-window width) of 
a BP-1 standard solution; (b) XIC at and m/z 213.0557 (0.005-Da mass-window 
width) of a wastewater sample and mass spectra (c). (d) XIC at m/z 229.0859 (0.005-
Da mass-window width) of a BP-3 standard solution; (e) XIC at and m/z 229.0859 




Figure S4.4 A systematic workflow for identification and selection of human 
biomarkers of exposure to environmental contaminants via combined in vitro, pooled 






















Further confirmation of fragmentation pattern using 
selected reaction monitoring (SRM) for low 
concentration and/or hard to fragment suspects
Step 5:
Confirming suspect structures via MS/MS 
fragmentation pattern in bbCID mode
Step 4: 
Matching measured and theoretical isotope pattern of 
suspects
Step 3: 
Matching measured retention time with predicted 
retention time of suspects 
Step 2:
Matching theoretical exact masses of the suspected 
metabolites with the exact masses found in analysed 
samples and peak detection
Step1: 
Generation of a list of suspected metabolites using 
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The scope of this work is to report a new analytical methodology to assess the presence 
of 37 chemically diverse endocrine disrupting chemicals (EDCs) used in personal care 
and consumer products in diverse environmental matrices (both solid and liquid 
matrices) utilising liquid chromatography coupled with tandem quadrupole time-of-
flight mass spectrometry (UHPLC-ESI-MS/MS). Solid-phase extraction (SPE) was 
applied to liquid matrices in order to reduce matrix effects, provide required sample 
concentration and ultimately, high sensitivity and selectivity of measurements. SPE 
recoveries in liquid samples ranged from 49 to 140% with method quantification limits 
not exceeding 1 ng L-1 for the majority of EDCs. Microwave assisted extraction 
(MAE) was applied to solid samples and when followed by SPE, it permitted the 
analysis of 22 EDCs in digested sludge. MAE/SPE recoveries varied from 11 to 186 
% and MQLs between 0.03 and 8.1 ng g-1 with the majority of compounds showing 
MQLs below 2 ng g-1. Mass error for quantifier and qualifier ions was below 5 ppm 
when analysing river water and effluent wastewater and below 10 ppm when analysing 
influent wastewater and solid samples. The method was successfully applied to 
environmental samples, with 33 EDCs identified and quantified in wastewater and 
receiving waters.  In addition, several of them were found in digested sludge, which 
confirms that for a more comprehensive understanding of exposure patterns and 
environmental impact, analysis of solids cannot be neglected. Finally post acquisition 
data mining permitted the identification and quantification for a metabolite of BPA 












Many chemicals in personal care and consumer products such as preservatives, UV 
filters, plasticizers, fragrances, antimicrobials, pesticides and flame retardants are 
suspected to have or are recognised as endocrine system disruptors (Tijani et al. 2016; 
Wong and Durrani 2017). Unfortunately, there is lack or limited understanding of the 
extent and patterns of human exposure to these chemicals. This is despite a critical 
need to obtain such data at a population level to inform future regulations.   
Several papers have been published attributing serious health issues to different EDCs 
and calling  for more research and regulations (Kovacic 2010; McCormick et al. 2010; 
Testai et al. 2013; Vandenberg et al. 2012) but there are also some that argue that the 
problem is quite small when compared to natural hormone affecting compounds that 
are consumed with  food, and that therefore think that such regulations would be 
unnecessary (Lamb et al. 2014; Nohynek et al. 2013; Rhomberg and Goodman 2012). 
Therefore, accurate and reliable exposure assessments of EDCs are required if any 
more regulatory measures are to be taken, but it is difficult to do such an assessment 
at a population level. During the past decade the field of wastewater based 
epidemiology (WBE) has been developed to address the need for accurate and reliable 
assessment of population based exposure to e.g. illegal drugs (Daughton 2001; 
Zuccato et al. 2005). WBE relies on the analysis of target compounds and their 
metabolites in wastewater so that accurate exposure levels can be back-calculated and 
it has been proven to give usage estimates of illegal drugs that match official numbers. 
Using a WBE approach it is also possible to follow the exposure trends on a real time 
basis so that trends over weeks or shorter and longer time periods can be observed, 
e.g. the increased use of some illegal drugs on weekends(Zuccato et al. 2008b). 
Several studies have investigated the presence of EDCs in different types of samples 
including surface waters, wastewater, digested sludge and solid samples (Azzouz and 
Ballesteros 2014, 2016; Benigni et al. 2015; Camilleri et al. 2014; Carvalho et al. 2015; 
Gorga et al. 2013; Marti and Batista 2014; Petrie et al. 2015; Tan et al. 2008; Zhang 
et al. 2011). These studies have utilized different analytical techniques for both sample 
preparation, separation and detection. The most common method for sample 
preparation is solid phase extraction (SPE), which has been used both online 





Gorga et al. 2013), but there are examples where stir bar sorptive extraction (SBSE) 
has been used instead (Tan et al. 2008). A few of the studies have analysed their target 
analytes using gas chromatography (GC) hyphened to mass spectrometer (MS) 
(Azzouz and Ballesteros 2014). Others have used liquid chromatography (LC) coupled 
with MS (Camilleri et al. 2014; Carvalho et al. 2015; Gorga et al. 2013). Sosa-Ferrera 
et al. (Sosa-Ferrera et al. 2013) compiled and compared different LC based methods 
that have been used to analyse different EDCs. However, most of these studies focus 
on a small number of EDCs generally from a limited number of chemical classes 
(Gago-Ferrero et al. 2013; He et al. 2017; Santiago-Morales et al. 2012; Wu and Ding 
2010) and/or are often investigated alongside other pharmaceuticals (Azzouz and 
Ballesteros 2016; Chen et al. 2010; Gasperi et al. 2014; Gorga et al. 2013; Petre et al. 
2016; Zhang et al. 2011). Moreover, they mostly use targeted MS detection meaning 
that their results cannot be used for retrospective data analysis.  
The aim of this work was to develop a robust analytical framework for selective and 
sensitive multi-residue analysis of structurally diverse EDCs (ranging from fragrances 
to brominated flame retardants) in wastewater (both solid and liquid samples) and 
receiving environment while giving the capability to undertake retrospective data 
analysis on analysed samples. To achieve this, ultra-high performance liquid 













5.4 Materials and methods 
5.4.1 Chemicals 
The following analytes were targeted in this study (Table S5.1): 2,4,5-trichlorophenol, 
2,4,6-trichlorophenol, 2-ethylhexanoic acid, 2-naphthol, 4,4’-
dihydroxybenzophenone, 4-benzylphenol, 4-chloro-3,5,dimethylphenol, 4-chloro-3-
methylphenol, 4-n-nonylphenol, 4-n-octylphenol, atrazine, benzophenone-1 (BP-1), 
benzophenone-2 (BP-2), benzophenone-3 (BP-3), benzophenone-4 (BP-4), 
benzylparaben, bisphenol A (BPA), bisphenol A bis(3-chloro-2-hydroxypropyl) ether 
(BADGE-2-Cl), butylparaben, chlorothymol, dibutyl phthalate (DBP), ethylparaben, 
galaxolide, 1,2,5,6,9,10-hexabromo-cyclododecane (HBCD), mono(2-
ethylhexyl)phthalate (MEHP), methylparaben, monobutyl phthalate (MBP), musk  
ketone,  padimate O, perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid 
(PFOA), phenylbenzimidazolesulfonic acid (PBSA, ensulizole), prochloraz, 
propylparaben, tetrabromobisphenol A (TBBPA), triclocarban, triclosan and 
vinclozolin (see Table S5.1 in the supplementary material section for further details). 
The internal standards used were: 4-chloro-3-methylphenol-d2, atrazine-d5, 
bezafibrate-d6, BP-3-d5, triclosan d3 and triclocarban-d4 (QMX (UK) or TRC (UK). 
Water was purified using a Milli-Q purification system from Millipore (Nottingham, 
UK). Methanol, formic acid (>95 %), HCl (concentrated), 1M NaOH, 1M NH4OH, 
NH4F and 2-propanol were purchased from Sigma (UK) and Fisher (UK). All solvents 
used were of LC grade or higher. 
Glassware was deactivated using 5 % dimethyldichlorosilane in toluene (DMDCS; 
Sigma, UK) to prevent losses from analyte adsorption. The deactivation procedure 
consisted of washing the glassware once with 5 % DMDCS followed by two washes 
with toluene and lastly three washes with methanol. 
5.4.2 Sample collection 
Pooled influent and effluent wastewater samples were collected at a wastewater 
treatment plant using ISCO 3700 portable samplers (RS Hydro, Worcestershire, UK) 
that were set up to do volume proportional collections of 10 mL portions with an 
average sampling rate of 15 min. The samples were kept at 4 °C until collection and 
transported on ice to the laboratory. After spiking with internal standards, pooled 24-





samples were also collected from receiving river waters from upstream and 
downstream of the effluent discharge point on each sampling day. Digested sludge 
was collected from an anaerobic digestion plant. 
5.4.3 Sample preparation 
Liquid matrix - solid-phase extraction. All liquid environmental samples were 
filtered using GF/F (0.7 µm) filters (Whatman, UK). After filtration samples 
underwent solid-phase extraction according to below procedures. 
100 mL of each sample were transferred to 125 mL plastic bottles (HDPE) and spiked 
with 25 µL of an internal standard mixture (100 µg L-1). After spiking the samples 
were extracted using three SPE protocols developed for HLB, MCX and MAX 
sorbents respectively.  
HLB extraction protocol included conditioning of 60 mg 3cc HLB cartridges (Waters, 
UK) with 2 mL of methanol followed by 2 mL of water. Samples were adjusted to a 
neutral pH with formic acid (>95 %) or 1 M NaOH and then applied to HLB cartridges 
using vacuum. After a 30 minute drying step all cartridges were stored in a freezer at 
-18 °C until elution. Elution was undertaken using 4 mL of methanol.  
MCX extraction protocol included conditioning of 60 mg 3cc MCX cartridges 
(Waters, UK) with 2 mL methanol followed by 2 mL of water with 2 % of formic acid. 
Samples were adjusted to a pH < 2.5 with the addition of 0.5 mL HCl and then applied 
using vacuum. After a 30 minute drying step all cartridges were stored in a freezer at 
-18 °C until elution. Elution was undertaken using 2 mL of methanol followed by 2 
mL of methanol with 5 % ammonium hydroxide.  
MAX extraction protocol included conditioning of 60 mg 3cc MAX cartridges 
(Waters, UK) with 2 mL of methanol followed by 2 mL of water with 5 % ammonium 
hydroxide. Samples were applied to the cartridges without pH adjustment using 
vacuum and after a 30 min drying step, they were stored in freezer at -18 °C until 
elution. Elution was made using 2 mL of methanol followed by 2 mL of methanol with 
2 % formic acid.  
All eluates were evaporated under a stream of nitrogen at 40 °C in a water bath 
(TurboVap evaporator (Caliper, UK)) and then reconstituted with 250 µL of 





Solid matrix -  microwave assisted extraction. The microwave assisted extraction was 
performed according to Petrie et al., 2015. After collection, digested sludge samples 
were frozen and then freeze dried using a ScanVac, CoolSafe freeze dryer (Lynge, 
Denmark). 1 h before the extraction, 50 ng of each internal standard were added to 0.5 
g of digested sludge and extraction was performed using 25 mL of 50:50 MeOH:H2O 
(pH 2) using a 800 W MARS 6 microwave (CEM, UK). Samples were heated at 110°C 
for 30 min. After extraction samples were filtered using GF/F filters (0.7 µm) and the 
content of MeOH was taken to < 5% using H2O (pH 2). Finally, samples were loaded 
at 5mL min-1 onto Oasis MCX cartridges conditioned with 2 mL of MeOH followed 
by 2 mL of H2O (pH 2) at 1 mL min
-1. MCX cartridges were then dried for 30 min and 
analytes were then eluted in separate acidic and basic fractions. For further detail see 
Petrie et al. (Petrie et al. 2015). 
5.4.4 Analysis 
Targeted UHPLC-QTOF analysis for selected EDCs: full structural confirmation 
with commercially available reference standards. The analysis was performed on a 
Dionex UltiMate3000 UHPLC system (Thermo Fisher UK Ltd.) connected to a maXis 
HD Q-ToF mass spectrometer (Bruker, UK) and controlled by the Compass software 
(HyStar™ Bruker, UK). 90 µL injections of analyte standard solutions (see section 
2.1) were made and the analytes were separated at a flow rate of 0.4 mL min-1 on a 
BEH C18 column (50 x 2.1 mm, 1.7 µm, Waters UK) using mobile phase A (1 mM 
ammonium fluoride in water) and mobile phase B (methanol) at the following 
gradient: 0-3 min 5 %B, 3-4 min 5-60 %B, 4-14 min 60 %B, 14-14.1 min 60-98 %B, 
14.1-17 min 98 %B, 17-17.1 min 98-5 %B, 17.1-20 min 5 %B.  
Mass calibration of the data was performed by an injection of 10 µL of a calibrant 
solution (3 parts of 1 M NaOH to 97 parts of 50:50 water:IPA with 2 % FA) at the 
start of each run before the sample injection. The resulting peak was used for internal 
mass calibration using the software DataAnalysis (Compass DataAnalysis 4.3 Bruker, 
UK). 
The mass spectrometer was equipped with an ESI source and was operated in both 
positive and negative ionisation mode. A capillary voltage was set at 4.5 kV, the end 
plate offset was set to 500 V, a pressure of 3 Bar was used for the nebulizer gas, the 





oC. The bbCID settings in negative mode were 0 eV of isCID energy in both MS and 
MS/MS while the respective collision energies were 7 and 20 eV. The bbCID settings 
in positive mode were 0 eV of isCID energy in both MS and MS/MS while the 
respective collision energies were 5 and 20 eV.  
Collected data was processed using DataAnalysis and QuantAnalysis. 
5.4.5 Method validation 
Extraction recovery. Three complementary SPE chemistries (HLB, MCX and MAX) 
were used to cover as large a spectrum of analytes as possible since the method was 
to be also used for retrospective analysis of analytes not yet targeted. Oasis HLB 
sorbents showed the highest SPE recoveries in all studied matrices and therefore HLB 
sorbent was selected for further study. Due to co-elution, 2,4,5-trichlorophenol and 
2,4,6-trichlorophenol were evaluated together as one peak. The method extraction 
recovery was evaluated by spiking 100 mL of influent and effluent wastewater and 
river water in triplicate at two different analyte concentrations: 100 and 200 ng L-1 
and internal standards: 100 ng L-1 after SPE. SPE recoveries were calculated as 
corrected recoveries (i.e. taking the internal standard concentration into consideration) 
by the ratio of the concentration of target analytes in wastewater solutions when spiked 
before SPE (minus the concentration of analyte in the blank wastewater sample), 
divided by the standard mobile phase concentration (Equation 1). 
𝑆𝑃𝐸 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑖𝑒𝑠𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = (
𝐴𝑠𝑝𝑖𝑘𝑒𝑑 𝑏𝑒𝑓𝑜𝑟𝑒 𝑆𝑃𝐸−𝐴𝑏𝑙𝑎𝑛𝑘
𝐴𝑚𝑜𝑏𝑖𝑙𝑒 𝑝ℎ𝑎𝑠𝑒
) 𝑥 100 % Equation 1 
Choice of internal standards. Internal standards for each analyte were chosen based 
on 4 different criteria. If an isotopically labelled analogue was available, then that was 
the internal standard of choice. If a labelled standard was not available, then the 
internal standard was chosen based on both similarities in physicochemical properties 
of analytes and similar behaviour during SPE and LCMS analysis.  
Linearity. The linearity in detector’s response for each analyte was evaluated by the 
construction of calibration curves from thirteen different concentration levels (ranging 
from 0.01 µg L-1 to 100 µg L-1) in mobile phase. The linearity was interpreted as the 
R2 for the resulting linear regressions (based on all concentration levels or a selection 





Instrument and method limits of detection and quantification. The instrument 
detection and quantification limits (IDL and IQL respectively) were evaluated through 
the use of the calibration curves to calculate the concentrations that gave signal-to-
noise ratios of 3 and 10 respectively. However for some compounds the IQL was found 
to be at a concentration that was below the linear range, in this case the lowest point 
of the calibration curve was selected as IQL. The IDLs and IQLs were then used to 
calculate the method detection and quantification limits (MDL and MQL respectively) 







          
 Equation 2 
ML and IL stand for MDL/MQL and IDL/IQL respectively. 400 is the concentration 
factor due to SPE and RC is the SPE recovery. When the calculated MQL was lower 
than the lowest concentration used in the calibration curve then the MQL was set to 
match the calibration curve. 
Inter- and intraday precision. Inter- and intraday precision for the instrument was 
evaluated from QC-standards up to three concentrations (0.1, 5 and 100 µg L-1) 
injected in triplicate. Standards that were within the linear range of the analyte were 
used for the calculations. The inter- and intraday precision for the method was 
evaluated by spiking wastewater and river water at two different concentrations (100 
and 200 ng L-1) followed by extraction in triplicate on three consecutive days (total 
n=9) using HLB cartridges.  
Accuracy. The accuracy was assessed by comparing calculated concentrations using 
established calibration curves with the theoretical concentrations and calculating the 
average error with its associated RSD. 
5.4.6 Post-acquisition data mining for metabolite identification and 
quantification  
The collection of full-scan spectra permits to measure compounds without previous 
compound-specific tuning with the possibility of retrospective data analysis, and the 
capability of performing structural elucidations and quantification of unknown or 





quantify metabolites with different levels of confidence was modified from 
Schymanski et al.,(Schymanski et al. 2014). Two confidence levels were investigated 
(level 1a and 1b) with minimum identification criteria required being: I) lower 
retention time then their respective parent compound given their lower lipophilicity; 
II) high mass accuracy (mass error below 10 ppm); III) isotope pattern matching the 
predicted one (within 5% error). 
Level 1a: Confirmed structure by commercially available reference standards 
followed by full quantification. The proposed structure of metabolites was confirmed 
via the utilisation of a reference standard with both MS and MS/MS mode and 
matching retention time.  
Level 1b: Confirmed structure by reference compound synthesised in vitro. An exact 
structure of metabolites has been proposed using in vitro HLM/S9 fraction assays (see 
Lopardo et al. (Lopardo et al. 2017) for details) as evidence. The proposed structure 
of metabolites was confirmed by comparing both MS and MS/MS mode and matching 
retention time to the in vitro produced metabolite as well as in vivo products in pooled 






5.5 Results and discussion 
5.5.1 Method development 
The aim of this manuscript was to develop a sensitive and selective multi-residue 
method for both quantification of trace concentrations of 37 EDCs in wastewater and 
in the receiving environment and a posteriori analysis of metabolites of interest. The 





5.5.2 UHPLC-QTOF method development  
Mobile phase composition. Initial experiments revealed that mobile phase composed 
of 0.1 % FA in water and methanol (linear gradient) did not provide satisfactory 
separation of all analytes and did not facilitate satisfactory signal intensities in 
negative ionization mode (e.g. BPA). On the other hand, 1 mM NH4F in water as the 
aqueous phase resulted in better signal intensities in negative ionisation mode but it 
also resulted in lower signal intensities in positive ionization mode. As the aim was to 
have one separation method serving both positive and negative ionisation modes, the 
gain in signal intensities in negative mode was weighed against the loss in signal 
intensities in positive mode. Since more analytes were detected using mobile phase 
containing 1 mM NH4F and the gain in signal intensities in negative mode was higher 
than the number of analytes and the loss of signal in positive mode, this mobile phase 
was selected for further experiments. In order to achieve best separation of analytes 
several mobile phase gradients were trialled. Although HRMS can be used to detect 
and quantify co-eluting analytes without problems, in many cases it was expected that 
the complex matrix of wastewater could cause problems if too many analytes co-
eluted. Several different gradients were therefore developed and tested to separate as 
many of them as possible using a 20 min long programme.  By using a hold time of 
three minutes at the starting condition of 5 % MeOH (B) followed by quickly ramping 
up to 60 % B and then holding there for 10 minutes it was possible to get separation 
both of low to mid non-polar compounds eluting during the first half of the run and of 
more non-polar compounds that were eluting at the end of the run. Without the long 
hold time at the start and the middle of the run the resolution within each group of 
compounds of similar polarity would be inadequate due to the expected interferences 
of the sample matrix. The final mobile phase composition was therefore as follows: 
mobile phase A (1 mM NH4F in water) and mobile phase B (methanol) at the following 
gradient: 0-3 min 5 %B, 3-4 min 5-60 %B, 4-14 min 60 %B, 14-14.1 min 60-98 %B, 






Figure 5.1 Schematic overview of the analytical protocol used to investigate the presence of EDCs in environmental matrices.   
 
Table 5.1 UHPLC-QTOF instrument performance parameters 
Analyte Internal standard used  ESI  Rt  
[min] 



















2,4,5 & 2,4,6-trichlorophenol Triclosan-d3 neg 9.1 0.28-69.5 0.9989 92.6 8.5 90.1 12.7 0.081 0.27 
2-ethylhexanoic acid*4 Triclosan-d3 neg 7.9 4-36.5 0.9978 / / / / / / 





4,4'-dihydroxybenzophenone Bezafibrate-d6 neg 6.6 0.008-21.5 0.9994 109.2 11.4 95.2 7.8 0.024 0.08 
4-benzylphenol Bezafibrate-d6 neg 8.3 0.1-55 0.9995 138.8 9.8 136.6 19.4 0.030 0.1 
4-chloro-3,5-dimethylphenol 4-Cl-3-methylphenol-d2 neg 8.2 0.04-27.5 0.9995 103.4 11.8 109.7 5.1 0.012 0.04 
4-chloro-3-methylphenol 4-Cl-3-methylphenol-d2 neg 7.5 0.064-27.5 0.9987 120.2 2.4 120.2 3.5 0.019 0.064 
4-n-nonylphenol Triclosan-d3 neg 17.3 0.6-63 0.9984 123.71 4.8 124.1 8.1 0.180 0.6 
4-n-octylphenol* 4-Cl-3-methylphenol-d2 neg 17 0.095-56 0.9954 / / / / / / 
Atrazine Atrazine-d5 pos 7.5 9.9-99 0.9984 102.1 1.6 102.1 3.3 0.010 0.034 
Benzophenone-1  4-Cl-3-methylphenol-d2 neg 7.8 0.11-31.8 0.9975 110.4 8.3 110.4 15.0 0.033 0.11 
Benzophenone-2  Bezafibrate-d6 neg 6.8 0.12-88 0.9996 98.0 6.5 98.0 10.1 0.036 0.12 
Benzophenone-3  BP-3-d5 pos 9.2 0.59-54 0.9992 104.4 8.4 113.5 4.2 0.177 0.59 
Benzophenone-4  Bezafibrate-d6 neg 6.5 0.14-11 0.9972 98.5 5.1 98.5 19.5 0.042 0.14 
Benzylparaben Bezafibrate-d6 neg 8.3 0.07-33 0.9998 74.8 8.9 74.8 19.3 0.021 0.07 
Bisphenol A 4-Cl-3-methylphenol-d2 neg 7.7 0.28-28.5 0.9972 114.8 2.5 114.8 9.4 0.084 0.28 
BADGE-2-Cl 4-Cl-3-methylphenol-d2 neg 13.1 0.1-4.7 0.9989 103.4 7.1 103.4 19.9 0.030 0.1 
Butylparaben  Bezafibrate-d6 neg 8.3 0.13-32 0.9994 93.4 8.8 93.4 15.6 0.039 0.13 
Chlorothymol Triclosan-d3 neg 10.7 0.1-48.5 0.9974 118.0 2.8 135.8 12.3 0.031 0.1 
dibutyl phthalate Atrazine-d5 pos 13.8 0.96-96 0.9899 81.3 3.0 80.5 3.3 0.288 0.96 
Ethyl paraben  Bezafibrate-d6 neg 7.0 0.27-100.5 0.9993 92.9 5.7 92.9 9.0 0.081 0.27 
Galaxolide Atrazine-d5 pos 17.1 0.45-51.5 0.9967 94.6 16.3 91.8 18.0 0.135 0.45 
HBCD* Bezafibrate-d6 neg 17.5 0.08-10.5 0.9966 / / / / / / 
MEHP  4-Cl-3-methylphenol-d2 neg 8.7 0.27-5.1 0.9952 90.4 7.4 90.4 19.6 0.081 0.27 
Methylparaben Bezafibrate-d6 neg 6.6 0.35-30.5 0.9990 131.7 10.8 131.7 16.3 0.105 0.35 
Monobutyl phthalate  4-Cl-3-methylphenol-d2 neg 6.7 0.16-39 0.9969 130.3 16.4 130.3 19.0 0.048 0.16 
Musk ketone  4-Cl-3-methylphenol-d2 neg 12 0.53-27.5 0.9952 129.9 9.1 94 12.2 0.159 0.53 
Padimate O Atrazine-d5 pos 17.3 0.39-27.4 0.9974 93.6 14.7 86.8 16.9 0.117 0.39 





Perfluorooctanoic acid  Triclocarban-d4 neg 8.2 1.37-104.5 0.9993 117.3 2.7 117.3 4.1 0.411 1.37 
PBSA Triclosan-d3 neg 6.1 0.16-11 0.9974 94.0 5.8 94.0 20.0 0.048 0.16 
Prochloraz* BP-3-d5 pos 11.6 0.3-12.7 0.9970 122.1 14.4 133.9 15.4 0.090 0.3 
Propylparaben 4-Cl-3-methylphenol-d2 neg 7.5 0.38-31.5 0.9996 122.0 6.3 122.0 15.7 0.114 0.38 
Tetrabromobisphenol A  Triclocarban-d4 neg 15.6 0.144-12 0.997 171.2 9.3 171.2 9.4 0.043 0.144 
Triclocarban Triclocarban-d4 neg 13.5 0.11-27.5 0.9993 114.5 3.5 114.5 4.6 0.033 0.11 
Triclosan  Triclosan-d3 neg 14.6 0.11-53.2 0.9997 102.1 2.9 102.1 7.0 0.033 0.11 
Vinclozolin 4-Cl-3-methylphenol-d2 neg 11.2 1.1-88 0.9972 104.8 14.4 104.8 19.4 0.330 1.1 
Solid analysis 
2,4,5 & 2,4,6-trichlorophenol 4-Cl-3-methylphenol-d2 neg 9.1 0.28-69.5 0.9980 83.2 8.1 83.2 19.0 0.084 0.28 
4-n-nonylphenol 4-Cl-3-methylphenol-d2 neg 17.3 0.63-63 0.9972 123.71 4.8 128.3 11.6 0.190 0.63 
Chlorothymol 4-Cl-3-methylphenol-d2 neg 10.7 0.25-48.5 0.9971 118.7 3.0 138.3 14.5 0.075 0.25 
PBSA 4-Cl-3-methylphenol-d2 neg 6.1 0.27-11 0.9969 111.9 6.0 94.1 19.5 0.081 0.27 
Triclosan  4-Cl-3-methylphenol-d2 neg 14.6 0.29-53 0.9997 122.8 2.8 122.8 7.8 0.090 0.29 
Note: 1: concentration levels: 0.1, 5 and 100 ng/mL used for inter- intraday precision and accuracy (only the levels within the linear range were used for each compound). 2: 5 replicates were injected of 
each concentration level for each day. 3: IQL is set as the lowest linear point that has a precision of <±20 %. 4; starred compounds denoted quality control criteria out of the acceptance range suggested 





Mass spectrometry parameters. MS/MS parameters were optimised for 37 analytes 
and their corresponding labelled internal standards (for details see Table 5.1). Of the 
37 compounds investigated only 6 denoted better sensitivity in ESI positive mode, 
while the vast majority provided better sensitivity in ESI negative mode. One SRM 
transition and high mass accuracy (< 10ppm mass error) for quantifier, qualifiers and 
isotope ions were used as criteria for identification and quantification purposes 
according to the EU guidelines (European commission 2002).  For all compounds the 
molecular mass plus/minus a hydrogen ion was selected as quantifier ion, while one 
SRM transition was monitored in complex matrices for confirmation purposes. 
Unfortunately, due to limited fragmentation, no SRM transition could be monitored 
for 3 compounds (BADGE-2-Cl, HBCD and triclosan). Nonetheless the level of 
certainty for those compounds is still high due to the presence of multiple halogens in 
their chemical structures, meaning complex and highly distinctive isotope patterns. 
Retention time and ion ratio within the standard tolerance were also monitored to 
ensure the quality of the data. Examples of two compounds (methylparaben and 
triclosan) identification in environmental matrices is reported in Figure 5.2 and 5.3.    
Solid-phase extraction. Three complementary SPE chemistries (HLB, MCX and 
MAX) were used to cover as large a spectrum of analytes as possible since the method 
was to be also used for retrospective analysis of analytes not yet targeted. SPE 
recoveries were evaluated in influent wastewater at two different levels of spiking. 
The observed recoveries are shown in Table 5.2. Due to co-elution, 2,4,5-
trichlorophenol and 2,4,6-trichlorophenol were evaluated together as one peak.  
Choice of IS. Not all analytes were available as isotope labelled standards that could 
be used as internal standards. For those analytes that did not have an isotope labelled 
analogue the IS was chosen by evaluating several labelled compounds in terms of 
extraction efficiency, retention times and analyte vs internal standard area ratios 






Table 5.2 SPE-UHPLC-QTOF method performance parameters 





























2,4,5 & 2,4,6-trichlorophenol 94.4 0.222 0.741 89.5 0.235 0.782 101.9 0.206 0.687 66.5 0.31 1.05 
2-naphthol*3 140.7 0.063 0.211 91.4 0.074 0.246 109.8 0.061 0.205 / / / 
4,4'-dihydroxybenzophenone 106.6 0.057 0.190 100.6 0.060 0.199 109.5 0.055 0.183 59.7 0.01 0.033 
4-benzylphenol* 105.2 0.083 0.275 80.1 0.094 0.312 100.9 0.074 0.248 / / / 
4-chloro-3,5-dimethylphenol 90.8 0.037 0.123 80.7 0.037 0.124 101.5 0.030 0.099 131.9 0.02 0.076 
4-chloro-3-methylphenol 81.5 0.097 0.326 89.9 0.053 0.178 105.6 0.045 0.152 68.9 0.07 0.232 
4-n-nonylphenol 49.1 0.882 2.941 43.8 1.027 3.425 67.7 0.665 2.216 18.4 2.5 8.176 
Atrazine 99.0 0.025 0.086 94.2 0.027 0.090 102.6 0.024 0.083 68.4 0.01 0.036 
Benzophenone-1  89.7 0.092 0.307 107.9 0.076 0.255 102.0 0.081 0.270 69.2 0.1 0.398 
Benzophenone-2  102.9 0.087 0.292 98.9 0.091 0.303 106.6 0.084 0.281 75.5 0.1 0.397 
Benzophenone-3  86.1 0.514 1.714 80.4 0.550 1.835 87.2 0.507 1.692 186.2 0.2 0.792 
Benzophenone-4  105.3 0.100 0.332 80.1 0.131 0.437 105.1 0.100 0.333 17.7 0.6 1.977 
Benzylparaben 122.4 0.043 0.143 100.1 0.052 0.175 99.7 0.053 0.176 145.9 0.03 0.120 
Bisphenol A 100.4 0.209 0.697 64.2 0.327 1.090 86.0 0.244 0.814 95.7 0.2 0.731 
BADGE-2-Cl 122.9 0.061 0.203 73.5 0.102 0.340 81.8 0.092 0.306 24.6 0.3 1.02 
Butylparaben* 105.3 0.093 0.309 95.1 0.103 0.342 107.4 0.091 0.303 / / / 
Chlorothymol 84.5 0.222 0.739 88.4 0.212 0.707 96.1 0.195 0.650 101.4 0.2 0.616 





Ethylparaben 87.9 0.230 0.768 108.4 0.187 0.623 107.1 0.189 0.630 112.1 0.2 0.602 
Galaxolide* 50.7 0.666 2.219 100.8 0.335 1.116 102.1 0.331 1.102 / / / 
MEHP* 110,5 0.183 0.611 82.4 0.246 0.819 95.6 0.212 0.706 61.6 0.3 1.1 
Methylparaben 80.5 0.326 1.086 109.3 0.240 0.801 104.6 0.251 0.837 86.4 0.3 1.013 
Monobutyl phthalate  84.2 0.143 0.475 84.9 0.141 0.471 87.1 0.138 0.459 26.3 0.5 1.52 
Musk ketone* 73.9 0.538 1.793 72.1 0.551 1.838 81.7 0.487 1.622 / / / 
Padimate O* 49.8 0.587 1.957 28.8 1.016 3.385 53.7 0.545 1.816 / / / 
Perfluorooctanesulfonic acid* 89.6 0.708 2.360 84.7 0.850 2.834 69.1 1.042 3.473 / / / 
Perfluorooctanoic acid  101.7 1.147 3.825 92.3 1.113 3.711 95.4 1.077 3.590 18.4 5.6 18.6 
PBSA 138.5 0.087 0.289 73.5 0.163 0.544 71.4 0.115 0.385 20.1 0.6 1.99 
Prochloraz* 95.7 0.235 0.784 83.8 0.268 0.895 107.0 0.210 0.701 / / / 
Propylparaben 89.2 0.319 1.065 112.9 0.252 0.841 93.5 0.305 1.016 86.4 0.3 1.099 
Tetrabromobisphenol A  88.3 0.122 0.408 71.0 0.151 0.507 83.8 0.128 0.430 11.3 1.0 3.176 
Triclocarban* 70.7 0.117 0.389 61.9 0.133 0.444 73.4 0.112 0.375 / / / 
Triclosan* 73.8 0.112 0.373 80.4 0.103 0.342 82.8 0.100 0.332 / / / 
Vinclozolin* 33.0 2.500 8.333 5.0 16.50 55.00 4.99 16.533 55.110 / / / 
Note: 1: based on triplicate extractions. 2: based on triplicate injections at three concentration levels (n=9), for some analytes one injection had to be removed making n=8 3: starred compounds showed 





5.5.3 MAE/SPE -UHPLC-QTOF method validation  
Solid-phase extraction. HLB gave good relative recoveries for most compounds with 
the 54 % of analytes having recoveries between 80 and 110 % (Table 5.2).  The 
difference in recoveries between high and low spiking levels was mostly below 10 % 
RSD. For MCX the relative recoveries were between 70 and 110 % for half of the 
analytes.  The relative recovery difference between high and low spiking levels was 
slightly higher with 27 of the analytes having an RSD % below 14 %.  MAX gave the 
largest spread for recoveries with half of the analytes having relative recoveries 
between 60 and 120 %.  For 25 of the analytes the RSD % for the two different levels 
of spiking was below 12 %. HLB recoveries were also evaluated at two different levels 
of spiking in effluent wastewater and river water. Relative recoveries for effluent 
wastewater were in between 80 % and 110 % for 68 % of the compounds with relative 
recovery difference between high and low spiking level mostly below 10 % RSD. 
Relative recoveries were better when SPE was performed on river water samples due 
to the lower complexity of the matrix. 84 % of the values were between 80 and 110 % 
with relative recovery difference between high and low spiking level mostly below 10 
% RSD. Due to the best performance, HLB sorbents were chosen for further method 
development and validation. 
MAE/SPE recoveries.  A microwave assisted extraction (MAE) method developed by 
Petrie et al. (Petrie et al. 2015) was selected to prepare solid samples as it provided 
good recoveries for over 60 of the 90 compounds investigated in the study, including 
some endocrine disruptors selected in the present work such as BP-1, BP-2, BP-4, 
BPA, triclosan and methyl-, ethyl-, propyl-, and butylparaben. In this study, MAE/SPE 
recoveries ranged from 11 to 186 % with the majority of compounds denoting 
recoveries between 59 and 115 % (Table 5.2). However, 8 compounds could not be 
analysed with the current method due to poor SPE recoveries, poor MAE efficiency 
or a combination of the two. More specific targeted analytical methods are therefore 
necessary for these EDCs.  
Inter and intra-day accuracy and precision. Intra and inter-day accuracy was typically 
within the range 80–130% for most chemicals both within the same day and between 
different days (Table 5.1). Instrumental intra and inter-day precision calculated for 





(Table 5.1). The precision of the method was also evaluated at three different 
concentration levels that were extracted in triplicate using HLB on three consecutive 






Figure 5.2 Separation and identification of ethylparaben in all analyzed matrices (influent and effluent wastewater, river water and 
digested sludge). XIC at m/z 165.0557 (0.005-Da mass-window width, black trace) and at m/z 136.0166 (0.005-Da mass-window width, 
blue trace) in four different matrices (from top to bottom), and respective low energy and high energy mass spectra (from left to right) of 

















Table 5.3 Environmental data week average 










2,4,5- & 2,4,6-trichlorophenol 2.5±1.4 2.4±1.0 0.1±0.3 0.04±0.16 57.5±3.7 
2-ethylhexanoic acid* 17612.3±21685.4 417.0±236.1 4290.5±2277.5 3030.9±1594.6 n.a. 
2-naphthol 78.0±20.5 9.3±6.4 7.9±9.2 6.7±8.0 n.a. 
4,4'-dihydroxybenzophenone  24.2±4.2 15.2±1.5 1.7±0.4 2.0±0.4 3.2±0.19 
4-benzylphenol  10.4±6.0 18.2±9.2 43.0±64.9 28.3±38.7 n.a. 
4-chloro-3,5-dimethylphenol 8492.4±3344.6 3975.2±932.8 34.7±13.7 100.8±29.5 455.6±7.5 
4-chloro-3-methylphenol 2632.9±903.7 43.3±16.2 4.4±1.5 3.3±0.9 520.5±16.6 
4-n-nonylphenol < MQL 31.2±16.5 12.1±7.9 13.3±6.5 3.4±0.06 
4-n-octylphenol n.d. n.d. n.d. n.d. n.d. 
Atrazine 48.3±4.1 45.3±6.7 66.6±5.2 59.5±9.6 n.d. 
Benzophenone-1  47.1±14.6 6.8±1.5 0.6±0.3 0.8±0.2 8±0.6 
Benzophenone-2 13.1±2.5 10.6±0.9 0.9±0.6 0.9±0.7 3.8±0.4 
Benzophenone-3  753.0±129.2 44.7±7.2 32.4±34.1 4.5±11.7 42.4±5 
Benzophenone-4  2711.5±808.1 660.9±157.7 41.6±19.4 55.3±27.9 33.1 
Benzylparaben n.d. n.d. n.d. n.d. 0.44±0.07 
Bisphenol A 812.5±52.2 23215.9±21945.31 14.3±8.5 12.9±3.4 15690±542 
BADGE-2-Cl 0.9±0.67 0.31±0.3 0.73±0.38 0.77±0.43 3.2±0.07 
Butylparaben  11.1±4.9 1.3±0.2 1.4±0.7 1.7±0.6 n.a. 
Chlorothymol  n.d. n.d. n.d. n.d. 5.6±0.1 
Ethylparaben;  143.3±23.2 1.1±0.3 2.6±3.5 1.2±1.3 5.34±1.5 
Galaxolide  164.5±40.2 50.2±18.7 11.0±4.2 9.4±2.7 n.a. 
HBCD* 1.29±0.84 0.73±0.33 0.93±0.88 0.57±0.49 6.03±1 





Musk ketone n.d. n.d. n.d. n.d. n.a. 
Padimate O 140.4±42.0 94.6±32.3 139.8±147.8 248.5±157.1 n.a. 
Perfluorooctanesulfonic acid  4.5±1.0 7.5±2.8 11.9±3.1 12.8±3.7 n.d. 
Perfluorooctanoic acid  10.0±6.7 12.3±7.6 12.6±3.6 12.1±4.5 4±0.7 
PBSA 2152.1±484.1 1606.0±473.9 3655. 4±5504.6 298.2±100.6 162±27.7 
Prochloraz 100±62 5±4.5 35.3±32.8 22±20.1 n.a. 
Propylparaben  143.1±23.3 4.7±0.7 1.5±1.2 1.4±1.8 4.4±0.5 
Tetrabromobisphenol A  13.9±11 1.67±0.32 n.d. n.d. 25.1±1.4 
Triclocarban 17.1±5.1 8.5±1.6 4.7±3.4 3.4±2.0 n.a. 
Triclosan  589.0±59.3 133.2±14.6 19.8±10.0 18.7±6.2 n.a. 
Vinclozolin  n.d. n.d. n.d. n.d. n.a. 
Note: 1: based on triplicate extractions. 2: based on triplicate injections, for some analytes one injection had to be removed making n=8 3: n.a. non analyzed as 
compounds showed poor or no recovery from solid samples; *- results are only semi-quantitative dues to poor accuracy and precision.  




























1.39 - 103.4 0.9972 98.3 2.1 0.41 1.39 63.7±6.3 0.016 0.055 2663.9±422 
*concentration levels: 0.1, 5 and 100 ng/mL used for precision and accuracy; ** based on duplicate extractions at two concentration levels; ***based on wastewater samples 





Overall, the intraday precision of the method is good with the majority of analytes 
giving precision values below 10 % RSD in both positive and negative mode with the 
highest value being 18.4 % RSD. For inter-day precision, the spread was a little bit 
higher with all analytes giving less than 20 % RSD. Three compounds (2-
ethylhexanoic acid, 4-n-octylphenol, HBCD) need to be discussed separately since 
their calibration curves showed satisfactory linearity across a good range of 
concentrations but accuracy and precision did not meet the criteria established by the 
European Commission. The high variability was due to poor ionization rate in the 
selected analytical conditions. Their analysis can therefore be considered only 
qualitative.  Detection and quantification limits. The method was developed to 
accommodate both negative and positive ESI polarity with the same mobile phase. 
Because the majority of the compounds ionised better in negative ionisation mode the 
mobile phase was geared towards negative ionisation. This can be observed in the 
instrumental detection and quantification limits that are in the low ng L-1 (between 10 
and 50 ng L-1) for most compounds analysed in negative mode while the compounds 
analysed in positive mode have IDL and IQLs in the hundreds of ng L-1 (Table 5.1 and 
5.2).  
Linearity range.  A set of 13 calibration solutions containing all analytes and internal 
standards were made up at the following concentrations: 0.01, 0.025, 0.05, 0.1, 0.25, 
0.5, 1, 2.5, 5, 10, 25, 50 and 100 ng mL-1. These solutions were analysed and integrated 
using the QuantAnalysis software. For each analyte the analyte/internal standard area 
ratio for the thirteen calibration levels were compared and investigated by drawing up 
calibration curves. The R2-value for the resulting calibration curves is presented 
alongside their linear range in Table 5.1. Most analytes showed good linearity 
(interpreted from the R2) with varying linear ranges (from two to three orders of 
magnitude) highly dependent on individual analytes.  
5.5.4 Targeted analysis of environmental samples with MAE/SPE-UHPLC-
QTOF including full structural confirmation with commercially available 
reference standards 
Environmental samples collected over one-week long sampling campaign were 
subjected to both quantitative and qualitative analysis. A summary for the quantified 





present at very high concentration levels in incoming and effluent wastewater that did 
not require any extraction steps to be undertaken (Table S5.3). 
 
 
Figure 5.3 Separation and identification of triclosan in all analyzed matrices (influent 
and effluent wastewater, river water and digested sludge). XIC at m/z 286.9439 (0.005-
Da mass-window width, black trace), at m/z 288.9413 (0.005-Da mass-window width, 
blue trace) and at m/z 290.9383 (0.005-Da mass-window width, red trace) in four 
different matrices (from top to bottom). The right column shows the mass spectra of 
the peak eluted at 14.6 minutes and the black, blue and red arrows indicate 
respectively [M]-, [M+2] -, [M+4] – peaks with relative intensities matching those 











Other compounds showed an irregular occurrence pattern. For example, 
phenylbenzimidazolesulfonic acid (also known as Ensulizole or PBSA) was detected 
at high levels (>1000 ng L-1) in influent and effluent wastewater with constant 
occurrence patterns. However, a spike in its concentration was observed on two 
consecutive days within the sampling week in the river water resulting in increased 
levels reaching 4000 ng L-1. This could be due to (accidental) disposal of larger 
quantities of PBSA upstream from the sampling point.   
Interesting was also the low presence (< MQL) of the surfactant 4-n-nonylphenol in 
influent wastewater while its concentration in effluent wastewater was calculated 
higher than > 30 ng L-1. That might be due to its formation during wastewater treatment 
as a result of decomposition of nonylphenol polyethoxylates (Minamiyama et al. 
2006). Similar pattern was observed for BPA whose concentrations were significantly 
higher in effluent rather than influent wastewater. It is suggested that the increase in 
concentration might be due to in situ degradation of conjugated metabolites (i.e. 
glucuronidates) as it has been previously observed for other compounds (Leclercq et 
al. 2009). Nonetheless in both cases further investigation is required. 
Out of the 37 compounds investigated only 3 compounds (n-octylphenol, musk ketone, 
vinclozolin) were not detected in studied environmental matrices, likely due to low 
sensitivity of the method towards some of these compounds.   
Significant concentrations of 22 endocrine disruptors were also found when analysing 
solid samples (digested sludge). Concentrations ranged from 0.44 ng g-1 for 
benzylparaben to 15 µg g-1 for BPA. The observation of benzylparaben, along with 
chlorothymol, was of particular interest given that these compounds were not detected 
in wastewater and river water samples, highlighting the importance of investigating 
the presence of chemicals in solid matrices alongside water samples. 
5.5.5 Post-acquisition data mining for metabolite identification and 
quantification  
The main advantage of LC-HRMS is the possibility of identifying compounds which 
were not included in the initial analysis (post-target or retrospective analysis) that can 





solvents, reagents and materials). This possibility enables the investigation of newly 
identified compounds that are not yet integrated into the monitoring strategies 
currently in use such as compound’s metabolites (e.g. BPA sulphate and 4-Cl-3-
methylphenol sulphate).  
As discussed in Experimental, the level system approach utilised in this paper to 
identify and quantify metabolites with different levels of confidence was modified 
from Schymanski et al.(Schymanski et al. 2014). Two confidence levels were 
investigated:  
Level 1a: Confirmed structure by commercially available reference standards followed 
by full quantification (BPA sulphate, metabolite of BPA).  
Level 1b: Confirmed structure by reference compound synthesised in vitro (4-Cl-3-
methylphenol sulphate, metabolite of 4-Cl-3-methylphenol).  
5.5.6 Confirmed metabolite structure by commercially available reference 
standards followed by full quantification 
From analyses previously carried out the signal at m/z 307.0646, corresponding to 
bisphenol A sulphate (elemental formula C15H16O5S with a mass error of 9 ppm), was 
extracted from the total ion current of each wastewater samples chromatogram (Figure 
5.4) and a chromatographic peak at 6.8 min was found in all the samples analysed. 
Retention time was expectedly lower in the used chromatographic conditions (reverse 
phase) due to the metabolite higher polarity than the parent compound. BPA was in 
fact eluted after 7.7 min.  In order to confirm that the chromatographic peak 
corresponds with the BPA sulphate, the workflow developed by Lopardo et al., 
(Lopardo et al. 2017) was employed and mass error, and a high-resolution MS/MS 
spectrum (Figure 5.4) were used. A further level of confidence was added when results 
were compared to a reference standard reaching the highest level of confidence 
according to the approach suggested by Schymanski et al.,(Schymanski et al. 2014). 
Subsequently a calibration plot (R2 = 0.997) at eight concentration levels (each one 
replicated three times) ranging from the LOQ (1.39 ng mL-1) to 103.4 ng mL-1 was 
used to quantify BPA sulphate. LOD and LOQ were expressed as the concentration of 
BPA sulphate that give a signal to noise ratio of 3 and 10. Once HLB recoveries were 





quantification limits (MDL and MQL) were established as respectively 0.016 and 
0.055 ng L-1. BPA sulphate was then found to be in wastewater at concentrations of 
circa 2500 ng L-1 (Table 5.4). 
5.5.7 Confirmed structure by reference compound synthesised in vitro  
Analyses of mass spectra lead to the identification of a compound previously observed 
after in vitro experiments (Lopardo et al. 2017). A signal at m/z 220.9681 
corresponding to 4-Cl-3-methylphenol sulphate (elemental formula C7H7ClO5S with a 
mass error of 6.4 ppm), was extracted from the total ion current of each wastewater 
samples chromatogram (Figure 5.5) and a chromatographic peak at 5.9 min was found 
in all the samples analysed. Retention time was expectedly lower in the used 
chromatographic conditions (reverse phase) due to the metabolite higher polarity than 
the parent compound. BPA was in fact eluted after 7.5 min.  In order to confirm that 
the chromatographic peak corresponds with the 4-Cl-3-methylphenol sulphate, the 
workflow developed by Lopardo et al., [32] was employed and mass error, and a high-
resolution MS/MS spectrum (Figure 5.5) were used. A further level of confidence was 
added when results (retention time, mass accuracy and MS/MS fragmentation pattern) 
were compared to results obtained after in vitro studies carried out by Lopardo et al., 







Figure 5.4 Detection and identification of BPA sulphated in wastewater by UHPLC-
QTOF-MS. XICs at m/z 307.0646 and 227.1096 (0.005-Da mass-window width) (a). 
(b) (top) Low-energy (full-scan analysis) and (bottom) high-energy (bbCID mode) 








Figure 5.5 Detection and identification of 4-Cl-3-methylphenol sulphated in 
wastewater by UHPLC-QTOF-MS. XICs at m/z 220.9681 and 141.0113 (0.005-Da 
mass-window width) (a, left). XICs at m/z 220.9681, 221.9723 and 222.9664 (0.005-
Da mass-window width) (a, right). (b) (left) High-energy (bbCID mode) and (right) 




















A new multi-residue method was developed for the analysis of 37 diverse endocrine 
disruptors in environmental samples. IQLs observed were < 1 µg L-1 for almost all 
compounds with some of them showing IQLs below 0.1 µg L-1. MQLs achieved were 
< 1 ng L-1 for most of the compounds detected in aqueous matrices and < 1 ng g-1 for 
those detected in digested sludge. The results were similar to other studies employing 
different analytical techniques such as LC-TQD (Chary et al. 2012; Petrie et al. 2014, 
2015; Vanderford et al. 2003). However the prospect of running on the same dataset 
retrospective analysis and/or untargeted screening in quest for new compounds of 
interest (i.e. new synthetic compounds, unknown metabolites, degradation products) 
makes the current method and others harnessing high resolution mass spectrometry 
much more versatile (Baz-Lomba et al. 2016; Boix et al. 2014; Lopardo et al. 2017; 
Rapp-Wright et al. 2017). Analysis of environmental samples revealed the presence of 
34 out of the 37 compounds investigated. In addition, several of them were found in 
digested sludge, which confirms that for a more comprehensive understanding of 
exposure patterns and environmental impact, solid analysis cannot be neglected. 
Furthermore, post-acquisition data mining allowed identification and quantification in 
wastewater of BPA sulphate and identification of 4-Cl-3-methylphenol sulphate 
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Table S 5.2 Mass spectrometry parameters used in the identification of endocrine 
disruptors including mass error in ppm in all different matrices 
Analyte Formula m/z 
MRM transitions 














































































2,4,5-trichlorophenol C6H3Cl3O 194.9177 158.9419 1.1 17 2.5 1.5 5 < 1 
2,4,6-trichlorophenol C6H3Cl3O 194.9177 158.9419 1.1 17 2.5 1.5 5 < 1 
2-ethylhexanoic acid C8H16O2 143.1078 127.1128 10000 18.6 < 
1 





2-naphthol C10H8O 143.0502 115.0556 8 20 < 
1 
< 1 3.5 3.5 
4,4'-
Dihydroxybenzophenone 
C13H10O3 213.0557 93.0350 9 20 3.5 <1 <1 <1 
4-benzylphenol C13H12O 183.0815 106.0412 250 13 5 <1 5 <1 
4-chloro-3,5-dimethylphenol C8H9ClO 155.0269 119.0502 66.7 15 2 2 3.3 <1 
4-chloro-3-methylphenol C7H7ClO 141.0113 92.0267 1.28 14.5 <1 <1 2.8 <1 
4-n-nonylphenol C15H24O 219.1754 106.0430 14.9 17 4.5 3 1 2.5 
4-n-octylphenol C14H22O 205.1598 106.0430 3.8 17 3 1 3.5 1 
Atrazine C8H14ClN5 216.1010 174.0561 0.9 17.4 4 2.5 4.5 9.5 
Benzophenone-1  C13H10O3 213.0557 135.0095 3.7 19 4 2 3.5 1.7 
Benzophenone-2  C13H10O5 245.0455 109.0301 3.5 12 2.4 2 3.6 1.2 
Benzophenone-3  C14H12O3 229.0859 151.0397 0.4 22 <1 2.6 5.6 5.6 
Benzophenone-4  C14H12O6S 307.0282 227.0721 2.5 27.4 3.3 3 2 <1 
Benzylparaben C14H12O3 227.0714 136.0169 1 19 3.5 2.6 3.6 2 
Bisphenol A C15H16O2 227.1078 211.0760 125 12 2.6 1 2 2.6 
BADGE-2-Cl* C21H26Cl2O4 411.1135 - - - <1 1.5 <1 <1 
Butylparaben C11H14O3 193.087 136.0169 2 17 3.5 2.5 3.5 2.5 
Chlorothymol C10H13ClO 183.0582 168.0348 166.7 14.5 4.4 2.7 5 <1 
dibutyl phthalate C16H22O4 277.1445 208.0858 7.7 20 < 
1 
< 1 3.9 1.4 
Ethylparaben C9H10O3 165.0557 136.0166 10 20 2.4 1.8 3 2.4 
Galaxolide C18H26O 259.2056 175.1126 0.5 17 < 
1 
1.5 3 5.4 
HBCD* C12H18Br6 634.6436 - - - 2 < 1 2.3 - 
MEHP C16H22O4 277.1445 233.1552 5.8 13.8 2.5 5 7.9 < 1 
Methylparaben; C8H8O3 151.0401 136.0169 1.7 15 2 < 1 5 < 1 
Monobutyl phthalate  C12H14O4 221.0819 121.0300 3.3 25 2.7 2.7 2.7 < 1 
Musk ketone C14H18N2O5 293.1143 251.1039 6.3 26 2 2.4 5 7.9 
Padimate O C17H27NO2 362.2115 166.0873 0.6 19 < 
1 
< 1 5.5 5.7 
Perfluorooctanesulfonic acid  C8F17O3S 498.9302 79.9580 200 31.5 3.8 5 < 1 < 1 
Perfluorooctanoic acid  C8HF15O2 412.9664 368.9783 0.1 11 4.3 4.3 1 < 1 
Phenylbenzimidazolesulfonic 
acid  
C13H10N2O3S 273.0339 193.0782 3.7 14 2.9 2.9 1.8 1.5 
Prochloraz C15H16Cl3N3O2 376.0381 308.0035 0.04 12.8 < 
1 
1.6 3.8 5.7 
Propylparaben C10H12O3 179.0714 136.0169 3.1 15 2.8 2.2 2.2 2.2 
Tetrabromobisphenol A  C15H12Br4O2 538.7498 288.8870 3 13.8 < 
1 
2.2 1.7 1.5 
Triclocarban C13H9N2OCl3 312.9708 126.0115 16 20 < 
1 
2.9 < 1 < 1 
Triclosan* C12H7Cl3O2 286.9439 - - - < 
1 
1.8 < 1 1 
Vinclozolin C12H9Cl2NO3 283.9887 140.0361 41.7 14 1.4 < 1 4.2 1.4 






Figure S 5.1 Separation and identification HBCD in all analyzed matrices (River 
water, influent and effluent wastewater). XIC at m/z 634.6436 (0.005-Da mass-window 
width, black trace), at m/z 638.6408 (0.005-Da mass-window width, red trace), at m/z 
640.6387 (0.005-Da mass-window width, blue trace) and at m/z 642.6367 (0.005-Da 
mass-window width, brown trace) in three different matrices (from top to bottom), and 
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6 Conclusions and future perspectives  
The present work highlighted and then filled several gaps present in literature 
regarding the metabolism of (and exposure to) EDCs used in personal care and 
consumer products. This was achieved by developing a new tool combining WBE with 
in vitro incubation techniques and urine analysis that enable wastewater profiling to 
be used for a better and more comprehensive understanding of exposure to known and 
newly identified potentially toxic compounds.  
WBE represents an exquisite monitoring strategy that is only applicable to broadly 
investigated chemicals. That because a key step when undertaking these kind of studies 
is establishing which metabolites are going to be good biomarkers of exposure. Up to 
date one of the most popular method to achieve that is to perform in vitro metabolism 
studies. Although these kind experiments are well-established techniques to 
investigate the metabolism of chemical compounds, they come with huge limitation 
when the final goal is to identify human metabolites that are excreted in urine and 
detected in wastewater. For example, in vitro experiments using human subcellular 
fractions can provide excellent information about what type of biotransformation is 
likely to occur, but at the same time provide no information about excretion and 
detectability in wastewater which are essential in WBE. On the other hand wastewater 
analysis cannot serve as the only tool for the selection of good biomarkers of exposure 
for new chemicals too. The identification of any new potential metabolite in 
wastewater in fact requires confirmation that the metabolites detected are human 
metabolites and not due to other physical-chemical or biological agents. The newly 
developed tool combining wastewater profiling, in vitro metabolism studies and urine 
analysis overcomes such limitations permitting what was not possible to achieve with 
a single study before. That includes monitoring studies on known chemicals and at the 
same time a fast and unequivocal identification of suitable biomarkers of exposure for 
new chemicals. Ultimately a preliminary assessment of the exposure of populations to 
the new compound of interest in question can be obtained, as the study on 4-Cl-3-
methylphenol proves, unveiling the great potential of the approach.  
Obtaining such essential information in such a short time for new compounds along 
with the monitoring of the known ones permits to have a more comprehensive 





advantage for public health decision making strategies. Some difficulties remain with 
the method. For example, it is lacking a tool that associates exposure to chemicals to 
the incidence of diseases. That can be overcome by future workers linking exposure 
patterns together with clinical studies that might shed light on the causes that favour 
the incidence of certain specific chronic diseases (e.g. diabetes, obesity, fertility 
problems etc.) in the studied population. Such proactive strategies could improve the 
overall quality of life of individuals with prevention rather than cure. Finally, 
prevention is also known to be more cost effective for the economy since it reduces 
health care costs and permits redirecting of more financial resources where needed. 
 Estimated spatiotemporal communitywide exposure to BPA via WBE 
This chapter focusses on a literature review analysing the state of the research carried 
out on EDCs used in personal care and consumer products and wastewater 
epidemiology. In the second part a case study is reported where a WBE approach is 
undertaken to investigate population exposure to BPA highlighting the great potential 
of such approach. 
Understanding the exposure pathways to emerging contaminants such as endocrine 
disruptors (EDCs) plays a key role for the public health monitoring. The newly 
emerging supra-disciplinary field of wastewater-based epidemiology (WBE), thanks 
to its unique approach towards retrieving epidemiological information from measuring 
biomarkers in wastewater, can overcome spatial and temporal limitations providing 
real time measurements of community-wide exposure to EDCs chemicals present in 
personal care products and a wider-group of chemicals that are not intended for human 
consumption and therefore lack comprehensive risk assessment data.  A 
comprehensive spatiotemporal community wide study assessing the exposure to BPA 
was undertaken to highlight the extraordinary potential of such approach. The study 
was applied to a large geographical area of 2,000 km2 and a population of ~1.5 million 
accounting for >75% of the overall population in the studied catchment area. For the 
first time the presence of BPA sulphate was monitored in wastewater and the exposure 
intended as intake of such chemical was evaluated using a WBA approach. Overall 
BPA intake was found to be below what EFSA set as the tolerable daily intake (TDI) 
in most locations but two WWTPs where exposure higher than the TDI was observed. 





different exposure rate throughout the week. In addition to that, the measurement of a 
non-consistent ratio between the amount of BPA and BPA sulphate between the 
different WWTPs suggests that the presence of parent compound can be due to other 
sources (e.g. industrial discharge and domestic direct disposal), and therefore it cannot 
be indicative of the exposure.   
 New analytical framework developed 
Most of the chemicals selected for the study were prioritised based on gaps in 
knowledge as they are not meant for consumption. As a consequence of that, their 
metabolism and excretion are unknown making a selection of metabolites suitable as 
biomarkers of exposure rather difficult. Identifying new metabolites for scarcely 
investigated compounds that can also be suitable as biomarkers of exposure plays a 
crucial role in the context of wastewater analysis. To achieve that a new tool that 
consisted in a multistep workflow that combined in vitro techniques to urine and 
wastewater analysis was developed. 
 A semi-targeted screening was undertaken. This approach, in contrast to non-target 
screening that starts without any a priori information on the compounds to be identified 
compares masses detected in a full scan analysis against only a limited number of 
chemically meaningful structures that show a close relationship with the parent 
compound. The steps were as follows: Step 1: In vitro HLM/S9 assay; Step 2: In vivo 
pooled urine assay; Step 3: In vivo wastewater fingerprinting assay; Step 4: Analysis 
with HR-MSMS. This step includes metabolites identification and confirmation. The 
process starts with the establishment of a list of suspected metabolites harnessing 
ACDLab software, false positives were then excluded monitoring retention time, mass 
accuracy and isotope pattern and finally the structure was then confirmed by analysing 
the MS/MS fragmentation pattern in bbCID mode; Step 5: Data processing and Step 
6: Selection of biomarkers. A further confirmation step performing a data-dependent 
MS/MS can be necessary for those metabolites that for different reasons do not provide 
an optimal MS/MS fragmentation pattern in bbCID. Four new possible metabolites 
were identified for the selected antimicrobial 4-Cl-3-methylphenol (PCMC) after in 
vitro HLM/S9 studies and the biotransformations observed were phase I and phase II. 
The comparison between the in vitro tests employing only HLM and those employing 





cytosolic enzymes to identify a more representative range of metabolites.  Of the four 
metabolites identified only one was confirmed in the urine and wastewater samples 
analysed suggesting that sulphation could be the preferential metabolism pathway of 
the investigated antimicrobial and that PCMC sulphated would be the only metabolite 
excreted. Furthermore, the presence of the metabolite in the analysed matrices 
indicates human internal exposure to the antimicrobial despite it being utilised in 
products meant for external use.  
 New biomarkers identified 
In this chapter   newly developed assays combining wastewater analysis, urine analysis 
and in vitro incubation techniques were applied to compounds with an unknown 
metabolism with the scope to identify metabolites produced in vivo, excreted in urine 
and present in wastewater, and can therefore represent suitable biomarkers of exposure 
for future studies.  
Similarly, to the previous study phase I and II biotransformations were observed. Five 
of the newly discovered metabolites (HO-Met1, OC-Met1, 4-BenzPh-Met4, 4-
BenzPh-Met5 and 4-BenzPh-Met6) and one previously known metabolite (BPA-
Met3) were then detected in urine and/or wastewater. The difference in number and 
type of compounds and metabolites observed in the two different samples was 
expected since the two different samples (urine and wastewater) were collected in two 
different times and locations representing two different populations that could have 
been exposed to different chemicals. However, consistency was observed in detecting 
metabolites of high usage UV filters. The findings confirm a significant potential for 
this new approach in particular in its future application in verification of public 
exposure to chemicals via WBE.  
 New quantitative method and EDCs quantified at a catchment scale 
A new analytical LC-MS method to perform the a quantitative analysis of all the 
selected compounds of interests (chemically diverse EDCs) and respective metabolites 
combined with an untargeted screening for more compounds of interest (in solid and 
liquid matrices) was needed to allow future monitoring studies, identification of new 





Finally, a new analytical method for a comprehensive investigation of 37 EDCs and 
newly identified biomarkers of exposure was developed. For the first time very diverse 
chemical compounds ranging from flame retardants to fragrances and including UV 
filters, plasticizers, polyfluorinated substances, surfactants and antimicrobials were 
analysed with one multiresidue method. Through this method, the prevalence of 37 
compounds was studied in influent and effluent wastewater samples, river water 
upstream and downstream to the WWTPs as well as in digested sludge. The 
significative presence of 60% of the analysed compounds in digested sludge confirmed 
that solid analysis is crucial for a comprehensive environmental risk assessment and 
for a correct evaluation of biomarkers loads in order to have an accurate estimate of 
internal exposure to parent compounds. Furthermore, the selection of high resolution 
mass spectrometry (HRMS) coupled with liquid chromatography (LC) provided the 
possibility of identifying compounds which were not included in the initial analysis 
(post-target or retrospective analysis) that can be achieved without the need for 
producing extra samples, on raw data that can be stored indeterminately. This 
possibility permitted the investigation of newly identified compounds or chemicals 
that were not yet integrated into the monitoring strategies currently in use such as 
compound’s metabolites (e.g. BPA sulphate and 4-Cl-3-methylphenol sulphate). 
Metabolites were identified on different levels of confidence and eventually quantified 
so that a WBE approach could be undertaken. The results obtained in this present work 
lead to the conclusion that the impact of the exposure to EDCs and other chemicals 
not intended for human consumption might need to be reconsidered and their impact 
on the aquatic ecosystem along with their metabolites should be also monitored to 
verify their potential environmental impact. 
 Future work 
Mechanisms of transformation of EDCs in wastewater and the environment are largely 
unknown therefore stability and mechanisms of transformation of EDCs and their 
metabolites in wastewater and the environment should be investigated undertaking 
microcosm experiments. Such studies are needed to verify the stability and usefulness 
of chosen biomarkers as well as to evaluate all exposure routes and risks. For newly 
discovered metabolites standards should be synthesised to permit a full quantification 
and in vivo metabolism studies should be performed to understand excretion ratio and 





biomarkers in wastewater). Finally, the validated method should be used to support 
monitoring studies to provide a greater understanding of the presence, fate, and 
ecological impact of EDCs in wastewaters and the environment in a vast catchment 
area in the south west of England with the ultimate goal of increasing knowledge of 
the effects of the exposure to these compounds on the whole populations. Furthermore 
the new analytical workflow represents a powerful tool that can change exposure 
studies coupling real-time monitoring with screenings performed with different 
degrees of selectivity for new compounds of interest that can improve human 
biomonitoring. In addition to that, thanks to the possibility of retrospective analysis, 
exposure to more compounds of interest can be investigated without more samples 
needed enabling a more comprehensive analysis of the relationship between exposure 
and effects. Ultimately the new analytical tool will permit proactive rather than 
reactive strategies. 
To further confirm WBE as a useful method in exposure assessments more studies will 
be performed. Sampling campaigns will be designed to asses more in detail spatial and 
temporal variability within communities. Once a large and comprehensive database is 
crated data mining and analytical modelling will be used to identify patterns that could 
help explaining and predicting the incidence of certain diseases. One limitation to such 
approach is the inability to understand exposure pathways as excretion of biomarkers 
depends on the overall intake regardless of the source. To overcome this limitation in 
vivo studies will be performed to investigate absorption, distribution, and excretion of 
the selected chemicals. A better understanding of absorption and distribution would 
provide for example more information about potential sources of exposure and 
potential for bioaccumulation. A better understanding of excretion rates would 
guarantee instead smaller uncertainty when back calculating intakes.    
Finally studies will be necessary to establish whether or not, at the assessed level of 
internal exposure to one or many compounds simultaneously, there is potential for 
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Sample Name S9_4-Cl-3-Me_B_6_Hour_Neg and 4_Cl_6hB_Neg XIC and mass spectrum of 
PCMC hydroxylated, PCMC glucuronidated, PCMC sulfated, PCMC sulfated and 
hydroxylated, PCMC and relative isotopes (including bbCID fragmentation pattern for phase 
II metabolites), following in-vitro HLM/S9 assay (6 hour sampling point) for verification of 
metabolic profile of PCMC. (duplicate sample) 
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spectrum of PCMC hydroxylated, PCMC glucuronidated, PCMC sulfated, PCMC sulfated and 
hydroxylated, PCMC and relative isotopes (including bbCID fragmentation pattern for phase 
II metabolites), following in-vitro HLM/S9 assay (6 hour sampling point) for verification of 
metabolic profile of PCMC. (blank control) 
Report 3 Detection and identification of PCMC metabolite by UHPLC-QTOF-MS following 
urine analysis. 
Sample Name Urine_141_A neg XIC and mass spectrum of PCMC sulfated (including bbCID 
fragmentation pattern) and relative isotopes, following direct in-vivo urine profiling assay. 
Sample Name Urine_141_B neg XIC and mass spectrum of PCMC sulfated (including bbCID 
fragmentation pattern) and relative isotopes, following direct in-vivo urine profiling assay. 
Report 4 Detection and identification of PCMC metabolites by UHPLC-QTOF-MS following 
wastewater analysis. 
Sample Name Inf day 1A neg XIC and mass spectrum of PCMC and PCMC sulphated 
(including bbCID fragmentation pattern) and relative isotopes. 
Report 5 MRM fragmentation pattern of PCMC standard solution. 
Sample Name MRM_4Cl3MPox_Met2_STD_5 MRM fragmentation pattern of PCMC 
standard solution 
 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 3:59:20 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_1_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO2 [M-H]- 157.0062±0.005 All MS 























155 156 157 158 159 160 161 m/z 
 
4-Cl-3-Me_1_neg_GA7_01_9763.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 3:59:20 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_1_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO2 [M-H]- 157.0062±0.005 All MS EIC 158.0079±0.005 -All MS 































155 156 157 158 159 160 161 m/z 
 
4-Cl-3-Me_1_neg_GA7_01_9763.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:26:22 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS 


























312 314 316 318 320 322 324 326 328 330 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD3_01_7239.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:26:22 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






















0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS EIC 319.0384±0.005 -All MS 





































312 314 316 318 320 322 324 326 328 330 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD3_01_7239.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:26:22 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






















 0 2 4 6 8 10 12 14 Time [min] 





































































145.0499    147.0442 
151.0382 155.1185 
132.5 135.0 137.5 140.0 142.5 145.0 147.5 150.0 152.5 155.0 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD3_01_7239.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 6:27:59 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_2_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO2 [M-H]- 157.0062±0.005 All MS 































155 156 157 158 159 160 161 m/z 
 
4-Cl-3-Me_2_neg_GB4_01_9770.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 6:27:59 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_2_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 


























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO2 [M-H]- 157.0062±0.005 All MS EIC 158.0074±0.005 -All MS 







































155 156 157 158 159 160 161 m/z 
 
4-Cl-3-Me_2_neg_GB4_01_9770.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:05:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS 






























312 314 316 318 320 322 324 326 328 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD2_01_7238.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:05:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS EIC 319.0390±0.005 -All MS 








































312 314 316 318 320 322 324 326 328 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD2_01_7238.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:05:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 



























0  2 4 6 8 10  12 14 16 18 Time [min] 



















130 135 140 145 150 155 160 165 170 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD2_01_7238.d 












  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:26:22 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 



























5 6 7 8 9 10 11 Time [min] 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS 




















142.0146 144.0266  
146.0236 150.0552 
136 138 140 142 144 146 148 150 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD3_01_7239.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:26:22 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 




























5 6 7 8 9 10 11 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS EIC 143.0081±0.005 -All MS 
























142.0146 144.0266  
146.0236 150.0552 
136 138 140 142 144 146 148 150 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD3_01_7239.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:05:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS 

























138 140 142 144 146 148 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD2_01_7238.d 
  Display Report  
Analysis Info Acquisition Date 11/11/2016 01:05:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name PCMC_10ul_enz_B_Neg_2 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































0 2 4 6 8 10 12 14 16 18 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS EIC 143.0079±0.005 -All MS 




























138 140 142 144 146 148 m/z 
 
PCMC_10ul_enz_B_Neg_2_BD2_01_7238.d 










6/18/2015 1:09:28 PM 
 
Sample Name 4-Cl-3-Me_Blank_neg Operator CCAF 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO2 [M-H]- 157.0062±0.005 All MS 






















































148 150 152 154 156 158 160 162 164 m/z 
 
4-Cl-3-Me_Blank_neg_GA2_01_9755.d 





  Display Report  
























Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 





























0  2 4 6 8 10 12 14 Time [min] 






















150 200 250 300 350 400 m/z 
 
PCMC_blank_Neg_BD4_01_7223.d 








  Display Report  
Analysis Info Acquisition Date 6/18/2015 1:09:28 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_Blank_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS 


































216 218 220 222 224 m/z 
 
4-Cl-3-Me_Blank_neg_GA2_01_9755.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 1:09:28 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_Blank_neg 
1820881.21247 














Set Dry Heater 
3.0 Bar 
220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 




Set Divert Valve 
Set APCI Heater 
Waste 
200 °C 
      
Intens.      
 
8000 
























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9630±0.005 All MS 






































232 234 236 238 240 m/z 
 
4-Cl-3-Me_Blank_neg_GA2_01_9755.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 1:09:28 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_Blank_neg 
1820881.21247 














Set Dry Heater 
3.0 Bar 
220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 




Set Divert Valve 
Set APCI Heater 
Waste 
200 °C 
      
Intens.      
 
8000 
























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS 































140 141 142 143 144 145 m/z 
 
4-Cl-3-Me_Blank_neg_GA2_01_9755.d 
  Display Report  
Analysis Info Acquisition Date 6/18/2015 1:09:28 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name 4-Cl-3-Me_Blank_neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0 2 4 6 8 10 12 14 16 18 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS EIC 142.0170±0.005 -All MS 



































140.5 141.0 141.5 142.0 142.5 143.0 143.5 144.0 144.5 m/z 
 
4-Cl-3-Me_Blank_neg_GA2_01_9755.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO2 [M-H]- 157.0051±0.005 All MS 





















160.0068 161.0455 162.0974 
163.1059
 
155 156 157 158 159 160 161 162 163 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO2 [M-H]- 157.0051±0.005 All MS EIC 158.0097±0.01 -All MS 






























160.0068 161.0455 162.0974 
163.1059
 
155 156 157 158 159 160 161 162 163 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:21:21 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hA_Neg 1820881.21247 
4_Cl_6hA_Neg_RA3_01_11221.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 






















0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS 





















































315 316 317 318 319 320 321 322 323 324 m/z 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:21:21 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hA_Neg 1820881.21247 
4_Cl_6hA_Neg_RA3_01_11221.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 
























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS EIC 319.0410±0.005 -All MS 



























315 316 317 318 319 320 321 322 323 324 m/z 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:21:21 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 





























0  2 4 6 8 10  12 14 16 18 Time [min] 






















135.0 137.5 140.0 142.5 145.0 147.5 150.0 152.5 155.0 m/z 
 
4_Cl_6hA_Neg_RA3_01_11221.d 





144.0459 147.0821 152.0227 156.1030 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS 



























219 220 221 222 223 224 225 226 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS EIC 221.9713±0.01 -All MS 



































219 220 221 222 223 224 225 226 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS   EIC 141.0117±0.01 -bbCID MS 

























140 141 142 143 144 145 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS 




























236 237 238 239 240 241 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS EIC 237.9660±0.01 -All MS 








































236 237 238 239 240 241 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS   EIC 157.0064±0.01 -bbCID MS 
























160.0067 162.0785 164.0719 
156 157 158 159 160 161 162 163 164 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO2 [M-H]- 157.0051±0.005 All MS 























160.0068 161.0451 162.0974 
156 157 158 159 160 161 162 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO2 [M-H]- 157.0051±0.005 All MS EIC 158.0095±0.01 -All MS 






























160.0068 161.0451 162.0974 
156 157 158 159 160 161 162 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:42:37 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hB_Neg 1820881.21247 
4_Cl_6hB_Neg_RA4_01_11222.d 














Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 
























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS 




















314 316 318 320 322 324 326 m/z 




















314 316 318 320 322 324 326 m/z 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:42:37 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hB_Neg 1820881.21247 
4_Cl_6hB_Neg_RA4_01_11222.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C13H15ClO7 [M-H]- 317.0434±0.005 All MS EIC 319.0414±0.005 -All MS 





























314 316 318 320 322 324 326 m/z 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 20:42:37 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4_Cl_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 



























0  2 4 6 8 10  12 14 16 18 Time [min] 


















140 160 180 200 220 240 260 280 300 320 m/z 
 
4_Cl_6hB_Neg_RA4_01_11222.d 









  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS 




































219 220 221 222 223 224 225 226m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS EIC 221.9709±0.01 -All MS 













































219 220 221 222 223 224 225 226m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS   EIC 141.0116±0.01 -bbCID MS 





















141 142 143 144 145 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS 





























236 237 238 239 240 241 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS EIC 237.9661±0.01 -All MS 




































236 237 238 239 240 241 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS   EIC 157.0064±0.01 -bbCID MS 
























160.0067 162.0785 164.0719 
156 157 158 159 160 161 162 163 164 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 














Set Dry Heater 
3.0 Bar 
220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 




Set Divert Valve 
Set APCI Heater 
Source 
200 °C 
      
Intens. 
x104 
     
4 






















0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS 

















141.0 141.5 142.0 142.5 143.0 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 8:13:51 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

































0 2 4 6 8 10 12 14 16 18 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS EIC 142.0162±0.01 -All MS 






















141.0 141.5 142.0 142.5 143.0 m/z 
 
S9_4-Cl-3-Me_A_6_Hours_Neg_RC6_01_14220.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS 


















141.0 141.5 142.0 142.5 143.0 143.5 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 10:21:32 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0 2 4 6 8 10 12 14 16 18 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS EIC 142.0160±0.01 -All MS 






















141.0 141.5 142.0 142.5 143.0 143.5 m/z 
 
S9_4-Cl-3-Me_B_6_Hours_Neg_RD3_01_14226.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 5:23:29 PM 




Sample Name S9_4-Cl-3-Me_Blank_6_Hours_Neg Operator CCAF 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 














0  2 4 6 8 10 12 14 16 18 Time [min] 







154 155 156 157 158 159 160 161 162 m/z 
S9_4-Cl-3-Me_Blank_6_Hours_Neg_RC1_01_14212.d 















  Display Report  
























Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 



























0  2 4 6 8 10 12 14 16 18 Time [min] 





















220 240 260 280 300 320 340m/z 
 
4_Cl_6hBlank_Neg_RA5_01_11223.d 








  Display Report  
Analysis Info Acquisition Date 1/12/2016 5:23:29 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_Blank_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9670±0.005 All MS 



























































216 218 220 222 224 226 228 m/z 
 
S9_4-Cl-3-Me_Blank_6_Hours_Neg_RC1_01_14212.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 5:23:29 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_Blank_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO5S [M-H]- 236.9619±0.005 All MS 




































232 234 236 238 240 242 m/z 
 
S9_4-Cl-3-Me_Blank_6_Hours_Neg_RC1_01_14212.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 5:23:29 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_Blank_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS 



















141 142 143 144 145 m/z 
 
S9_4-Cl-3-Me_Blank_6_Hours_Neg_RC1_01_14212.d 
  Display Report  
Analysis Info Acquisition Date 1/12/2016 5:23:29 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_4-Cl-3-Me_Blank_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO [M-H]- 141.0102±0.005 All MS   EIC 143.0086±0.01 -All MS 



















141 142 143 144 145 m/z 
 
S9_4-Cl-3-Me_Blank_6_Hours_Neg_RC1_01_14212.d 
  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:03:25 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 


















221.0 221.5 222.0 222.5 223.0 223.5 m/z 
 
Urine_141_A neg_RA5_01_8119.d 






  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:03:25 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS EIC 222.9640±0.005 -All MS 























221.0 221.5 222.0 222.5 223.0 223.5 m/z 
 
Urine_141_A neg_RA5_01_8119.d 






  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:03:25 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 





























5.5 6.0 6.5 7.0  7.5 8.0 8.5 Time [min] 



















141.0 141.5 142.0 142.5 143.0 143.5 m/z 
 
Urine_141_A neg_RA5_01_8119.d 




  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:45:56 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_B neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS 































   
 
  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:45:56 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_B neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























0 2 4 6 8 10 12 14 16 18    Time [min] 
 
 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS EIC 222.9640±0.005 -All MS 














































220 221 222 223 224 225 m/z 
 
Urine_141_B neg_RA6_01_8121.d 
  Display Report  
Analysis Info Acquisition Date 11/23/2016 9:45:56 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Urine_141_B neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 































0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS   EIC 141.0114±0.005 -bbCID MS 



























  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 


































2 4 6 8 10 12 14 16 Time [min] 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS 




















140.0 140.5 141.0 141.5 142.0 142.5 143.0 143.5 m/z 
 
Inf day 1A neg_RD2_01_6298.d 
  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 



































2 4 6 8 10 12 14 16 Time [min] 
 
 
EIC C7H7ClO [M-H]- 141.0113±0.005 All MS EIC 143.0092±0.005 -All MS 






















140.0 140.5 141.0 141.5 142.0 142.5 143.0 143.5 m/z 
 
Inf day 1A neg_RD2_01_6298.d 
  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























0  2 4 6 8 10 12 14 16 18 Time [min] 


















220.5 221.0 221.5 222.0 222.5 223.0 m/z 
 
Inf day 1A neg_RD2_01_6298.d 





  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 
































2 4 6 8 10 12 14 Time [min] 
EIC C7H7ClO4S [M-H]- 220.9681±0.005 All MS  EIC 141.0120±0.005 -bbCID MS 





















141 142 143 144 145 m/z 
 
Inf day 1A neg_RD2_01_6298.d 
  Display Report  
Analysis Info Acquisition Date 7/20/2016 6:17:37 PM 




Sample Name MRM_BPAandBPAox_Met1_testSTD_2 Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 4.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 












5 6 7  8 9 10 Time [min] 
MS(n): TIC -MS2(227.1078)   MS(n): TIC -MS2(243.1027) 








































  Display Report  
Analysis Info Acquisition Date 7/21/2016 5:00:16 PM 




Sample Name MRM_4Cl3MPox_Met2_STD_5 Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 4.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 












5 6 7 8 9 10 Time [min] 
MS(n): TIC -MS2(141.0113) 




























Appendix B: List of reports 
Report 1 XICs and mass spectra of BPA metabolites identified following in vitro experiments 
Report 2 XICs and mass spectra of BP1 metabolites identified following in vitro experiments 
Report 3 XICs and mass spectra of BP2 metabolites identified following in vitro experiments 
Report 4 XICs and mass spectra of 4,4-DHBP metabolites identified following in vitro 
experiments 
Report 5 XICs and mass spectra of 4-BenzPh metabolites identified following in vitro 
experiments 
Report 6 XICs and mass spectra of HO metabolites identified following in vitro experiments 
Report 7 XICs and mass spectra of OC metabolites identified following in vitro experiments 
Report 8 XICs and mass spectra of 3BC metabolites identified following in vitro experiments 
Report 9 XICs and mass spectra of compounds identified in urine 
Report 10 XICs and mass spectra of compounds identified in wastewater 
  Display Report  
Analysis Info Acquisition Date 3/24/2016 11:38:56 PM 




Sample Name HLM_A_Neg Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 










































































245.1757   246.1138 247.1339 
249.1498
 
 240.1313 242.0458   248.1294 250.1452 
 240 242 244 246 248 250 m/z 
 
  Display Report  
Analysis Info Acquisition Date 3/25/2016 12:00:08 AM 




Sample Name HLM_B_Neg Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






















241 242 243 244 245 246 m/z 
HLM_B_Neg_BE6_01_93.d 
EIC C15H16O3 [M-H]- 243.1027±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 7/20/2016 7:23:57 PM 




Sample Name MRM_BPAandBPAox_Met1_testHLM Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 4.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 










































210 215 220 225 230 235 240 m/z 
 
MRM_BPAandBPAox_Met1_testHLM_RA4_01_4600.d 





  Display Report  
Analysis Info Acquisition Date 3/25/2016 12:21:20 AM 




Sample Name HLM_Blank_Neg Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 




















240 242 244 246 248 250 m/z 
HLM_Blank_Neg_BE7_01_94.d 
EIC C15H16O3 [M-H]- 243.1027±0.005 All MS 







246.1248 247.1462 248.1283 248.9350 250.1451 
  Display Report  
Analysis Info Acquisition Date 11/03/2016 15:39:05 
Operator CCAF 
Instrument maXis-HD Sample Name FinMet_BPA_6hA2_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































0 200 400 600 800 1000 m/z 
 
FinMet_BPA_6hA2_Neg_BC6_01_15381.d 
EIC C21H24O8 [M-H]- 403.1387±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 11/03/2016 15:39:05 
Operator CCAF 
Instrument maXis-HD Sample Name FinMet_BPA_6hA2_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 
















































210 220 230 240 250 260 m/z 
 
FinMet_BPA_6hA2_Neg_BC6_01_15381.d 
EIC C21H24O8 [M-H]- 403.1387±0.005 All MS EIC 227.1079±0.005 -bbCID MS 
FinMet_BPA_6hA2_Neg_BC6_01_15381.d: -bbCID MS, 20.0eV, 6.7-6.8min #860-872 
221.1295 
227.1072 
215.1285 229.1437 235.1082 245.1385 
255.2323 
253.2161 
  Display Report  
Analysis Info Acquisition Date 11/03/2016 19:12:24 
Operator CCAF 
Instrument maXis-HD Sample Name FinMet_BPA_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 













































300 350 400 450 500 550 600 650 m/z 
 
FinMet_BPA_6hB_Neg_BD5_01_15391.d 
EIC C21H24O8 [M-H]- 403.1387±0.005 All MS 




  Display Report  
Analysis Info Acquisition Date 11/03/2016 19:12:24 
Operator CCAF 
Instrument maXis-HD Sample Name FinMet_BPA_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 












































210 220 230 240 250 260 m/z 
 
FinMet_BPA_6hB_Neg_BD5_01_15391.d 
EIC C21H24O8 [M-H]- 403.1387±0.005 All MS EIC 227.1079±0.005 -bbCID MS 




209.1185 215.1288 229.1445 235.1089 245.1391 
  Display Report  
Analysis Info Acquisition Date 11/03/2016 22:24:37 
Operator CCAF 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 22:05:16 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































-100 0 100 200 300 400 m/z 
 
FinMet_BPA_6hBlank_Neg_BE3_01_15400.d 
EIC C21H24O8 [M-H]- 403.1387±0.005 All MS 
FinMet_BPA_6hBlank_Neg_BE3_01_15400.d: -MS, 6.5-6.7min #842-862 
157.0609 
121.0412 255.2331 
  Display Report  
Analysis Info Acquisition Date 1/13/2016 8:11:34 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_BPA_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 










































306.5 307.0 307.5 308.0 308.5 m/z 
 
S9_BPA_A_6_Hours_Neg_RC6_01_14270.d 
EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 
S9_BPA_A_6_Hours_Neg_RC6_01_14270.d: -MS, 6.6-6.6min #848-856 
307.0642 
308.0674 
306.6175 307.6166 308.6484 
  Display Report  
Analysis Info Acquisition Date 1/13/2016 8:11:34 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_BPA_A_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

























0 2 4 6 8 10 12 14 16 18 Time [min] 
 
BPC -bbCID MS EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 























227.00 227.05 227.10 227.15 227.20 227.25 227.30 227.35 227.40 m/z 
 
S9_BPA_A_6_Hours_Neg_RC6_01_14270.d 






227.0711 227.1432 227.1788 227.2365 227.2932 227.3279 227.3889 
  Display Report  
Analysis Info Acquisition Date 1/13/2016 10:19:14 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_BPA_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 












































306.5 307.0 307.5 308.0 308.5 m/z 
 
S9_BPA_B_6_Hours_Neg_RD3_01_14276.d 
EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 




  Display Report  
Analysis Info Acquisition Date 1/13/2016 10:19:14 PM 
Operator CCAF 
Instrument maXis-HD 
Sample Name S9_BPA_B_6_Hours_Neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 












































226.95 227.00 227.05 227.10 227.15 227.20 227.25 227.30 227.35 m/z 
 
S9_BPA_B_6_Hours_Neg_RD3_01_14276.d 
EIC C15H16O5S [M-H]- 307.0646±0.005 All MS EIC 227.1078±0.01 -bbCID MS 





226.9425 227.0070 227.0705 227.2317 227.3394 
  Display Report  
Analysis Info Acquisition Date 3/24/2016 10:35:20 PM 




Sample Name S9_6hBlank_Neg Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 




















306.5 307.0 307.5 308.0 308.5 m/z 
S9_6hBlank_Neg_BE3_01_89.d 
EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 1/13/2016 8:11:34 PM 




Sample Name S9_BPA_A_6_Hours_Neg Operator CCAF 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 






























210 220 230 240 250 260 m/z 
 
S9_BPA_A_6_Hours_Neg_RC6_01_14270.d 
EIC C15H16O2 [M-H]- 227.1078±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 1/13/2016 10:19:14 PM 




Sample Name S9_BPA_B_6_Hours_Neg Operator CCAF 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 


















210 220 230 240 250 260 m/z 
S9_BPA_B_6_Hours_Neg_RD3_01_14276.d 
EIC C15H16O2 [M-H]- 227.1078±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 3/24/2016 10:35:20 PM 




Sample Name S9_6hBlank_Neg Operator BDAL@DE 
Instrument maXis-HD 1820881.21247 
Acquisition Parameter 
Source Type ESI Ion Polarity Negative Set Nebulizer 3.0 Bar 





Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 

















210 220 230 240 250 260 m/z 
S9_6hBlank_Neg_BE3_01_89.d 
EIC C15H16O2 [M-H]- 227.1078±0.005 All MS 
S9_6hBlank_Neg_BE3_01_89.d: -MS, 7.6-7.7min #985-993 
227.1080 
242.1762 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































250 300 350 400 450 500 550 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 





321.2163 357.1711 405.0830 451.1681 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































100 150 200 250 300 350 400 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS EIC 213.0561±0.005 -bbCID MS 







  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































325 350 375 400 425 450 475 500 525 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 
BP1_6hA_Neg_RB4_01_11163.d: -MS, 6.5-6.6min #843-857 
389.0888 
489.1838 
321.2162 357.1706 431.0637 451.1670 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































150 200 250 300 350 400m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS EIC 213.0560±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 16:22:15 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































100 200 300 400 500 600 700 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 













































380 390 400 410 420 430 440 450 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS 










  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 












































340 360 380 400 420 440 460 480 500 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 























2 4 6 8 10 12 Time [min] 
 




























































224 226 228 230 232 234 236 238 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 











































390 395 400 405 410 415 420 425 430 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS 










  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 













































380 400 420 440 460 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































380 400 420 440 460 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS EIC 229.0508±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 16:24:48 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































225 250 275 300 325 350 375 400 425 450 475 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C19H18O10 [M-H]- 405.0827±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































280 290 300 310 320 330 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























4 5 6 7 8  9 10 11 12 Time [min] 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS  EIC 213.0561±0.005 -bbCID MS 














































208 210 212 214 216 218 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































260 270 280 290 300 310 320 330 340 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 








261.1421 287.1774 327.1111 
339.2283 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































190 200 210 220 230 240 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS EIC 213.0560±0.005 -bbCID MS 
BP1_6hA_Neg_RB4_01_11163.d: -bbCID MS, 20.0eV, 6.8-6.9min #880-892 
221.1301 
207.1504 213.0557 226.9784 
237.1610 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 16:26:32 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































180 200 220 240 260 280 300 320 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 








295.0092 314.8643 330.8901 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































100 200 300 400 500 600 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 





221.1299 273.1819 387.1754 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































160 180 200 220 240 260 280 300 320 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC 229.0509±0.005 -bbCID MS EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 





213.0559 255.2331 309.0075 
192.0489 317.1968 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































150 200 250 300 350 400 450 500 550 600 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































210 220 230 240 250 260 270 280 290 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS EIC 229.0508±0.005 -bbCID MS 








  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 16:27:29 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































180 200 220 240 260 280 300 320 340 360 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 






237.1245 309.2185 360.2388 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































200 250 300 350 400 450 500 550 600 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































220 230 240 250 260 270 280 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS EIC 245.0457±0.005 -bbCID MS 






  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































250 300 350 400 450 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 












  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP1_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































200 220 240 260 280 300 320 340 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS EIC 245.0454±0.005 -bbCID MS 








222.1498 270.1249 293.1157 338.2082 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 16:29:19 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































50 100 150 200 250 300 350 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:58:26 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 12:09:38 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































50 100 150 200 250 300 350 400 m/z 
 
BP1_6hB_Neg_RB5_01_11164.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
BP1_6hB_Neg_RB5_01_11164.d: -MS, 7.7-7.8min #995-1005 
213.0565 
112.9862 
96.9602 143.0241 257.1758 
329.2335 
367.2128 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 23:37:10 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/201715 :02:08 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 















































50 100 150 200 250 300 350 400 m/z 
 
BP1_6hA_Neg_RB4_01_11163.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
BP1_6hA_Neg_RB4_01_11163.d: -MS, 7.7-7.9min #987-1013 
213.0564 
112.9861 
96.9602 143.1080 257.1758 
329.2332 
391.2122 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:19:42 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/201716 :16:58 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































50 100 150 200 250 300 350 400 450 m/z 
 
BP1_6hBlank_Neg_RB6_01_11165.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
BP1_6hBlank_Neg_RB6_01_11165.d: -MS, 7.8-7.8min #999-1009 
213.0566 
112.9864 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:40:59 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hA_Neg 1820881.21247 
BP2_6hA_Neg_RB7_01_11166.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 







































250 300 350 400 450 500 550 m/z 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 




368.2201 420.0903 462.1473 552.1765 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 00:40:59 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hA_Neg 1820881.21247 
BP2_6hA_Neg_RB7_01_11166.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































225 250 275 300 325 350 375 400 425 m/z 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS EIC 245.0458±0.005 -bbCID MS 
BP2_6hA_Neg_RB7_01_11166.d: -MS, 6.2-6.2min #807-817 
325.0035 
235.1092 255.2334 277.2179 
301.1206 368.2201 




279.2332 350.2092 401.1862 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 01:02:18 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hB_Neg 1820881.21247 
BP2_6hB_Neg_RB8_01_11167.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































250 275 300 325 350 375 400 425 450 m/z 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 




314.8760 336.8590 354.8091 401.1858 434.8267 452.7771 
  Display Report  
Analysis Info Acquisition Date 15/03/2017 01:02:18 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hB_Neg 1820881.21247 
BP2_6hB_Neg_RB8_01_11167.d 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 















































240 260 280 300 320 340 360 380 400 m/z 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS EIC 245.0458±0.005 -bbCID MS 
















  Display Report  
Analysis Info Acquisition Date 15/03/2017 01:23:33 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 
Scan End 
Intens. 




Set Divert Valve 













































50 100 150 200 250 300 350 400 450 m/z 
 
BP2_6hBlank_Neg_RC1_01_11168.d 
EIC C13H10O8S [M-H]- 325.0024±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 15/03/2017 01:23:33 
Operator BDAL@DE 
Instrument maXis-HD Sample Name BP2_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































0 100 200 300 400 500 600 700 800 m/z 
 
BP2_6hBlank_Neg_RC1_01_11168.d 
EIC C13H10O5 [M-H]- 245.0455±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 20:33:32 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 











































150 200 250 300 350 400 450 500 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O4 [M-H]- 229.0506±0.005 All MS 





156.1030 357.1706 441.1589 
501.1742 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 20:35:13 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































150 200 250 300 350 400 450 500 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O4 [M-H]- 229.0506±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 07/08/2017 14:55:33 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 07/08/2017 23:18:14 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 200 °C 
Scan Begin 75 m/z Set End Plate Offset -500 V Set Dry Gas 8.0 l/min 
Scan End 
Intens. 




Set Divert Valve 












































108 109 110 111 112 113 114 m/z 
 
44BP_30eV_RA6_01_14655.d 
TIC -All MSn 







  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:40:08 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 21:06:54 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































190 200 210 220 230 240 250 260 270 m/z 
 
44Dihy_6hBlank_Neg_RB6_01_11236.d 
EIC C13H10O4 [M-H]- 229.0506±0.005 All MS 










  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 
Scan End 
Intens. 




Set Divert Valve 










































300 350 400 450 500 550 600 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 
Scan End 
Intens. 




Set Divert Valve 









































190 200 210 220 230 240 250 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS BPC 213.0559±0.005 -bbCID MS 
44Dihy_6hA_Neg_RB4_01_11234.d: -bbCID MS, 20.0eV, 4.9-5.2min #658-688 
204.9444 213.0558 
195.1498 220.9164 227.2020 232.9227 
243.1710 
249.1861 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































300 325 350 375 400 425 450 475 500 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 
44Dihy_6hB_Neg_RB5_01_11235.d: -MS, 4.9-5.2min #661-697 
389.0876 436.0958 
303.2335 458.0763 
324.8683 341.1094 357.2601 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 
Scan End 
Intens. 




Set Divert Valve 








































200 205 210 215 220 225 230 235 240 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC 213.0560±0.005 -bbCID MS EIC C19H18O9 [M-H]- 389.0878±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































150 200 250 300 350 400 450 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 














































125 150 175 200 225 250 275 300 325 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS BPC 213.0559±0.005 -bbCID MS 






  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































150 200 250 300 350 400 450 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 







370.2150 420.0889 462.1450 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































125 150 175 200 225 250 275 300 325 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS EIC 213.0560±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:40:08 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 21:09:39 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































150 200 250 300 350 400 450 m/z 
 
44Dihy_6hBlank_Neg_RB6_01_11236.d 
EIC C13H10O6S [M-H]- 293.0125±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































225 250 275 300 325 350 375 400 425 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 




350.2072 370.2149 390.2202 420.0880 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 00:57:38 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































175 200 225 250 275 300 325 350 375 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS EIC 229.0510±0.005 -bbCID MS 







  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































225 250 275 300 325 350 375 400 425 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 






350.2080 370.2150 390.2193 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:18:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 44Dihy_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































125 150 175 200 225 250 275 300 325 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS EIC 229.0508±0.005 -bbCID MS 






134.0472 154.1236 174.0773 
  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:40:08 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 21:10:32 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































150 200 250 300 350 400 450 m/z 
 
44Dihy_6hBlank_Neg_RB6_01_11236.d 
EIC C13H10O7S [M-H]- 309.0074±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 16/03/201700 :57:38 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 20:08:57 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 














































100 150 200 250 300 350 400 m/z 
 
44Dihy_6hA_Neg_RB4_01_11234.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
44Dihy_6hA_Neg_RB4_01_11234.d: -MS, 6.7-6.7min #867-875 
213.0562 
112.9858 
  Display Report  
Analysis Info Acquisition Date 16/03/201701 :18:53 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 20:15:22 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































100 150 200 250 300 350 400 m/z 
 
44Dihy_6hB_Neg_RB5_01_11235.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 




  Display Report  
Analysis Info Acquisition Date 16/03/2017 01:40:08 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 20:30:14 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 














































50 100 150 200 250 300 350 400 450 m/z 
 
44Dihy_6hBlank_Neg_RB6_01_11236.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
44Dihy_6hBlank_Neg_RB6_01_11236.d: -MS, 6.6-6.7min #863-871 
213.0565 
112.9865 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 07/07/2017 12:24:37 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































170 180 190 200 210 220 230 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O2 [M-H]- 199.0765±0.005 All MS 
4Benz_6hA_Neg_RB7_01_8621.d: -MS, 7.5-7.6min #971-981 
199.0756 
215.1637 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 07/07/2017 12:04:47 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 














































160 180 200 220 240 260 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O2 [M-H]- 199.0765±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 07/08/2017 23:54:18 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 08/08/20170 0:15:08 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 200 °C 
Scan Begin 75 m/z Set End Plate Offset -500 V Set Dry Gas 8.0 l/min 
Scan End 
Intens. 




Set Divert Valve 











































100 120 140 160 180 200 m/z 
 
4BenzylPhenolMet1_5_30eV_RA4_01_14677.d 
TIC -All MSn 




  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































300 320 340 360 380 400 420 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C19H20O7 [M-H]- 359.1136±0.005 All MS 
4Benz_6hA_Neg_RB7_01_8621.d: -MS, 6.7-6.9min #877-895 
359.1125 
309.0992 321.0030 345.2257 375.1064 
405.1141 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 














































160 170 180 190 200 210 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C19H20O7 [M-H]- 359.1136±0.005 All MS EIC 183.0801±0.005 -bbCID MS 







  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































160 170 180 190 200 210 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C19H20O7 [M-H]- 359.1136±0.005 All MS EIC 183.0808±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 










































160 170 180 190 200 210 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C19H20O7 [M-H]- 359.1136±0.005 All MS EIC 183.0808±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































340 350 360 370 380 390 400 410m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C19H20O8 [M-H]- 375.1085±0.005 All MS 




375.1067 385.2209 405.1142 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 17:35:44 by: chpc-tof\admin Page 1 of 1 
 
 
EIC 199.0752±0.005 -bbCID MS EIC C19H20O8 [M-H]- 375.1085±0.005 All MS 
Acquisition Parameter 









Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 


























5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 Time [min] 
 
 













































190.0 192.5 195.0 197.5 200.0 202.5 205.0 207.5 210.0 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 



























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C19H20O8 [M-H]- 375.1085±0.005 All MS 





















365 370 375 380 385 390 395 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 












































190.0 192.5 195.0 197.5 200.0 202.5 205.0 207.5 210.0 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C19H20O8 [M-H]- 375.1085±0.005 All MS EIC 199.0748±0.005 -bbCID MS 





195.1486 197.1167 201.1111 
203.1165 205.1322 207.1477 
209.1161 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































175 200 225 250 275 300 325 350 375 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O4S [M-H]- 263.0384±0.005 All MS 






305.1586 321.0024 345.2261 369.2264 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































100 125 150 175 200 225 250 275 300 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O4S [M-H]- 263.0384±0.005 All MS EIC 183.0801±0.005 -bbCID MS 





167.1178 199.0751 305.1587 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































200 250 300 350 400 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O4S [M-H]- 263.0384±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































160 170 180 190 200 210 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O4S [M-H]- 263.0384±0.005 All MS EIC 183.0808±0.005 -bbCID MS 





  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































200 220 240 260 280 300 320 340 360 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































200 220 240 260 280 300 320 340 360 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS 






255.2307 293.1370 309.0988 
345.2261 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































150 200 250 300 350 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS EIC 199.0753±0.005 -bbCID MS 











  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































200 250 300 350 400 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































200 250 300 350 400 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS 




199.0748 316.2100 385.2210 409.2210 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































170 180 190 200 210 220 230 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS EIC 199.0753±0.005 -bbCID MS 





194.1535 207.1482 229.1425 
237.1586 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































200 250 300 350 400 450 500 550 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS 











  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































200 250 300 350 400 450 500 550 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS EIC 215.0696±0.005 -bbCID MS 











  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































5 6 7 8 9 10 11 Time [min] 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS 
























301.0837 304.1352 307.1151 
309.0982 
311.1592 313.1825 
290 295 300 305 310 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































200 210 220 230 240 250 260 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS EIC 215.0694±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:00:46 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 6/07/2017 18:05:51 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































0 50 100 150 200 250 300 350 400 m/z 
 
4Benz_6hA_Neg_RB7_01_8621.d 
EIC C13H12O [M-H]- 183.0815±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:22:02 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 7/07/2017 12:03:24 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 













































140 160 180 200 220 m/z 
 
4Benz_6hB_Neg_RB8_01_8622.d 
EIC C13H12O [M-H]- 183.0815±0.005 All MS 




  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































100 125 150 175 200 225 250 275 300 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C13H12O2 [M-H]- 199.0765±0.005 All MS 













  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































50 100 150 200 250 300 350 400 450 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C19H20O7 [M-H]- 359.1136±0.005 All MS EIC C19H20O8 [M-H]- 375.1085±0.005 All MS 





85.0105 360.2374 434.9956 
  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 
Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 11.0 l/min 
Scan End 
Intens. 




Set Divert Valve 










































340 350 360 370 380 390 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C19H20O8 [M-H]- 375.1085±0.005 All MS 
4Benz_6hBlank_Neg_RC1_01_8623.d: -MS, 6.7-6.7min #871-877 
360.2378 
356.9804 




  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 















































50 100 150 200 250 300 350 400 450 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C13H12O4S [M-H]- 263.0384±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































50 100 150 200 250 300 350 400 450 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C13H12O5S [M-H]- 279.0333±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 06/12/2016 21:43:17 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 4Benz_6hBlank_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 








































50 100 150 200 250 300 350 m/z 
 
4Benz_6hBlank_Neg_RC1_01_8623.d 
EIC C13H12O [M-H]- 183.0815±0.005 All MS 
4Benz_6hBlank_Neg_RC1_01_8623.d: -MS, 8.2-8.4min #1053-1075 
183.0811 
121.0411 157.1226 255.2312 
307.2375 
385.1640 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 02:15:51 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Hom_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































110 120 130 140 150 160 170 180 m/z 
 
Hom_6hA_Neg_RB4_01_8067.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 23/11/2016 02:15:51 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Hom_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 














































85 90 95 100 105 110 115 m/z 
 
Hom_6hA_Neg_RB4_01_8067.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS EIC 93.0378±0.005 -bbCID MS 







101.0264 111.0214 119.0359 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 02:37:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Hom_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































100 110 120 130 140 150 160 170 180 m/z 
 
Hom_6hB_Neg_RB5_01_8068.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS 







  Display Report  
Analysis Info Acquisition Date 23/11/2016 02:37:06 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Hom_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































90 95 100 105 110 115 m/z 
 
Hom_6hB_Neg_RB5_01_8068.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS EIC 93.0378±0.005 -bbCID MS 
1- 
93.0370 








  Display Report  
Analysis Info Acquisition Date 23/11/2016 02:58:22 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 06/07/2017 14:33:00 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































75 100 125 150 175 200 225 250 m/z 
 
Hom_6hBlank_Neg_RB6_01_8069.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS 





112.9866 161.0452 180.9884 221.0002 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 03:19:39 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Oct_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 








































244 246 248 250 252 254 256 m/z 
 
Oct_6hA_Neg_RB7_01_8070.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 03:19:39 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Oct_6hA_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS  EIC 204.0804±0.005 -bbCID MS 






























197.5 200.0 202.5 205.0 207.5 210.0 212.5 215.0 217.5 m/z 
 
Oct_6hA_Neg_RB7_01_8070.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 03:40:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Oct_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 




























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 






























244 246 248 250 252 254 256 m/z 
 
Oct_6hB_Neg_RB8_01_8071.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 03:40:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Oct_6hB_Neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 



























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS  EIC 204.0805±0.005 -bbCID MS 


































198 200 202 204 206 208 210 212 214 216 m/z 
 
Oct_6hB_Neg_RB8_01_8071.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 04:2:10 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 05/07/2017 15:06:23 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































235 240 245 250 255 260 265 m/z 
 
Oct_6hBlank_Neg_RC1_01_8072.d 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 16/3/2017 20:06:13 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 19:38:40 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 














































50 100 150 200 250 300 350 400 450 m/z 
 
3BenzCamph_6hA_Neg_RB4_01_11285.d 
EIC C17H20O2 [M-H]- 255.1391±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 16/03/2017 20:27:28 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 02/08/2017 19:42:03 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































50 100 150 200 250 300 350 400 450 m/z 
 
3BenzCamph_6hB_Neg_RB5_01_11286.d 
EIC C17H20O2 [M-H]- 255.1391±0.005 All MS 





  Display Report  
Analysis Info Acquisition Date 07/08/2017 18:58:40 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 3benzCanphMet2_50eV 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 200 °C 
Scan Begin 75 m/z Set End Plate Offset -500 V Set Dry Gas 8.0 l/min 
Scan End 
Intens. 




Set Divert Valve 










































224 226 228 230 232 m/z 
 
3benzCanphMet2_50eV_RB8_01_14669.d 
TIC -All MSn 




  Display Report  
Analysis Info Acquisition Date 07/08/2017 18:58:40 
Operator BDAL@DE 
Instrument maXis-HD Sample Name 3benzCanphMet2_50eV 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 200 °C 
Scan Begin 75 m/z Set End Plate Offset -500 V Set Dry Gas 8.0 l/min 
Scan End 
Intens. 




Set Divert Valve 










































224 226 228 230 232 m/z 
 
3benzCanphMet2_50eV_RB8_01_14669.d 
TIC -All MSn 




  Display Report  
Analysis Info Acquisition Date 23/11/2016 21:03:25 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 01/08/2017 13:16:12 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































150 175 200 225 250 275 300 325 350 m/z 
 
Urine_141_A neg_RA5_01_8119.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 






299.1860 317.0587 337.1659 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 21:45:56 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 01/08/2017 13:18:13 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 














































160 180 200 220 240 260 280 300 320 m/z 
 
Urine_141_B neg_RA6_01_8121.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 






  Display Report  
Analysis Info Acquisition Date 14/03/2017 21:08:18 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 03/08/2017 19:13:30 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































-100 0 100 200 300 400 500 600 700 m/z 
 
BP1_3hBlank_Neg_RA8_01_11156.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
BP1_3hBlank_Neg_RA8_01_11156.d: -MS, 7.7-7.9min #993-1015 
213.0564 
112.9862 
  Display Report  
Analysis Info Acquisition Date 24/11/2016 03:25:59 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 01/08/2017 13:08:26 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























2 4 6 8 10 12 14 16 18 Time [min] 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 



































227 228 229 230 231 232 m/z 
 
Urine_141_A pos_RA5_01_8137.d 
  Display Report  
Analysis Info Acquisition Date 24/11/2016 04:08:30 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 01/08/2017 13:11:49 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































2 4 6 8 10 12 14 16 18 Time [min] 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 



































227 228 229 230 231 232 m/z 
 
Urine_141_B pos_RA6_01_8139.d 
  Display Report  
Analysis Info Acquisition Date 24/11/2016 02:43:30 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 31/07/2017 18:41:32 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































125 150 175 200 225 250 275 300 325 m/z 
 
QC13 pos_RA4_01_8135.d 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 




145.1222 199.1690 217.1797 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 22:28:28 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 











































246 247 248 249 250 251 m/z 
 
Urine_593_A neg_RA7_01_8123.d 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 







246.5759 247.5850 249.6210 250.5948 251.6223 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 22:28:28 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























2 4 6 8 10 12 14 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS   EIC 204.0804±0.005 -bbCID MS 















































200 202 204 206 208 210 212 m/z 
 
Urine_593_A neg_RA7_01_8123.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 23:10:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_B neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































246 247 248 249 250 251 252 m/z 
 
Urine_593_B neg_RA8_01_8125.d 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 








246.5758 247.5839 252.5911 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 23:10:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_B neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 





























2 4 6 8 10 12 14 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS   EIC 204.0805±0.005 -bbCID MS 








































200 202 204 206 208 210 212 m/z 
 
Urine_593_B neg_RA8_01_8125.d 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 22:28:28 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































280 290 300 310 320 330 m/z 
 
Urine_593_A neg_RA7_01_8123.d 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS 











  Display Report  
Analysis Info Acquisition Date 23/11/2016 22:28:28 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS  EIC 215.0696±0.005 -bbCID MS 



























































     
 
  Display Report  
Analysis Info Acquisition Date 23/11/2016 23:10:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_B neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































270 280 290 300 310 320 330 m/z 
 
Urine_593_B neg_RA8_01_8125.d 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS 










  Display Report  
Analysis Info Acquisition Date 23/11/2016 23:10:56 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Urine_593_B neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 






























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C13H12O6S [M-H]- 295.0282±0.005 All MS  EIC 215.0696±0.005 -bbCID MS 
















































     
 
  Display Report  
Analysis Info Acquisition Date 22/10/201606 :41:01 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































212.6 212.8 213.0 213.2 213.4 213.6 m/z 
 
Inf day 1A neg_RD2_01_6411.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 




   
 
  Display Report  
Analysis Info Acquisition Date 22/10/201607 :02:15 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































212.6 212.8 213.0 213.2 213.4 213.6 m/z 
 
Inf day 2A neg_RD3_01_6412.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 




   
 
  Display Report  
Analysis Info Acquisition Date 14/03/2017 21:08:18 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 03/08/2017 19:13:30 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































-100 0 100 200 300 400 500 600 700 m/z 
 
BP1_3hBlank_Neg_RA8_01_11156.d 
EIC C13H10O3 [M-H]- 213.0557±0.005 All MS 
BP1_3hBlank_Neg_RA8_01_11156.d: -MS, 7.7-7.9min #993-1015 
213.0564 
112.9862 
  Display Report  
Analysis Info Acquisition Date 23/10/2016 04:37:53 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A pos 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 


































224 226 228 230 232 234 236 m/z 
 





  Display Report  
Analysis Info Acquisition Date 23/10/2016 04:59:05 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A pos 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 




















































0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 







































224 225 226 227 228 229 230 231 232 m/z 
 







  Display Report  
Analysis Info Acquisition Date 24/11/2016 02:43:30 
Operator BDAL@DE 
Bruker Compass DataAnalysis 4.3 printed: 31/07/2017 18:41:32 by: chpc-tof\admin Page 1 of 1 
 
 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 










































125 150 175 200 225 250 275 300 325 m/z 
 
QC13 pos_RA4_01_8135.d 
EIC C14H12O3 [M+H]+ 229.0859±0.005 All MS 




145.1222 199.1690 217.1797 
  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 














































280 290 300 310 320 330 340 350 360 m/z 
 
Inf day 1A neg_RD2_01_6298.d 
BPC -bbCID MS EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 









  Display Report  
Analysis Info Acquisition Date 10/19/2016 8:26:24 PM 
Operator BDAL@DE 
Instrument maXis-HD 
Sample Name Inf day 1A neg 
1820881.21247 






















Set End Plate Offset 
Set Charging Voltage 
-500 V 
2000 V 
Set Dry Gas 




















4 5 6 7 8 9 Time [min] 
 
BPC -bbCID MS EIC C15H16O5S [M-H]- 307.0646±0.005 All MS 






















226.0 226.5 227.0 227.5 228.0 228.5 m/z 
 
Inf day 1A neg_RD2_01_6298.d 




  Display Report  
Analysis Info Acquisition Date 19/10/2016 20:47:37 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 







































280 290 300 310 320 330 340 m/z 
 
Inf day 2A neg_RD3_01_6299.d 
EIC C15H16O5S [M-H]- 307.0635±0.005 All MS 








  Display Report  
Analysis Info Acquisition Date 19/10/2016 20:47:37 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 











































226.9 227.0 227.1 227.2 227.3 227.4 227.5 227.6 227.7 m/z 
 
Inf day 2A neg_RD3_01_6299.d 
EIC C15H16O5S [M-H]- 307.0635±0.005 All MS EIC 227.1079±0.005 -bbCID MS 





   
 
  Display Report  
Analysis Info Acquisition Date 22/10/2016 06:41:01 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 











































115 120 125 130 135 140 145 150 155 m/z 
 
Inf day 1A neg_RD2_01_6411.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS 





116.0507 144.0456 148.0406 153.0198 
  Display Report  
Analysis Info Acquisition Date 22/10/2016 06:41:01 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 









































80 90 100 110 120 130 140 150 160 m/z 
 
Inf day 1A neg_RD2_01_6411.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS EIC 93.0378±0.005 -bbCID MS 









  Display Report  
Analysis Info Acquisition Date 22/10/2016 07:02:15 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 












































115 120 125 130 135 140 145 150 155 m/z 
 
Inf day 2A neg_RD3_01_6412.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS 





116.0509 144.0459 148.0409 153.0201 
  Display Report  
Analysis Info Acquisition Date 22/10/2016 07:02:15 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 













































80 85 90 95 100 105 110 m/z 
 
Inf day 2A neg_RD3_01_6412.d 
EIC C7H6O3 [M-H]- 137.0244±0.005 All MS EIC 93.0378±0.005 -bbCID MS 







  Display Report  
Analysis Info Acquisition Date 22/10/2016 06:41:01 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 



























0  2 4 6 8 10 12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 







































246 247 248 249 250 251 252 m/z 
 





  Display Report  
Analysis Info Acquisition Date 22/10/2016 06:41:01 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 1A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 





























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS  EIC 204.0804±0.005 -bbCID MS 













































201 202 203 204 205 206 207 208 209 m/z 
 
Inf day 1A neg_RD2_01_6411.d 
  Display Report  
Analysis Info Acquisition Date 22/10/2016 07:02:15 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 










Set Divert Valve 














































246 247 248 249 250 251 m/z 
 
Inf day 2A neg_RD3_01_6412.d 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS 








   
 
  Display Report  
Analysis Info Acquisition Date 22/10/2016 07:02:15 
Operator BDAL@DE 
Instrument maXis-HD Sample Name Inf day 2A neg 1820881.21247 













Focus Active Set Capillary 4500 V Set Dry Heater 220 °C 









Set Divert Valve 





























0  2 4 6 8 10  12 14 16 18 Time [min] 
EIC C16H11O2N [M-H]- 248.0717±0.005 All MS  EIC 204.0804±0.005 -bbCID MS 


































201 202 203 204 205 206 207 208 209 m/z 
 
Inf day 2A neg_RD3_01_6412.d 
